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GENERAL ABSTRACT 
 
Glutamate is the main excitatory neurotransmitter of the mammalian nervous system and is  
involved in neuronal plasticity, memory and learning. 
Emerging evidences suggest that glutamate is also present in peripheral tissues, where it plays 
a role in both cellular homeostasis and in autocrine/paracrine communication as an 
extracellular signalling molecule [Hedigerand Welbourne, 1999; Nedergaard et al., 2002].  
The extracellular glutamate concentration is tightly controlled by high affinity glutamate 
transporters, whose expression and modulation in the peripheral tissues have been poorly 
investigated. In this work we analyse the high affinity glutamate transporters EAAC1 and 
GLT1 in epithelia and endocrine pancreas, respectively. 
 
EAAC1 was cloned from rabbit intestine [Kanai and Hediger, 1992] and its expression and 
function have been well characterised in absorptive epithelia, such as intestine and kidney, 
where it represents the major transporter for the dicarboxylic amino acids [Peghini et al.,  
1997]. Less is known about the molecular mechanisms that regulate its surface expression and 
activity.  
During the past few years, it has become clear that the activity of these transporters can be 
rapidly regulated by redistribution of proteins to and from the plasma membrane: a process 
that can be controlled by dynamic protein-protein interactions. 
Therefore, the research presented in the chapter II focuses on the molecular mechanisms  
which regulate EAAC1 trafficking in epithelial cells. EAAC1 has a conserved sequence 
present in the C-terminal domain of EAAC1, that mediates interactions with class I PDZ 
proteins. In the past years, we demonstrated that the PDZ-target sequence and PDZ proteins 
are responsible for the retention and stability of EAAC1 at the plasma membrane [D’Amico et 
al., 2010]. 
The aim of the present work is to verify whether this PDZ-target sequence is also important 
for the transporter’s biosynthetic delivery. 
Our data indicate that PDZ interactions occur early in the biosynthetic pathways and are 
involved in the ER-to-Golgi trafficking, as well as in Post-Golgi trafficking of EAAC1. 
Removal of the PDZ motif delays rather than prevents the ER export and the plasma 
membrane delivery of the transporter, thus indicating that PDZ interactions facilitate the ER-
Golgi trafficking. Possibly, PDZ-interactions favour the transporters homo-oligomerization, a 
process required for the efficient ER export of EAAC1. Alternatively, PDZ domain-proteins 
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may couple EAAC1 with protein complexes required for the efficient fusion of carrier 
vesicles to the appropriate target membranes. Further studies will be needed to identify the 
PDZ protein/s involved in the EAAC1 biosynthetic delivery. 
 
On the other hand, the presence of glutamate as an intercellular signal mediator in endocrine 
pancreas is well established [Moriyama and Hayashi, 2003]. In the Central Nervous System 
(CNS), glutamate may cause cell death by excitotoxicity, that is physiologically prevented by 
glutamate clearance systems [Choi et al., 1988]. The effect of glutamate on islet viability, the 
expression of glutamate transporters and their physiological roles in the endocrine pancreas  
are still unclear. 
Thus, in the III chapter we examine the effects of glutamate and the function of sodium 
dependent glutamate transporters in clonal β-cells and in human isolated islets of Langerhans. 
We demonstrate that exposure to elevated glutamate concentrations induces a significant  
cytotoxic effect in pancreatic β-cells, due to the prolonged activation of ionotropic glutamate 
receptors. We provide evidence that the key regulator of the extracellular glutamate clearance 
in the islet is the glial glutamate transporter 1 (GLT1/EAAT2). GLT1 is the only high affinity 
glutamate transporter expressed in the islets and localizes to the β-cell plasma membrane. 
Finally, as diabetes is characterized by selective beta-cell death, and our data indicate that 
GLT1 controls beta-cell survival, we investigate the expression of GLT1 in type 2 diabetes  
mellitus (T2DM) patients. We show an altered GLT1 localisation in pancreases from T2DM 
patients, suggesting a decreased glutamate clearance ability in these subjects. 
 
In chapter IV, is reported the experience at University of Texas Health Science Center at San 
Antonio (UTHSCSA), USA. The aim of this project is to find interactors of IAPP, a protein 
involved in diabetes, by means of Yeast Two Hybrid Screening, a technique which allows the 
identification of direct protein-protein interactions. In prospect, this technique will be useful 
to find proteins that are associated with glutamate transporters and that potentially regulate 
their expression and function. 
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CHAPTER I: General Introduction 
 
Glutamate has been traditionally characterised as an excitatory neurotransmitter in the 
mammalian nervous system. An increasing number of evidences suggests that glutamate can 
also play a significant role in peripheral tissues, where it can be a central metabolite for 
cellular homeostasis as well as an extracellular signal mediator. 
 
1 GLUTAMATE IN THE CENTRAL NERVOUS SYSTEM 
 
In the Central Nervous System (CNS), glutamate is the major excitatory neurotransmitter, and 
it controls several important functions, such as neuronal plasticity in cognitive tasks, memory 
and learning [Fonnum 1984; Ottersen and Storm-Mathisen, 1984; Collingridge and Lester, 
1989; Headley and Grillner, 1990]. 
Glutamate signalling between cells involves several distinct phase of activity: 
1-Presynaptic neurotransmitter release 
2-Receptor activation 
3-Neurotransmitter uptake. 
In a pre-synaptic cell, glutamate is stored into vesicles, ready for release in response to a 
stimulus. Following vesicular exocytosis, the transmitter diffuses across the synaptic cleft and 
binds to post-synaptic receptors, that are specifically positioned by membrane clustering 
proteins. Receptors activation induces cascades of intracellular activity in the post-synaptic 
cell.  Finally the transmitter is taken up by transporters, which control temporally and spatially 
the glutamate-mediated signalling and allow the transmitter recycling. 
 
 
 
FIG. 1: Glutamate Synapse 
[Skerry and Genever, 2001] 
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1.1 Presynaptic neurotransmitter release 
The cytosolic concentration of glutamate is 5 mM in neurons and around 2-3 mM in 
astrocytes [Fitzpatrick et al., 1988; Osen et al., 1995]. 
As the blood brain barrier has a very low permeability to glutamate, most of the glutamate 
present in the brain is synthesised de novo. Essentially, all glutamate in the brain is  
synthesised by transamination of α-ketoglutarate, in both neurons and glia. In addition, in 
glial cells is expressed glutamine synthetase, an enzyme that converts glutamate to glutamine, 
before it is released into the extracellular space [Fonnum, 1993].  
Then, glutamine is taken up by neurons and converted to glutamate before being packaged 
into synaptic vesicles. Glutamate uptake into the secretory granules is driven by vesicular 
glutamate transporters and represents the rate limiting step for glutamate release. These 
transporters localise to the vesicle membrane and their transport activity depends on 
electrochemical proton gradient across the vesicle membrane generated by H+ ATPase 
[Maycox et al. 1988]. 
 
 
 
FIG. 2: Glutamine-Glutamate cycl e in 
CNS. Glutamate released from the nerve 
terminal by exocytosis is taken up by 
glutamate transporters present 
presynaptically (VI), postsynaptically (I) 
and extrasynaptically in astroglial cells 
(II). Astroglia converts glutamate into 
glutamine. Glutamine is subsequentely 
released from the glial cells by means of 
glutamine transporter (III) and taken up 
by neurons by another glutamine 
transporter (IV). Neurons convert 
glutamine back to glutamate and load 
synaptic vesicles (V) [Danbolt, 2001]. 
 
 
1.2 Receptor activation 
There are two broad categories of glutamate receptors, the ion channel-forming or 
“ionotropic” receptors and the “metabotropic” receptors, coupled to GTP binding proteins (G 
proteins). The ionotropic receptors are further classified into three populations: those 
activated by N-methyl-D-Aspartate (NMDA), those that respond to Kainic acid (KA), and 
those sensitive to a-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). Glutamate 
binding to these receptors promotes channel opening and the entry of cations (Na, K, Ca) into 
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the cell, that induces membrane depolarisation. Ionotropic glutamate receptors are produced 
by the homo- and/or heteromeric combination of different subunits, whose composition 
determines the selective conductances.  
Metabotropic glutamate receptors have seven membrane spanning domains and can be 
expressed in both pre- and post-synaptic membranes. These receptors are subdivided into 
three groups based on sequence information and intracellular effectors systems. Group I 
receptors (mGluI and mGlu3) are coupled to Phospholipase C (PLC) and lead to activation of 
Protein Kinase C (PKC) and to an increase in intracellular calcium concentration. Group II 
receptors (mGlu2 and mGlu5) and Group III receptors (mGlu4, mGlu6, mGlu7, mGlu8) 
initiate the inhibitory cAMP cascade, through adenilate cyclases (AC). 
The intracellular signals generated by activation of the ion channels and the effects of the 
receptors on PLC and AC enzymes are determined by the different intracellular environments  
in which these receptors operate [Michaelis, 1998]. 
 
1.3 Neurotransmitter uptake 
Responsible for most of the glutamate uptake in the brain, high affinity plasma membrane 
glutamate transporters fulfil a crucial role in glutamatergic neurotransmission by removing 
glutamate from the synaptic cleft. 
Glutamate transporters are transmembrane glycoproteins, facing the extracellular environment  
and thus well positioned to regulate extracellular Excitatory Amino Acids (EAA) 
concentrations. 
These transporters maintain the glutamate gradient 10000 fold higher in intracellular (3-10 
mM) than extracellular (0,3- 10 µM) compartments, using the energy available from the 
transmembrane membrane potential and ion gradients to drive their neurotransmitter substrate 
against concentration gradient [Auger and Attwell, 2000]. The transport stoichiometry is such 
that the inward movement of one glutamate, three sodium and one proton is coupled to the 
outward transport of one potassium ion [Danbolt, 2001; Barbour et al.,  1988]. Thus, the 
transport is electrogenic, because it causes a net transport of positive charge inside the cell.  
Recent data indicate the mechanism for transport cycle, that comprises several steps (Fig. 3). 
Under steady state conditions the empty glutamate carrier is in outward-facing mode, with the 
binding sites exposed to the extracellular side. After interaction with 1 molecule of substrate-
/H+ and 3 Na+, the loaded transporter responds with a conformational change, that induces 
closure of an external gate (HP2 domain, Fig. 4), leading to an occluded state. Another 
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conformational change determines the opening of the internal gate (HP1 domain, Fig. 4), 
resulting in the inward facing configuration, with substrate release in the cytoplasm. 
Thereafter, K+ binds to the carrier inside and promotes the relocation of the empty carrier 
[Boudker et al., 2007]. If the transporter does not bind the K+, it can operate in exchange 
mode, binding again sodium and glutamate from the intracellular side [Zerangue and 
Kavanaugh, 1996b]. 
 
 
 
FIG. 3: Glutamate transporters’ transport cycle [Boudker et al. 2007]. 
 
The cycling time of the human glutamate transporter has been estimated to be approximately 
50 ms [Wadiche et al. 1995], which is significantly slower than the rate of synaptic glutamate 
release. Thus, the emerging view is that when carriers are present at a high density, they may 
serve as glutamate binding sites, thus limiting neurotransmitter actions on receptors [Seal and 
Amara, 1999]. 
Glutamate binding rapidly reduces the extracellular glutamate concentration and slows down 
the diffusion of the neurotransmitter away from the release site. However, this mechanism 
could lead to a paradoxical effect: given that the bond is reversible, glutamate may re-enter 
the cleft, upon unbinding from the transporters [Rusakov and Kullmann, 1998].  
The traditional view is that transporters are important for neurotransmitter clearance and 
glutamate recycling after vesicular release. 
However, the presence of EAATs in non-glutamatergic systems suggests that they could have 
also metabolic functions. Indeed, in GABAergic neurons, glutamate uptake can provide the 
substrate for the intracellular production of GABA or in Dopaminergic neurons transporters 
may carry cysteine, a fundamental building block for glutathione [Seal and Amara 1999]. 
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There is also evidence that transporters may be more important for prevention of glutamate 
spillover onto extrasynaptic receptors and crosstalk to neighbouring neurons, rather then 
simply controlling the duration of the EPSCs (Excitatory Post Synaptic Currents) [Overstreet 
et al., 1999; Rusakov et al., 1999].  
 
Astrocytes and neurons express high affinity, sodium dependent excitatory amino-acid 
transporters, belonging to SLC1 family. They are classified in five different subtypes, 
including: glutamate aspartate transporter (GLAST/EAAT1), glutamate transporter 1 
(GLT1/EAAT2), excitatory amino acid carrier (EAAC1/EAAT3), EAAT4 and EAAT5.  
Family members share 40% to 65% of sequence identity and a common structure, as 
hypothesized from the crystallised prokaryotic analogous [Yernool et al.,  2004]. In figure 4 is  
shown the transporter structure, with intracellular N and C terminal tails, 8 transmembrane 
loops and two re-entrant hairpin loops (HP1 and HP2), that partially span the phospholipidic 
bilayer. The sodium and substrate binding sites are defined by the 8th transmembrane domain 
and the two re-entrant loops.  
 
 
 
FIG. 4: (a) Sketch represent ation of the hypothetical membrane spanning domains in high affinity glutamate 
transporters. (b) Tridimensional representation of predicted domains.  [Torres and Amara, 2007] 
 
These glutamate transporters display heterologous regional and cellular expression profiles 
[Nakayama et al., 1996]. 
The two astrocytic glutamate transporters GLAST and GLT1 display a 65% identity of the 
amino acid sequences and are present in the same cells. Indeed, both GLAST and GLT1 
localise to astrocytes, with a predominant expression of GLAST in Bergmann glia in the 
cerebellum and GLT1 in astrocytes in the cortex and forebrain [Rothstein et al., 1994]. More 
recent studies indicate these two glutamate transporters are expressed in a subgroup of 
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neurons. These transporters are believed to sequester the majority of extracellular glutamate 
released from neurons. More detailed studies have uncovered that GLT1 and GLAST 
expressions are not restricted to the central nervous system alone (see below). 
EAAC1 localise to neurons throughout the CNS and is particular abundant in glutamatergic 
neurons of the cortex (layers II-IV), striatum and hippocampus (pyramidal cells of the CA2-
CA4 regions), and in the granular layer of cerebellum (purkinje cells) [Bar-Peled et al.,  1997]. 
Interestingly, among all the SLC1 members, EAAC1 is the transporter mainly expressed and 
characterized in peripheral tissues [Kanai and Hediger, 1992, Mukainaka et al., 1995]. 
EAAC1 is also able to transport L-Cysteine, with an affinity constant of 190 µM and a 
maximal rate flux similar to that of glutamate. Cysteine not only competes with L-glutamate 
uptake but also causes transporter-mediated release of transmitter by heteroexchange, leading 
to elevated extracellular glutamate concentrations [Zerangue and Kavanaugh 1996].  
It has been hypothesised that following oligomeric assembly, EAAC1 can also operate in the 
chloride channel mode [Eskandari et al., 2000]. 
EAAT4 is predominantly expressed in cerebellar Purkinje cells on postsynaptic dendritic 
spines [Nagao et al., 1997]. It shows also an uncoupled chloride conductance associated with 
substrate transport.  
EAAT5 is primarily expressed in the retina [Arriza et al.,1997]; it is associated with rod 
photoreceptors and some bipolar cells and exhibits a high chloride conductance, that may 
participate in visual processing. 
1.3.1 Glutamate mediated excitotoxicity 
Glutamate can cause neuronal cell death due to its excessive accumulation and subsequent 
overstimulation of ionotropic receptors. The mechanism described involves cell swelling and 
disintegration [Choi et al., 1988]. 
The extracellular glutamate concentration has been estimated around 1-2 µM, but it can 
increase in many pathological conditions that are characterised by defect in the blood brain 
barrier and/or by cellular damage, such as stroke, trauma, multiple sclerosis and meningitis  
[Auger and Attwell, 2000]. Also astrocytes can release glutamate in response to molecules  
such as prostaglandin E, ATP, glutamate and bradikinin [Parpura et al.,  1994; Bezzi et al.,  
1998; Jeremic et al., 2001]. Finally, sodium-dependent glutamate transporters can release 
glutamate when they operate in reverse mode and also the cysteine-glutamate exchanger xc- 
can contribute to this release [Barbour et al., 1988; Rossi et al., 2000; Warr et al., 1999]. 
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Glutamate transporters are important to prevent neurotoxicity mediated by glutamate. Glial 
but not neuronal glutamate transporters are critical to maintain extracellular glutamate below 
toxic levels [Kanai and Hediger 2004]. 
Consistent with the role of GLT1 in neuroprotection, GLT1 knock out mice revealed selective 
neuronal degeneration in the hippocampal CA1 region [Tanaka et al., 1997]; GLAST knock 
out mice develop normally but they exhibited motor dis-coordination during difficult tasks, 
consistent with abnormality in the cerebellum, where it is mainly expressed [Watase et al.,  
1998].  
On the other hand, knock out mice for the neuronal transporter EAAC1 develop normally and 
have a regular motor coordination, showing no apparent neurological disorders, but a 
decreased spontaneous locomotory activity  [Peghini et al., 1997]. 
Interestingly, a reduction in the expression and function of glutamate transporters has been 
detected in several neurodegenerative diseases, thus indicating that they may be involved in 
the onset and progress of neurodegeneration. 
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2 GLUTAMATE IN PERIPHERAL TISSUES 
An increasing number of evidence suggests that glutamate serves for important functions also 
outside the CNS. In particular, glutamate can play a dual role in peripheral tissues: the first in 
cellular homeostasis and the second as an extracellular signal mediator, in autocrine and 
paracrine systems. Consequently, also the glutamate transporter function can be extended to 
the regulation of cellular metabolism and organ homeostasis as well as to cell signalling 
within non-excitable cells. Accordingly, the localisation of GLAST, GLT1 and EAAC1 in 
peripheral tissues is not only associated with nerve terminals, suggesting that they fulfil 
additional roles in these organs. 
 
2.1 Cellular and organ homeostasis 
Glutamate outside the CNS is present at millimolar concentrations in the cytosol of most cell 
types. At cellular level, glutamate contributes to the production of several important 
molecules, including proteins, nucleic acids, glutathione, polyamines and aminosugars. In 
addition, it has important roles as an intermediate metabolite (figure 5) [Newsholme et al.,  
2003]. 
Transamination of ketoglutarate, an intermediary of the citric acid cycle, produces glutamate, 
whereas glutamine is synthesised by incorporation of an ammonium ion into glutamate. The 
two enzymes that catalyse these reactions, glutamate dehydrogenase and glutamine 
synthetase, are present in almost all life forms [Nedergaard et al., 2002]. 
Glutamate and glutamine act as nitrogen exchanging factors, and they are involved in the 
acid-base homeostasis, both at cellular and at organism level.  
The normal arterial glutamate concentration is 10-30 µM, which is similar to the Km of the 
high affinity transporter, thus indicating that the activity of the transporters may be 
determinant for glutamate/glutamine inter- and intra-organ fluxes. 
The source of circulating L-glutamate is not dietary intake but the liver, where glutamate 
transporters facing the sinusoidal capillaries release glutamate produced from glutamine in a 
reaction catalysed by the phosphate dependent glutaminase (PDG). Glutamate generated by 
these upstream periportal hepatocytes is in part captured by glutamate transporter activity 
(maybe GLT1) in the downstream perivenous hepatocytes, coupled with glutamine synthesis 
and release, supporting an inter-organ glutamine flux. 
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EAAC1 present in muscles and lung takes up glutamate coupled to glutamine synthesis, 
reinforcing the interorgan glutamine flux. 
 
 
 
FIG. 5: Role of glutamate as a key metabolite [Nedergaard et al., 2002]. 
 
 
 
FIG. 6: Interorgan and intraorgan 
glutamate fluxes. Organs showing net 
glutamate rel ease or upt ake are shown as 
open circles with + or -, respectively. 
Organs with high unidirectional uptake but 
not removal are shown as empty open 
circles. Liver heterogeneity is presented by 
periportal (pph) or perivenous (pvh) 
hepatocytes and in renal  tubule, proximal 
convoluted (S1) and straight (S3) are 
shown.  
Double-arrowed dotted lines  represent 
bidirectional fluxes. 
Gln: glutamine 
GSH: glutathione 
PIG: Phosphate independent but 
bicarbonat e dependent glutaminase 
PDG: Phosphate dependent glutaminase 
GS: Glutamine synthetase 
ALT: Alanine aminotransaminase 
BBB: Blood Brain Barrier 
LSGT: Low affinity transporter 
HSGT: High affinity transporter 
 
[Hediger and Welbourne, 1999] 
 
In renal tubules, glutamate transport and glutamine hydrolysis are physically and functionally 
coupled. Low and high affinity sodium dependent glutamate transporters are present in the 
different membrane domains of epithelial cells: the high affinity EAAC1 is distributed along 
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the apical brush border, increasing in density from early to late proximal tubule, whereas  
another transporter subtype is present on the basal membrane.  
In the renal lumen, the distribution of the apical membrane EAAC1 overlaps the expression of 
Phosphate independent, but bicarbonate dependent glutaminase (PIG), that catalyses 
glutamine hydrolysis to glutamate. Together with γ-glutamil-transferase, PIG and EAAC1 
form a functional unit that not only regulates glutamine metabolism, but it also controls 
paracellular permeability. 
Moreover, it has been hypothesised that this functional unit produces three intracellular 
signals: (I) changes in intracellular glutamate concentration; (II) Localised increase in ADP, 
which stimulates glycolysis and ATP production; (III) intracellular rise in H+ concentration, 
resulting from the transport of glutamate and protons into the cell [Welbourne and Matthews 
1999].  
GLAST is expressed in basolateral membranes of the transitional epithelium in kidney, where 
it may be involved in glutamate homeostasis. Its role is likely related to the uptake of 
glutamate from the blood side into the epithelial cells for sustenance. Together with the 
glutamate transporter EAAC1, GLAST likely contributes to the inter-organ glutamine flux.  
In kidney, these transporters cooperate for the reabsorption of most amino acids that are 
filtered at the glomeruli, thus leaving only small amounts excreted in the final urine.  
The first third of the proximal convoluted tubule is responsible for the reabsorption of >90% 
of filtered glutamate by a low-affinity high-capacity transporter, that has not been cloned yet. 
EAAC1 will participate in the final recovery of di-carboxylic amino acids that may escape the 
early part of the tubule [Shayakul et al., 1997].  
Moreover, an old study supports a role of EAAs in hepatic and renal gluconeogenesis  
[Heitmann and Bergman, 1981]. 
 
2.2 Glutamate signalling in peripheral tissues 
Recent studies indicate that in non-neuronal tissues, cytosolic glutamate represents also a 
potential transmitter pool with signalling functions. Indeed it has been suggested that 
glutamate may act in autocrine and paracrine systems, such as pancreas, bone, stomach, 
intestine, liver, lung and kidney [Skerry and Genever, 2001; Danbolt, 2001; Rzeski et al.,  
2001]. 
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In general, peripheral cells are not specialized to transmit electrical signals, thus rapid 
membrane currents evoked by glutamate might be less effective than long term effects on 
intracellular messengers.  
To fulfil signalling functions, peripheral tissues should express the necessary machinery for 
glutamate signal transduction, as happens in the CNS: vesicles storage systems, functional 
receptors and plasma membrane transporters. 
2.2.1 Glutamate storage into synaptic vesicles 
The detection of VGLUTs in non-neuronal peripheral tissues has been used to demonstrate 
the presence of peripheral glutamatergic paracrine/autocrine systems [Moriyama and Omote, 
2008]. 
These vesicle transporters are widely distributed in Peripheral nervous system (PNS), such as  
in the retina [Fremeau et al., 2002; Mimura et al., 2002], trigeminal ganglion [Li et al.,  2003], 
dorsal root ganglia (DRG) [Olivera et al., 2003; Li et al., 2003], intraganglionic laminar 
endings (IGLEs) of esophagus [Rabb et al., 2003] and enteric neuron [Tong et al., 2001]. 
Interestingly, their expression is also extended in various non neuronal tissues such as bone 
cells, pancreatic islet cells and pineal cells [Skerry and Genever, 2001].  
It was found that pineal SLMVs contain both VGLUT1 and 2, as revealed by biochemical,  
immunohistochemical and electronmicroscopical evidence [Morimoto et al., 2003]. 
The same approaches indicated the presence of both VGLUT1 and 2 in glucagon-containing 
secretory granules of α cells, suggesting that L-glutamate is co-secreted with glucagon upon 
low glucose stimulation [Hayashi et al., 2003]. Vesicular transporters are also expressed in F 
cells, and are associated with pancreatic polypeptide-containing secretory granules, 
suggesting that F cells are also glutamatergic, and that pancreatic polypeptides and L-
glutamate are co-secreted [Hayashi et al., 2003b]. By contrast, neither VGLUT1, 2 nor 3 are 
expressed in β and δ cells, thus these cells can not be considered glutamatergic cells  
[Moriyama and Hayashi 2003]. 
In the gastrointestinal tract, L cells, that secrete glucagon-like peptide 1 (GLP-1) and 
polypeptide YY (PYY), express VGLUT2 in secretory granules [Hayashi et al.,  2003]. The 
stomach mucosa, especially the antrum and pylorus regions, contains VGLUT2. 
Also in bone vesicular glutamate transporters have been identified, but there are some 
discrepancies regarding the isoform expressed in osteoblasts, as some groups have detected 
VGLUT1 and other VGLUT2 [Hayashi et al., 2003; Hinoi et al.,  2002; Redecker et al.,  
2003].  
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2.2.2 Glutamate receptors 
Glutamate receptors (GluRs) are widely expressed outside the CNS by cells that have not 
been traditionally associated with glutamate mediated signalling.  
Some of the peripheral glutamate receptors have been cloned and sequenced and seem to be 
identical to those involved in neurotransmission [Gill and Pulido 2001]. However, it is likely 
that rapid excitatory currents are less important in non-excitable cells, whereas long term 
effects on membrane potential, cytosolic calcium levels and second messenger system might  
be more relevant. 
Moreover, the glutamate concentration outside the brain is higher than its receptor affinity. It 
has been hypothesised that post-translational modifications, such as glycosylation or 
phosphorilation, might reduce the affinity of glutamate receptors in peripheral tissues, 
compared with receptors in the CNS [Gill and Pulido 2001].  
Studies of the distribution of radiolabelled glutamate receptor binding agents revealed 
significant binding in the spleen, bone, pancreas, lung, heart, liver, kidney and intestine 
[Samnick et al., 1998; Nasstrom et al., 1993]. 
The table below summarizes the glutamate receptors subtypes found in peripheral tissues, 
together with the proposed function in the particular environments.  
 
Glutamate receptors expressed Tissue/Cell Type NMDA AMPA Kainate Metabotropic Proposed function 
Astrocytes - + + + Neuron-Astrocytes communication 
Cerebral 
Endothelium + + - + Unknown 
Osteoblasts + + - + Modulate differentiation and bone-forming activity 
Osteoclasts + - - - Modulate differentiation and resorption 
Megakaryocytes + - - - Modulate differentiation and maturation 
Platelets + - - - Regulate adhesiveness 
Keratinocytes + + - + Regulate differentiation 
Melanocytes - - - + Control proliferation and cytotoxicity 
Merkel cells ? ? ? - Mechanosensation 
Pancreas + + + + Regulate hormone secretion 
Lung + - - - Provoke edematous lung injury? 
Ileum + - - + Modulate contractili ty 
Hepatocytes - - - + Protect from hypoxic injury 
Heart + + + + Modulate cardiac function 
Thymus - - - + Unknown 
Kidney + - - - Cytoprotective 
Adrenal gland + - - - Unknown 
Taste buds ? - ? + Sense umami taste 
 
TABLE 1: Tissue distribution and function of glutamate receptors [Skerry and Genever, 2001]. 
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The localisation of GluRs to specific structures in peripheral tissues hints at their importance 
in the control of cellular homeostatic mechanisms, cell differentiation, excitability, cell injury 
and metabolism [Rockhold et al., 1989; Said, 1999; Said et al.,  1996]. Their presence in 
several endocrine organs, such as pancreas, pituitary, testis, and kidney, implicates these 
receptors in the regulation of hormone secretion [Inagaki et al., 1995].  
In the stomach, glutamate modulates histamine-induced acid secretion in rats and glutamate is  
also able to mediate contractility in the gastric fundus, jejunum, ileum and large intestine 
[Tsai et al., 1999, Shannon and Sawyer, 1989]. 
Expression of various glutamate receptors has been reported in testes, suggesting the 
occurrence of glutamatergic system [Gill et al.,  2000; Storto et al., 2001]. Indeed, GluR5 and 
KA1, the functional units of kainate receptors, are both expressed and present in the inner 
acrosomal membrane, where glutamate is also stored, suggesting an intracrine signalling [Re, 
2002]. 
Pinealocytes express metabotropic glutamate receptor types 3 and 5, and AMPA type 
ionotropic receptors [Moriyama et al., 2000; Yatsushiro et al., 2000]. Stimulation of mGluR3 
causes inhibition of melatonin synthesis through an inhibitory cAMP cascade. 
Ionotropic and metabotropic glutamate receptors have been found in lingual tissues and are 
responsible for sensing the umami taste, the taste deriving from monosodium glutamate 
[Monastyrskaia et al., 1999; Sako and Yamamoto, 1999].  
Glutamate receptors can also act as mediators of injury or inflammation [Said 1999; Said et 
al., 1996; Lipton and Rosenberg, 1994] and peripheral tissues containing GluRs are also 
potential target sites for excitotoxicity.  
In general, sustained activation of peripheral NMDA and AMPA receptors does not mediate 
excitotoxic cell death. A probable explanation is that both the depolarization and the increase 
in intracellular calcium levels in response to glutamate may be only transient in these tissues. 
However, it has been reported a case of peripheral excitotoxicity in the lung [Said et al.,  
1996]. 
In the lung, receptor expression has been demonstrated and glutamate has been shown to 
induce excitotoxic changes that are inhibited by receptor antagonists. Furthermore, NMDA 
alters hypoxic pulmonary vasoconstriction in isolated perfused rat lung [Said et al., 1996]. 
Also in the liver, mGlu5 receptors are expressed by hepatocytes and may be involved in 
hypoxic injury [Storto et al., 2000]. 
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2.2.3 Glutamate transporters 
Glutamate levels in blood and other fluids are tightly controlled around 30-80 µM [Meldrum, 
2000]. Most organs, including the kidneys, intestine, lungs, muscles and liver, express highly 
efficient glutamate transport systems. The high capacity of the peripheral glutamate 
transporters is exemplified by the observation that continuous intravenous infusion of 
glutamate causes only a transient elevation of the plasma concentration of the amino acid 
[Hanley and Varelas, 1999]. 
Amino acid transporters have been involved in protein synthesis, regulation of cellular 
metabolism, production of metabolic energy, cell growth, cell volume regulation, nerve 
transmission, and absorption of amino acids from the lumen in polarised epithelia. 
 
 
 
FIG. 7: Potential mechanisms of signal transduction mediated by amino acid transporters  
[Hyde et al., 2003]. 
 
In addition to a traditional role in amino acid transport, transporters may function as amino 
acid sensors. Direct and indirect mechanisms have been hypothesised for the sensing of amino 
acids levels (Fig. 7). Transporters may undergo conformational changes (Fig. 7A) or their 
activity may change pH or membrane potential (Fig. 7B). They may also regulate external 
amino acid concentration and consequent receptor activation (Fig. 7D). Alternatively, they 
may control amino acid access to intracellular receptors mechanism (Fig. 7 C) [Hyde at al.,  
2003; Kwon, 2004]. 
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Sodium dependent glutamate uptake systems have been identified in the following 
tissues: 
 
Intestine:  
In intestine, dietary proteins are absorbed in the form of small di-tri-peptides and individual 
amino acids, resulting from enzymatic breakdown. Thus, glutamate transporters serve for 
intestinal absorption of acidic amino acids, a sort of “nutritional uptake”. 
EAAC1 was first cloned from rabbit intestine [Kanai and Hediger 1992]. Its highest  
expression is in small intestine mucosa, but it is also present in neurons of the enteric nervous  
system, where it can cooperate in signal transmission. 
 
Kidney: 
Most amino acids, including EAA, are filtered by the kidney and reabsorbed via specialised 
transport system in the tubuli, so that most of the filtered amino acids are recovered from the 
final urine. The amino acids reabsorption is mainly mediated by Na/K coupled amino acid  
transporters, situated on the apical membrane and basolateral membrane of the epithelial cells  
[Kanai et al., 2000]. 
 
 
 
FIG. 8: Trans-epithelial transport of amino acids in the renal tubule [Kanai  
et al., 2000] 
 
For EAAs uptake, EAAC1 is present in the apical membrane of proximal tubules, in 
particular in S2-S3 segments and to a less extent in S1, suggesting that an additional 
glutamate transporter probably exists in the kidney [Kanai and Hediger 2003].  
EAAC1 is an important regulator of kidney metabolism, acid-base balance and osmolar 
homeostasis. The importance of EAAC1 for the functioning of the kidney is evident from 
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studies with EAAC1 knock out mice: they develop dicarboxilic aminoaciduria, an increased 
EAA renal excretion, consisting in 1400 fold for glutamate and 10 fold for aspartate. All other 
amino acids are excreted in comparable amounts and other renal amino acid transporters do 
not compensate for the loss of EAAC1 function [Peghini et al., 1997]. 
GLAST mRNA and protein were found in the transitional surface epithelium of the renal 
pelvis and in the macula densa portion of the distal convoluted tubules.  
GLT1 mRNA has also been detected in the kidney, but no significant expression of GLT1 
protein was observed [Berger and Hediger, 2006] . 
 
Pancreas: 
Hormone secretion in the endocrine pancreas is not a simple response to glucose and other 
nutrients: the endocrine cells express several receptors for neurotransmitters, including 
acetylcholine, GABA and glutamate [Molnar et al., 1995; Weaver et al., 1996, Liu et al.,  
1997]. 
The role of glutamate in the pancreas was first suggested in 1992, in studies using a perfused 
pancreas model where insulin secretion was abolished by infusion of AMPA receptor 
antagonist [Bertrand et al., 1992]. 
It has been hypothesised that glutamate may act as an intracellular messenger in beta cells  
[Maechler and Wollheim, 1999]. If true, glutamate transporters may be directly involved in 
the modulation of insulin release.  
A glutamate transporter similar to GLT1 has been cloned from pancreas [Manfras et al.,  
1994], however cellular localisation of this transporter is still unclear. The only finding in 
isolated islets incubated with D-aspartate, showed sodium dependent accumulation almost  
exclusively in cells at the islet periphery, supposed to be alpha cells [Weaver et al., 1998]. 
 
 
 
FIG. 9: Glutamate signalling in pancreas. In 
the islet of Langerhans, functional GluRs, 
which could modulate secretion of hormones,  
are identi fied in α cells [AMPA receptors, KA 
receptors and mGluRs), in β cells (AMPA 
receptors), and in δ cells (KA receptors),  
respectively. High affinity Glu transporters and 
VGLUTs are also expressed in the islet. 
 
[Hinoi et al., 2002] 
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Heart: 
Amino acids, and in particular glutamate, aspartate, glutamine and alanine, play important 
roles in the metabolism of heart myocytes. During ischemia, glutamate infusion improves the 
mechanical function of the myocardium. 
GLAST and EAAC1 mRNA have been detected in the heart [Nakayama et al., 1996]. 
 
Placenta:  
This important tissue has a primary role in the life of a foetus, secreting hormones and 
providing nutrients and oxygen.  
GLAST, GLT1 and EAAC1 have been identified in the placenta, but the interesting aspect is 
that while placenta supplies the foetus with most of the amino acids, it removes glutamate 
from the foetal circulation [Schneider et al., 1979]. Since the blood brain barrier is incomplete 
in foetus, glutamate removal may be important for normal brain development and can provide 
a protection mechanism. 
 
Mammary Gland: Only GLAST and GLT1 are expressed in the lactating mammary gland 
[Martinez-Lopez et al., 1998]. 
 
Bone: 
Glutamate may be one of the endogenous paracrine/autocrine factors used for intercellular 
communication in bone cells. NMDA receptors appear to be involved in the process of bone 
formation [Dobson and Skerry, 2000]. 
Osteoblasts and osteoclasts within the bone cortex express the GLAST glutamate transporter, 
whereas mononuclear marrow cells express the GLT1 [Espinosa et al., 1999]. 
 
Skin:  
Keratinocyte differentiation might be regulated by glutamate communication pathway. There 
is also evidence that other non-keratinized cells that reside within the epidermis, as 
melanocytes, also use glutamate as a signalling molecule [Frati et al.,  2000]. It has been 
proposed that a sub-epidermal source of glutamate might be involved.  
A high level of expression of glutamate transporters has been demonstrated in basal epidermal 
keratinocytes, and also dermal fibroblasts express functional glutamate transporters, GLAST 
and GLT1 [Cooper et al., 1998]. 
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AIM OF THE THESIS 
 
Glutamate is known as an excitatory neurotransmitter in the mammalian nervous system. 
Emerging evidence suggests that glutamate is also present in peripheral tissues, where it can 
play a dual role: the first in cellular homeostasis and the second as an extracellular signal 
mediator, in autocrine and paracrine systems. Relatively little attention has been paid to the 
functional expression of molecules required for glutamate signalling (receptors, plasma 
membrane and vesicular transporters) in peripheral non-neuronal tissues.  
Given the crucial roles of glutamate transporters in the different peripheral tissues, it can be 
significant to analyse their functional expression in those environments. 
In particular, in this work we analyse the two high affinity glutamate transporters EAAC1 and 
GLT1. 
 
EAAC1 is present in the renal tubule, where it mediates acidic amino acid reabsorption and 
regulates acid-base homeostasis. Recent studies indicate that protein-protein interactions and 
intracellular trafficking represent an important mechanism to regulate transporter activity at 
the plasma membrane. Therefore, our studies focus on EAAC1 trafficking in epithelial cells  
(Chapter II). 
 
On the other hand, the role of glutamate as an intercellular signal mediator in endocrine 
pancreas is established, while the effect of glutamate on islet viability, the expression of 
glutamate transporters and their physiological functions in the endocrine pancreas are still 
unclear. In this study we examine the effects of glutamate and the function of the sodium 
dependent glutamate transporter GLT1 in islet cell models and in isolated islets of Langerhans  
(Chapter III). 
 
In chapter IV, is reported the experience at University of Texas Health Science Center at San 
Antonio (UTHSCSA), USA. The goal of this project is to find out interactors of IAPP, a 
protein involved in diabetes, by means of Yeast Two Hybrid Screening, that allows the 
identification of direct protein-protein interactions. In prospect, this technique will be a tool to 
find proteins associated with glutamate transporters. 
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CHAPTER II: Role of PDZ-mediated interactions in 
EAAC1 biosynthetic delivery in epithelial cells 
 
1 ABSTRACT 
EAAC1 is a high affinity glutamate transporter expressed in neurons and in epithelia. In the 
Central Nervous System (CNS), EAAC1 controls synaptic transmission and it is involved in 
long term potentiation (LTP) in memory and learning. In absorptive epithelia, in particular in 
intestine and kidney, EAAC1 is the major transporter for the dicarboxylic amino acid uptake, 
as shown by the fact that EAAC1 was first cloned from rabbit intestine [Kanai and Hediger, 
1992] and EAAC1 knock out mice develop dicarboxylic aminoaciduria, a disease 
characterized by increased glutamate and aspartate excretion in urines [Peghini et al., 1997]. 
In order to be functional, the transporter must be expressed at the plasma membrane, thus 
alterations of its delivery to or retention in the plasma membrane may be involved in 
aminoaciduria. 
Aim of this work is to study trafficking of the high affinity glutamate transporter 
EAAC1/EAAT3 in epithelial cells. 
Studies performed in the recent years indicate that the surface expression of EAAC1 is 
controlled by associated proteins that remain to be investigated. 
We have focused our attention on a conserved sequence present in the C-terminal domain of 
EAAC1, that mediates interaction with class I PDZ proteins. PDZ-based interactions and the 
PDZ protein network ensure that the membrane proteins are correctly delivered to and 
efficiently retained at the cell surface. 
In the past years, we demonstrated that the PDZ-target sequence and therefore PDZ proteins 
are responsible for the retention and stability of EAAC1 at the plasma membrane. Indeed, 
removal of this sequence causes the transporter relocalisation from the surface to endocytic 
compartments [D’Amico et al., 2010]. 
In this work, we aim at demonstrating whether this PDZ-target sequence is important also for 
biosynthetic delivery of the transporter. 
Our data indicate that PDZ interactions occur early in the biosynthetic pathways and are 
involved in the ER-to-Golgi trafficking, as well as in Post-Golgi trafficking of EAAC1. 
Removal of the PDZ motif delays rather than prevents the ER export of the transporter, thus 
indicating that PDZ interactions facilitate the ER-Golgi trafficking. Possibly, PDZ-
interactions favour the transporters homo-oligomerization, a process required for the efficient  
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ER export of EAAC1. Alternatively, PDZ domain-proteins may couple EAAC1 with protein 
complexes required for the efficient fusion of carrier vesicles to the appropriate target 
membrane. 
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2 INTRODUCTION 
2.1 Epithelia 
A primary function of epithelial cells is to provide tissue compartmentalization, determining 
an interface with the external environment, while supporting specialized functions internally.  
To establish defined boundaries, cells that cover the external surface and line internal 
compartments must form barriers to prevent unrestricted exchange of materials.  
The plasma membranes of these cells effectively prevent most hydrophilic solutes from 
crossing the boundary, but also the paracellular pathway between cells is sealed by the 
junctional complexes. Tight junctions seal the paracellular pathway, the adherens junctions 
and desmosomes provide the strong bonds necessary to maintain cellular proximity and allow 
tight junction assembly. Adherens junctions are also critical for epithelial polarization and 
differentiation. Gap junctions are cell-cell contacts that provide cellular communication. 
 
 
 
FIG. 1: Schematic representation of an epithelium. The apical,  
lateral and basal domains are indicat ed. The junctional complexes 
are shown. 
 
The deriving absolute barrier would prevent any communication with the external 
environment, at least via the paracellular pathway. For this reason, the boundaries formed by 
epithelia are essential for life, but this tissue must be also selectively permeable to ensure the 
correct composition of, and transport between, distinct compartments. 
This is particularly true in the absorptive epithelia, such as intestine and kidney, where the 
epithelial barrier supports molecule transport while preventing microbial contamination of the 
surrounding tissues. 
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2.2 Epithelia Polarity and Trafficking 
2.2.1 Absorptive epithelia: Intestine and Kidney 
The major function of small intestine epithelium is the absorption of dietary nutrients, water, 
electrolytes and vitamins, while in the kidney the re-absorption of those substances regulates  
and maintains body fluid composition. 
Intestinal absorption or renal re-absorption implies the movement of a solute from the 
intestinal/renal lumen to the blood, passing through the epithelium. This transcellular 
transport is characterised by active or passive movement of solutes and water through cells by 
means of the specific transmembrane transport proteins. To ensure directional transport of 
nutrients across the epithelia, these systems are expressed and targeted to different membrane 
compartments in epithelial cells. As a consequence, these cells exhibit cell-surface polarity, 
which means that their plasma membrane is divided into specialized regions, apical and 
basolateral, that are exposed to different environments and which have a characteristic protein 
and lipid composition.  
The maintenance of tissue polarity and regulation of plasma membrane stability of these 
transporters are fundamental, and are achieved by the highly elaborated cell machinery. 
2.2.2 Epithelia polarity 
In the past years, an increasing number of disease have been shown to involve defective 
targeting and trafficking of proteins. These diseases can be grouped under the name of 
“sorting disorders” and they result from abnormal delivery of functional important proteins to 
the cell surface [Brown and Breton, 2000]. 
The plasma membrane of epithelial cells is divided into subdomains of distinct molecular 
composition: the apical, basal-lateral, and junctional membrane domains (Fig. 1). The apical 
domain of epithelial cells forms a continuous plane at the cell apex, that is specialised with 
microvilli. The apical domain is usually in contact with the external surface of an organism, 
such as developing urine in renal tubule, luminal content in the intestine and secretory 
material in exocrine glands. In contrast, the basolateral surface faces the internal surface of 
the organism, being in contact with the blood circulation and adjacent cells.  
Each domain has specific protein complexes composed of distinct transmembrane, 
membrane-associated and cytosolic compartments. These protein complexes mediate the 
adhesive properties of cells, the formation of the paracellular barrier,  and ensure the vectorial 
solute transport that occurs in absorptive epithelia.  
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The structural and functional polarity of epithelial cells relays on the selective insertion of 
proteins and lipids into distinct plasma membrane domains. Proteins are specifically targeted 
to distinct plasma membrane domains by mechanisms that include an interaction between 
signals within the protein itself (sorting signal) and a cellular sorting machinery which 
recognizes the sorting motif. Formation of these protein complexes is determined in large part 
by interactions of modular protein-binding domains. 
2.2.3 Vesicular transport 
The basic mechanism to transfer proteins between organelles is mediated by carrier vesicles  
that continually bud from one membrane and fuse with other and is driven by protein-protein 
interactions. 
Each vesicle transport reaction can be divided into four essential steps, that include vesicle 
budding, transport, tethering and fusion [Bonifacino and Glick, 2004]. 
 
 
 
FIG. 2: The Four Essential Steps in Vesicle Transport. (1) Budding: coat proteins are 
recruited onto the donor membrane to induce the formation of a vesicle. Cargo and SNAREs 
are incorporat ed into the budding vesicle by binding to coat subunits. (2) Movement: the 
vesicle moves toward the acceptor compartment by di ffusion or with the aid of a 
cytoskeletal track. (3) Tethering: tethering factors work in conjunction with Rab GTPases to 
tether the vesicle to their acceptor membrane. (4) Fusion: the vesicle-associated SNARE and 
the SNARE on the acceptor membrane assemble into a four-helix bundle (trans-SNARE 
complex), which drives membrane fusion and the delivery of cargo. [Cai et al., 2007] 
 
A fundamental element of membrane traffic is vesicle formation, or budding, that is initiated 
by the selection and concentration of cargo proteins within a plasma membrane subdomain. 
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This occurs through interactions between sorting determinants on the cargo protein and 
cytosolic coat components that direct cargo to the forming vesicles [Aridor et al., 1996].  
Protein coats are dynamic structures that are recruited from the cytosol onto donor membrane 
by small GTPases and they deform flat membranes into round buds, which leads to the release 
of the coated vesicle. 
Vesicular transport within the early secretory pathways is mediated by two types of non-
clathrin coated vesicles: COP-I and COP-II [Allan and Balch 1999]. COP-I primary acts from 
the Golgi to the endoplasmic reticulum (ER) and between Golgi cisternae. COP-II mediates  
trafficking from the ER to Golgi [Barlowe et al.,  1994; Letourneur et al., 1994; Waters et al.,  
1991]. 
Clathrin coated vesicles, the first identified [Pears, 1975], are mainly derived from the plasma 
membrane or the Trans-Golgi network (TGN) and are transported to endosomes [Owen et al.,  
2004]. The main adaptors are proteins of AP2 complex. 
Coat recruitment is coupled with the acquisition of SNAREs (SNAP- Soluble N-
ethylmaleimide sensitive-factor Attachment Protein- Receptors) proteins that direct the 
vesicles to their target membranes [Söllner et al., 1993].  
After budding, cargo vesicles are transported to their final destination by diffusion or by 
motor-mediated transport along a cytoskeletal track.  
In particular, vesicles interact with microtubules, by means of the so-called “microtubule 
motors”, dynein and kinesin families [Schroer and Sheetz, 1991]. It has been shown that 
microtubule disruption perturbs the delivery of proteins to the cell surface, and causes a 
marked shift in the distribution of many membrane proteins from their usual surface location 
onto scattered intracellular vesicles  [Brown and Stow, 1996]. In the absence of an intact  
microtubule network, also the exocytic step of the recycling pathway is inhibited, thereby 
causing the same phenotype. Thus, microtubule are involved both in the initial delivery of 
newly synthesised proteins to the cell surface and in the continued maintenance of specific 
cell surface domains. Moreover, not only apical targeting is achieved by microtubules, as it is  
now clear that also basolateral protein trafficking can also involve microtubules [Brown et al.,  
1991; Lafont et al., 1994] . 
Also the actin cytoskeleton may serve as mechanical element that drives and guides vesicles  
movement within the cells [Rogers and Gelfand, 1998]. In addition, the actin cytoskeleton 
may directly concur to cell polarity by anchoring proteins in specific plasma membrane 
domain [Hammerton et al., 1991]. This interaction is usually mediated by cross-linking and 
anchoring proteins such as ankirin and fodrin [Nelson and Hammerton, 1989]. 
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The last step in vesicle-mediated transport is the recognition and fusion of the vesicle with its  
target membrane, that involves the so-called tethering factors and SNAREs. 
Acting upstream of the SNAREs, tethering factors mediate the first point of contact and the 
specificity of vesicle targeting, interacting and working together with coat proteins. Tethering 
is a term used to describe the initial interaction between a vesicle and its target membrane. 
Tethering factors may couple the recognition of a vesicle to the process of vesicle uncoating 
and then bring the vesicles in closer contact with its target compartment [Malsam et al.,  
2005].  
Almost all tethering factors fall into two broad categories: long putative coiled coil proteins 
and multi-subunit complexes. To date, eight conserved complexes have been identified as  
crucial for exocytic and endocytic trafficking events (Fig. 3) [Cai et al., 2007].  
Tethers can be also Rab effectors and Rab exchange factors. Rabs are small GTPases of the 
Ras superfamily that continuously cycle between the cytosol and membranes. Rabs act at  
multiple stages of the exocytic and endocytic pathway, and in their GTP-bound form they 
appear to facilitate the recruitment of tethers to specific locations. 
Tethering factors may actively promote SNARE-mediated membrane fusion by stimulating 
the formation of trans SNARE complexes [Shorter et al., 2002]. 
SNAREs, a family of membrane proteins that are related to three different neuronal proteins: 
sinaptobrevin, syntaxin and SNAP-25. Specific membrane associated SNAREs form a sort of 
lock and key that is activated by selective recognition among these proteins. A SNARE on a 
transport vesicle (v-SNARE) pairs with its cognate SNARE-binding partner (t-SNARE) on 
the appropriate target membrane [Rothman, 1994; Sollner et al., 1993].  
 
 
 
FIG. 3: Tethering complexes that act in the 
secretory and endocytic pathways. Protein 
complexes that play a role in vesicle tethering are 
indicated. TRAPPI acts in  ER-to-Golgi traffic,  
while Dsl 1 operate in the reverse transport. 
TRAPPII has  been implicated in t ransport events  
that take place within the Golgi, and from the 
endosome to the late Golgi. COG has been 
proposed to tether vesicles from the endosome to  
the cis-Golgi. GARP/VFT complex has been 
implicated in traffi c from the endosome to the 
trans-Golgi. The CORVET complex may be 
required for t ethering events between the trans-
Golgi and endosome. HOPS functions between 
the endosome and vacuole and in homotypic 
vacuole fusion. The exocyst complex binds to  
post-Golgi and recycling vesicles at the plasma 
membrane. [Cai et al., 2007] 
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2.2.4 Protein delivery to the plasma membrane 
 
 
 
FIG. 4: Schematic 
representation of 
protein trafficking. 
Protein density at the 
plasma membrane is the 
result of dynamic 
movement to and from the 
plasma membrane. 
 
The correct surface expression of membrane proteins is a multistep process [Mostov et al.,  
2003] involving: 
1- Protein folding and maturation  
2-Export from the ER 
3-Golgi processing 
4-Biosynthetic sorting from the Trans-Golgi Network to the correct plasma membrane 
domain (apical or basolateral) 
5- Anchoring and/or retention at the plasma membrane 
 
1) Protein folding and maturation 
Protein folding and maturation are essential to ensure efficient protein transport through the 
secretory pathway. In eukaryotic cells, newly synthesised transmembrane proteins are inserted 
co-translationally into the endoplasmic reticulum (ER), with the assistance of molecular 
chaperons and folding enzymes [Nickel and Wieland, 1998; Nishikawa et al.,  2005]. These 
enzymes interact with the nascent polypeptide chains and facilitate its folding, 
oligomerization, maturation and post-translational modifications, important for the correct 
protein trafficking.  
Incorrectly folded or incorrectly oligomerized proteins are potentially cytotoxic, and are 
removed by a quality control system [Bychkova and Ptitsyn, 1995; Kim and Arvan, 1998]. 
When mis-folded proteins accumulate in the ER, prolonged ER chaperon binding reduces the 
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concentration of free chaperones, that represents a key step in ER quality control. To cope 
with the resulting ER stress, cells induce the transcription of gene products that facilitate the 
processing of aberrant proteins and that attenuate protein translation. If protein repair by ER 
chaperons is unsuccessful, aberrant proteins are cleared from the ER by a mechanism termed 
ER associated degradation (ERAD) [Brodsky and McCracken 1997; McCracken and 
Brodsky, 2003; Tsai and Rapoport, 2002]. In this process, aberrant proteins are translocated to 
the cytosol and degraded by the ubiquitin-proteasome system. A single point mutation can 
have a dramatic effect on this folding process, as observed for the cystic fibrosis 
transmembrane regulator (CFTR) deleted in position 508 [Brown et al., 1998; Qu et al.,  
1997]. 
In ER compartments, occurs the first modification of proteins after synthesis: the addition of 
mannose-6-phosphate group [Sly and Fischer, 1982]. This sugar residue binds to specific 
mannose-6-phosphate receptors in the Golgi cisternae and causes these proteins to be selected 
for packaging into specific vesicles directed to lysosomes.  
 
 
 
 
 
FIG. 5: Lectin-mediated glycoprotein transport in the 
secretory pathway. After synthesis and N-glycosylation, 
glycoproteins bind to the calnexin and/or calreticulin. Then, 
the glycoproteins are arranged by glucosidase II (GlcII) and, 
if still incompletely folded (white), they are reglycosylat ed by 
GT and re-directed to another cycle of quality control. 
After prolonged residence in the ER, mannosidase I (ER Man 
I) removes one mannose residue. Incompletely folded and 
reglycosylated glycoproteins are targeted to the cytosol and 
degraded by the proteasome. 
Correctly folded proteins (bl ack) are transport-competent and 
some of them (*) may bind to ERGIC-53, which recruits them 
to COPII buds and thereby facilitates transport to the ERGIC. 
In the cis-Golgi, glycoproteins  are either t rimmed to Man5 
prior to reglucosyl ation by Golgi glycosyltransferases, or 
tagged with the lysosomal signal Man-6-P by sequential 
action of phosphotransferase (PT) and phosphodiesterase 
(PD). 
Some glycoproteins escape cis-Golgi trimming but may be 
recognized by VIP36 and recycl ed to the cis-Golgi for another 
attempt. Proteins carrying Man-6-P residues are recognized 
by MPRs in the trans-Golgi and sorted to endosomes via 
clathrin-coated vesicles. 
N-Glycans also serve as signals for Golgi exit and apical 
targeting in epithelial cells. 
 
ECV, endosomal carrier vesicles; EE, early endosome;  LE, 
late endosome; TC, translocation channel. 
[Hauri et al., 2000] 
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2)Export from the ER 
Correctly folded proteins are then ready for the export from the ER. For the ER-to-Golgi 
transport and recycle between the ER and the cis face of the Golgi stack, SNARE proteins are 
also required [Wooding and Pelham, 1998; Banfield et al., 1995; Rowe et al., 1998].  
At the level of the ER, proteins destined for export are thought to become concentrated into 
departing transporter vesicles, while residents of the ER are excluded [Balch et al., 1994], 
indicating the existence of a machinery involved in active packaging of cargo molecules. The 
selection of cargo molecules at this step could be mediated by p24 proteins. 
Cargo might interact with coat components either directly or indirectly via cargo-coat  
receptors. Among these, ERGIC-53 has been described as a mannose-specific lectin that 
constitutively cycles through the early secretory pathway, implicating a role of sorting of 
mannose-containing cargo molecules.  
Simultaneously, retrograde protein transport occurs from the Golgi to ER [Tsai et al., 2002]. 
It is not clear if this retrograde transport involves the intermediate compartment or if proteins 
can be transported directly to the ER. 
The traffic from the ER is mediated by protein-protein interactions, that involve adaptor 
proteins and sequences on the cargo protein. The VMI-motif of GAT1 provides an example of 
a cargo-based motif that specifies export from the ERGIC (ER to Golgi Intermediate 
Compartment) [Farhan et al., 2008]. 
 
3)Golgi processing  
During their transport to the surface, cargo proteins pass through the various cysternae of the 
Golgi apparatus. In mammalian cells, multiple Golgi stacks are linked together to form a 
reticular structure that is actively maintained around the centrosome by interactions with 
microtubules and accessory proteins [Rios and Bornens., 2003]. The cis and trans side of 
these stacks are associated with networks of tubular structures: the cis-Golgi network or 
endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and the trans Golgi 
network (TGN) respectively, representing the cargo entry and exit points [Allan and Balch, 
1999]. 
As cargo moves through the Golgi stack, it is modified by Golgi-associated processing 
enzymes, that ensure correct post-translational modification of proteins and promote efficient 
sorting and trafficking of secretory proteins. 
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The most common form of post-translational processing is glycosylation [Wang et al.,  1994]. 
Vertebrates and especially mammals, have evolved a highly complex glycan repertoire, that 
represents the molecular base for interspecies recognition systems.  
In mammals, the enzymatic process of glycosylation utilizes nine monosaccarides, that are 
provided by conserved biosynthetic reactions and are produced predominantly in the secretory 
pathway of the cell [Ohtsubo and Marth, 2006]. Within the Golgi apparatus, glycans become 
increasingly oligomeric and branched as they transit to the latter portion of the secretory 
system; the final proteins are then delivered to the cell surface and extracellular 
compartments. 
 
 
 
FIG. 6: Glycosylation 
pattern along the 
biosynthetic pathway. 
Different glycans  
composition is achieved 
gradually and is  
characteristic of each 
cellular compartment. 
 
[Dennis et al., 2009] 
 
 
There are several types of glycosylation, whose classification depends on target amino acids. 
N-glycans are linked to asparagine residues of the protein, in the Asn-X-Ser/Thr motif. O-
glycans are attached to a subset of serines and threonines [Schachter, 2000; Yan and Lennarz, 
2005].  
Glycans produced in the secretory pathway participate in multiple mechanisms of cellular 
regulation. The influence of glycans on protein-protein interactions encompasses a large 
number of cellular functions that span from nascent protein folding and intracellular 
 43 
trafficking to roles in extracellular compartments where cell-cell communication is  
modulated. 
 
 
 
FIG. 7: Glycan functions. 
Glycans function is not  
limited to intracellular traffic.  
It serves for several cellular 
functions, that are 
represented here [Ohtsubo 
and Marth, 2006]. 
 
4)Biosynthetic sorting from the Trans-Golgi Network to the correct plasma membrane 
domain (apical or basolateral) 
 
 
 
FIG. 8: Targeting of 
membrane proteins in 
polarised cells. The different 
types of t argeting signals that 
mediate apical or basolateral 
transport are indicated. 
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Following post-translational modifications, the trans side of the Golgi stack serves as a key 
sorting station, directing cargo to multiple intracellular and extracellular destinations. Indeed, 
the stack in the trans cysternae are sorted into constitutive secretory vesicles that fuse with the 
plasma membrane. In epithelial cells, at the level of TGN, apical or basolateral proteins are 
sorted into different vesicles that fuse with the respective apical or basolateral domain [Brown 
and Breton, 2000]. 
In the table below, the main sorting signals are summarised: 
 
 
 
Apical sorting determinants and their cellular adaptors or receptors are still unclear and 
remain to be identified. Until know, an heterogeneous population of apical sorting signals  
have been described (Fig. 8).  
Among them, is the lipid anchoring glycosyl-phosphatidylinositol bridge (GPI), a post-
translational modification in the ER, which is the first apical sorting signal that was described 
[Lisanti et al., 1988; Brown et al., 1989]. Other determinants for proper apical delivery are the 
presence of N- or O-glycans [Le Bivic et al.,  1993; Yeaman et al., 1997; Benting et al., 1999; 
Alfalah et al., 1999; Jacob, et al., 2000].  
Specialised lipid rich membrane segments, called glycolipid rafts, appear to be involved in 
this process [Harder et a., 1998]. Some polypeptides of the annexin family also participate in 
apical transport of raft-associated membrane proteins. Recent data have highlighted the 
involvement of a new lectin family for apical trafficking, the galectins. In enterocytes, 
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interaction between galectin-4 and sulfatides plays a role in the organisation of lipid rafts for 
efficient apical surface delivery [Danielsen and van Deurs, 1997]. On the contrary, galectin-3 
in MDCK cells seems to target apical vesicle in a raft-independent mechanism [Delacour et 
al., 2006]. 
Apical sorting signals that mediate the incorporation into membrane microdomains have also 
been identified in the transmembrane domains of proteins. The length and the primary amino 
acid sequence of the transmembrane domain seem to be important for rafts association and 
lipid based sorting [Munro, 1995; Nezil and Bloom, 1992]. 
In addition, apical sorting signals of different nature have been identified in the cytosolic tails  
of rhodopsin [Chuang and Sung, 1998], megalin [Marzolo, et al., 2003; Takeda et al., 2003] 
and receptor guanylyl cyclases [Hodson et al.,  2006]. There is still a significant number of 
apical proteins with unknown apical sorting information, and therefore other signals variants  
hidden in proteins may also play a role in apical protein delivery. 
Basolateral signals are localised in the cytoplasmic domain of basolateral proteins and consist 
of tyrosine or dileucine motifs, which are often found in the vicinity of stretches of amino 
acids. 
 
5) Anchoring and/or retention at the plasma membrane 
The fine modelling of plasma membrane domains is achieved by protein-protein interactions, 
that may increase the residence time of a specific protein at the plasma membrane. Many of 
these ancillary proteins act as a bridge between the transmembrane protein and the 
cytoskeleton, creating a stable complex at the plasma membrane. This interactions may 
prevent plasma membrane protein internalisation in endocytic or degradative compartments. 
It has been established that receptor mediated endocytosis and sorting in endosomal-
lysosomal system occur through coated areas of the membranes. Protein coats are mainly 
composed of the structural protein clathrin, of adaptor proteins (AP) and other accessory 
factors. The recognition of specific sorting motifs in the intracellular tails of membrane 
proteins by these adaptor proteins activates the internalisation processes via protein 
interactions. The signals are similar to that of basolateral targeting, as they contain tyrosine-
based sequences and di-leucine motifs. 
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2.3 PDZ Domain-containing proteins 
Essentially, protein trafficking along the biosynthetic route strongly relies on the coordinated 
cooperation of proteins. At molecular level the interactions are driven by structurally 
conserved domains that specifically recognise peptide ligands in other proteins [Pawson et al.,  
2002]. Among these, in the recent years, PDZ domains have been described and involved in 
several step of the biosynthetic pathway. 
The most abundant protein-protein interaction domains that contribute to tethering proteins to 
the cytoskeleton and to the trafficking machinery are PDZ domains [Ponting 1997; Rongo, 
2001], contained in the so-called PDZ proteins.  
PDZ domains are modular domains of 90 amino acids . They were originally identified as  
conserved sequence elements within the post synaptic density protein PSD95, the Drosophila 
tumour suppressor dlg-A, and the tight junction protein ZO-1 [Pawson and Scott, 1997]. PDZ 
domains are often found in proteins with other known interaction domains or signalling 
domains. 
The primary function of PDZ domain is to recognise and bind specific amino acid sequences  
localized at the COOH terminus of target proteins. Depending on the target sequence, PDZ 
domains are traditionally classified as class I, class II and class III domains, which recognise 
the consensus sequences listed in the table below [Brone and Eggermont, 2005]: 
 
PDZ domain Consensus sequence 
Class I X-S/T-X-Φ 
Class II X- Φ-X-Φ 
Class III E-D-X-W-C/S 
 
Cristallographic studies demonstrate that the PDZ domain is composed of six β strands 
forming two opposing antiparallel sheets flanked by two alpha helices. The COOH terminus 
of the interacting protein lies within an elongated surface groove as an antiparallel beta strand 
and the hydrophobic side chain inserts into an hydrophobic cavity at the end of the groove 
[Doyle et al., 1996]. 
PDZ proteins often contain multiple protein-protein interaction domains that can cooperate to 
bind more than one target ligand. They have also been demonstrated to bind directly to other 
PDZ proteins, forming homomeric and heteromeric complexes [Brenman et al., 1996]. 
On the basis of their domains, PDZ proteins can be divided into three major groups: 
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1-PDZ-only proteins: containing one or more PDZ domains 
2-Membrane associated guanylate kinase (MAGUK) domain-containing proteins 
3-PDZ proteins that contain other protein interacting domains, e.g. SH3, PH and L27 domains  
in addition to their PDZ domains. 
PDZ interactions are not limited to transmembrane proteins, but also include a large number 
of different cytosolic proteins comprising components of signal transduction pathways and 
the cytoskeleton (Fig. 9).  
The interaction of PDZ domains with binding partners can be directly regulated by 
posttranslational modification triggered by receptor activation. Both intracellular and 
extracellular signals can control the phosphorilation of residues within the C-terminal target  
sequences of interacting partner or within the PDZ domain itself.  
Thus, it seems likely that regulated association of PDZ-containing proteins may represent a 
general mechanism for regulating the temporal and spatial assembly of complexes.  
 
 
 
 
FIG. 9: Schematic structure of PDZ domain-
containing 
proteins that play a role in the polarized expression 
of membrane proteins. Alternative names of the PDZ 
proteins are indicated in brackets. Possible interactions 
between PDZ proteins  
in epithelial cells (solid lines) and neurons (dashed 
lines) are indicated. Possible binding to the actin 
cytoskeleton is indicated by dotted lines.  
 
4.1, protein 4.1-interacting domain or Hook domain; CAL, CFTR-
associated ligand; CaMK, calmodulin kinase II-like domain; CAP70, 
CFTR accessory  protein-70; CASK, calcium/calmodulin-dependent 
serine protein kinase; CID, CASK-interacting domain; CC, coiled-
coil domain; E3KARP, NHE3 kinase A regulatory protein ; EBP50, 
ezrin-radixinmoesin-binding phosphoprotein-50; ERM, ezrin-
radixinmoesin-binding domain; FIG, Fused in glioblastoma; GOPC, 
Golgi-associated PDZ and coiled-coil motif-containing protein; GuK, 
guany late kinase-like domain; L27, L27 domain; MALS, mammalian 
Lin-7; Mint, Munc18-1-interacting protein; NaPi-Cap1, 
Na+/phosphate cotransporter-CFTR accessory  protein 1; NHERF, 
Na+/H+exchanger regulatory  factor; P4.1, protein 4.1; PDZ, PDZ 
domain; PDZK1, PDZ containing 1; PIST, PDZ domain protein 
interacting specifically  with TC10; PTB, phosphoty rosine-binding 
domain; SAP97, sy napse-associated protein 97; SH3, SH3 domain; 
Veli, vertebrate Lin-7. 
 
[Brone and Eggermont, 2005] 
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2.3.1 Role of PDZ domains in cell polarity and protein trafficking 
PDZ domains have been involved in several processes that may be relevant to protein delivery 
to polarized domains.  
• ER export: PDZ proteins have been involved in the early events of assembly, 
processing and delivery of interacting partner. The interaction of SAP97 (a PDZ 
protein) with NMDA receptors occurs in the endoplasmic reticulum and is critical for 
the delivery of receptor complexes to synapses [Sans et al., 2001; Hayashi et al., 2000; 
Shi et al., 2001; Prybylowski et al., 2002; Sprengel et al., 1998; Mori et al., 1998]. It 
has been proposed that in neuronal processes NMDA receptors are retained in the ER, 
unless an interaction with PDZ proteins occurs, thus allowing receptor transport to the 
plasma membrane. 
• Selective plasma membrane targeting:  Each PDZ protein is generally restricted to 
specific subcellular domains, such as synapses, cell-cell contacts, or the 
apical/basolateral cell surface [Fanning and Anderson, 1999]. This leads to the 
speculation that PDZ domains are necessary for the biosynthetic targeting and 
polarised expression of membrane proteins. An example is the GAT2 transporter, that 
has a sequence of 22 amino acids at the C terminus required for the transporter's 
basolateral distribution. Whereas the GAT3 C-terminal sequence contains a PDZ 
consensus sequence, necessary for its apical targeting [Muth et al., 1998]. 
• Retention and stabilisation in specific subdomains: PDZ network ensures that the 
membrane proteins are efficiently delivered and retained at the cell surface. As PDZ 
proteins contain actin binding domains, they appear to act as a bridge between PDZ 
binding proteins and actin cytoskeleton, therefore anchoring target proteins to the cell 
surface. For example, actin confines GAT1 to the plasma membrane via ezrin, and this  
interaction is mediated through the PDZ-interacting domain of GAT1 [Imoukhuede et 
al., 2009] 
• Organization of functional domains. PDZ proteins have been involved also in 
tethering or clustering functionally interdependent proteins in specific cell surface 
domains, thereby increasing the efficiency of their functions. Indeed, the structural 
features of PDZ domains allow them to mediate more than one specific protein-protein 
interaction. The ability to cluster transmembrane receptors and channels has great  
functional significance. Receptor clustering is a well-established prerequisite for 
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receptor activation and might also provide a mechanism to coordinate activity of 
different transmembrane receptors and ion channels. 
An example is provided by the PDZ protein NHERF (Na+/H+exchanger regulatory 
factor), that has two PDZ domains and binds directly to both the β2-adrenergic 
receptor and NHE-3. It has been demonstrated that activation of β2-adrenergic 
receptor can alter the activity of NHE and that NHERF is required for this regulation 
[Hall et al.,  1998]. In addition, the PDZ protein NHERF both binds to the cystic 
fibrosis transmembrane regulator (CFTR) chloride channel and the Na+/H+ exchanger 
on the apical plasma membrane [Short et al., 1998].  
2.4 Regulation of EAAC1 surface expression, function and trafficking 
2.4.1 Intestinal and renal transport systems 
In kidney and intestine, an important category of polarized proteins are amino acids  
transporters. Indeed, to perform a directional transepithelial solute transport, membrane 
transporters need to be targeted selectively to either the apical or basolateral membrane 
domain.  
Amino acid transporters are important for organism physiology as they can influence normal 
cell function, can regulate synaptic signalling, neuronal excitability and pH homeostasis in 
several tissues [Bröer, 2008].  
Definitely, amino acids transporters expressed in absorptive epithelia are critical for the 
homeostasis of plasma amino acid levels and for the supply of amino acids to all tissues, 
where they serve as building blocks for protein synthesis, as precursors for a wide variety of 
bioactive molecules, and as energy metabolites. This is illustrated by a number of inherited 
disorders affecting amino acid transport in epithelial cells, such as cystinuria, lysinuric protein 
intolerance, Hartnup disorder, iminoglycinuria, dicarboxylic aminoaciduria, and some other 
less well-described disturbances of amino acid transport. 
 
 50 
 
 
Summary of the major apical amino acid transporters found in kidney and intestine. AA°, neutral amino acids: 
HO-P, hydroxyproline; β-A, beta-Alanine; O, Ornitine; All the other amino acids are listed in one-letter code;  
Br, Brain; Ht, Heart; Ki, Kidney; Lu, Lung; SI, small intestine. [Broer, 2008b] 
 
Based on functional studies in kidney and intestine and the amino acid profile in the urine of 
individuals with different aminoacidurias, five transport activities were proposed [Milne, 
1964; Scriver et al., 1976; Thier and Alpers, 1969; Young JA, Freedman, 1971]. 
1) the “neutral system” or “methionine preferring system” transporting all neutral amino 
acids;  
2) the “basic system” transporting cationic amino acids together with cystine; 
3) the “acidic system” transporting glutamate and aspartate; 
4) the “iminoglycine system” transporting proline, hydroxyproline, and glycine; 
5) the β-amino acid system. 
2.4.2 EAAC1 
We have focused our study on the glutamate transporter excitatory amino acid carrier 1 
(EAAC1/ EAAT3) [Royle et al., 2003]. 
EAAC1 is largely distributed in absorptive epithelial tissues such as kidney and intestine. 
EAAC1 was first cloned from rabbit intestine [Kanai and Hediger 1992] and EAAC1 mRNA 
was found in the small intestine where its amount increases after a high protein diet in animals  
[Erickson et al., 1995]. Moreover, there is evidence of the presence of EAAC1 protein in 
enteric nervous  system [Liu et al., 1997]. In rat kidney, the transporter is predominantly 
located in the brush border membrane of proximal tubule S2 and S3 segments [Shayakul et 
al., 1997]. In this location, the primary function of EAAC1 transporter is the final re-
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absorption from the glomerular filtrate of glutamate and aspartate that escaped the early part 
of the proximal tubule [Burch et al.,  1978; Silbernagl, 1983]. The EAAC1-mediated 
absorption is highly effective since more than 90% of the filtered dicarboxylic amino acids  
are recovered from the final urine [Hediger, 1999].  
EAAC1, located in the apical membrane of proximal tubules epithelia, is functionally and 
physically coupled to the phosphate-independent but bicarbonate-dependent glutaminase 
(PIG) and regulates both glutamine metabolism and paracellular permeability [Welbourne & 
Matthews, 1999] (Fig. 10).  
EAAC1 has also been involved in glutathione homeostasis as it can transport cysteine, whose 
abundance is the rate limiting step in glutathione synthesis [Zerangue et al., 1996; Aoyama et 
al., 2006]. 
 
 
 
FIG. 10: Metabolic acidosis and glutamate metabolism in rat kidney proximal tubule cells. Image 
modified from Hediger, 1999. 
 
Alterations in the human EAAC1 transporter activity are associated with dicarboxylic 
aminoaciduria, an inborn error of glutamate/aspartate transport across epithelial cells of 
kidney and intestine, characterized by an excessive excretion of glutamate and aspartate. The 
importance of EAAC1 in kidney function is confirmed by mice models deficient in EAAC1 
that develop dicarboxylic aminoaciduria without neurological or cognitive abnormalities  
[Peghini et al., 1997].  
 
In order to be functional, EAAC1 must localize to the apical plasma membrane of epithelial 
cells [Beckman and Quick, 1998].  
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A hierarchy of trafficking processes, coordinated by several distinct signals, and interacting 
proteins must control EAAC1 density at the plasma membrane. However, our understanding 
of the molecular mechanisms which govern EAAC1 delivery and dynamics at the cell surface 
is at the beginning.  
 
Plasma membrane delivery of EAAC1 is a complex mechanism that requires homo-
oligomerization and efficient export of newly synthesized transporters from the Endoplasmic 
Reticulum (ER), a process which is regulated by interactions with accessory proteins, like 
GTRAPs (Glutamate transporter associated proteins). These proteins are structurally related to 
the Ras Superfamily, but they lack a GTP-binding consensus motif. In the last years, it has 
been demonstrated that GTRAP 3-18 delays the ER exit of EAAC1 by interaction with its C-
terminus [Lin et al., 2001; Haase et al., 2001; Ruggiero et al., 2008]. 
The EAAC1 targeting to polarized domains of epithelia and neurons relays on selective 
sorting into transport carriers by a not-yet identified sorter complex, and subsequent delivery 
to the plasma membrane [Cheng et al., 2002].  
The surface density of EAAC1 is also controlled by rapid constitutive cycling between the 
plasma membrane and intracellular compartments, with the proportions at the cell surface and 
in endosomal compartments depending on the relative rates of transporter insertion or 
removal from the plasma membrane [Fournier et al., 2004; Gonzalez et al., 2007]. 
Interestingly, this mechanism has been found to be involved in long term potentiation and fear 
conditioning [Levenson et al.,  2002; Pita Almenar et al., 2006] and may also play an 
important role in epithelia homeostasis. Several proteins may play a role in this process, in 
particular proteins involved in the fusion of vesicles  to the plasma membrane such as SNAPs 
(soluble N-ethylmaleimide–sensitive attachment proteins) and SNAP receptors (SNAREs) 
[Deken et al., 2000; Quick, 2003; Sung et al., 2003]. Indeed, there is evidence that synthaxin 
1A and SNAP23 are required for the trafficking of EAAC1 [Fournier and Robinson, 2006; Yu 
et al., 2006; Zhu et al., 2005]. 
In addition, it is known that EAAC1 interacts with PICK-1 (protein interacting with C-kinase) 
[Gonzalez and Robinson 2003]; that may recruit PKC or other signalling molecules into a 
complex with the transporter. 
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In the past years, we have shown that in the extreme cytoplasmic C-terminus of EAAC1 there 
is a consensus sequence for class I PDZ domain-binding ligands (X-S/T-X-Φ, where X is any 
amino acid and Φ a hydrophobic amino acid) (Figure 11A). 
 
 
 
Fig. 11: EAAC1 has a conserved class I PDZ target motif. A) The 
COOH-terminal amino acids of the glutamate transporter EAAC1 from 
the various  speci es, obtained from the National Center for 
Biotechnology Information dat abases. The putative PDZ target moti f 
“SQF” is highlighted in green. B) Schematic representation of the wild 
type (WT) and deleted (∆TSQF) transporters used in the project. 
 
 
 
Fig. 12: Deletion of the PDZ target 
motif decreases the surface 
expression of the EAAC1 
transporter in MDCK cells. MDCK 
clones expressing the indicated 
constructs (green) were grown to  
confluence on transwell filters, fixed, 
stained with anti-β-cat enin (red) 
antibody and analysed using confocal  
microscope. Apical, Lateral  and x-z 
scanning are shown. Scale bar: 20 µm. 
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This sequence would potentially provide docking sites for proteins involved in the targeting, 
scaffolding and clustering, but its role in transporter function and localisation was not 
formally proved [D’Amico et al., 2010]. 
To understand its function, a truncated mutant lacking the PDZ target motif (∆TSQF EAAC1) 
and fused to GFP was generated (Fig. 11B). Its distribution was analysed in the Madin Darby 
Canine Kidney (MDCK) epithelial cell line, a line that endogenously expressed EAAC1 
[Shayakul et al., 1997] and therefore all proteins involved in its regulation. Differently from 
the wild-type transporter, the ∆TSQF EAAC1 mutant prevalently localised in intracellular 
vesicles (Fig. 12), which have been identified as endocytic and degradative compartments.  
Thus, these data suggested that PDZ target sequence plays an important role in transporter 
trafficking. 
We previously demonstrated that the PDZ-target sequence was required to prevent the 
transporter endocytosis and degradation. 
The aim of the present project is to understand whether the class I PDZ binding domain could 
also affect the biosynthetic delivery of EAAC1 in MDCK cells. We demonstrate that this 
motif increases EAAC1 trafficking efficiency at different steps of the biosynthetic pathway. 
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3 RESULTS 
3.1 Removal of the PDZ target sequence impairs EAAC1 membrane 
stability in MDCK cells. 
In the previous studies, we demonstrated that the removal of the PDZ target motif SQF 
increased the transporter’s internalisation in endocytic compartments. To confirm these 
findings, we measured the cell surface resident time of GFP-wild-type and GFP-∆TSQF 
transporters (Fig. 1) by means of time-lapse TIRF imaging, after the trafficking of newly 
synthesized proteins to the plasma membrane had been blocked by Brefeldin A (BFA) 
incubation. 
Total internal reflection fluorescence microscopy (TIRFM) allows the selective excitation of 
GFP-labelled transporters located in or immediately below the plasma membrane (100 nm 
above the glass coverslip) and the exclusion of signals arising from structures in the cell 
interior [Axelrod, 2001]. 
BFA is a fungal metabolite that is used to accumulate newly synthesised transporters in the 
ER, thus blocking both the apical and basolateral delivery of membrane proteins in MDCK 
cells [Lippincott-Schwartz et al., 1989; Low et al., 1992; Wagner et al., 1994]. This strategy 
allowed us to analyse the membrane stability of EAAC1, isolating the endocytic pathway 
without the contribution of the biosynthetic delivery. Under these conditions, if the GFP 
transporter is internalized, the fluorescence signal recorded by TIRFM should progressively 
decrease, because the transporter distance from the plasma membrane increases. Figure 1 
shows representative image sequences of the wild-type and ∆TSQF EAAC1 transporters, 
together with the averaged fluorescence intensity curves. The total (punctate and diffuse) 
fluorescence intensity of the wild type GFP-transporter remained almost constant during the 
3-min recording, but that of the ∆TSQF mutant markedly decreased. Quantification of the 
fluorescence changes indicated a 15.92 ± 0.31% decrease in the total EGFP-EAAC1 ∆TSQF 
signal after 3 min, but only a 2.02 ± 0.03% decrease in that of the wild-type transporter (p < 
0.05), thus indicating that the PDZ target sequence controls the transporter resident time in the 
plasma membrane and prevents its internalization. 
 
 56 
 
 
Fig. 1: Removal of the PD Z 
interacting motif increases the 
transporter internalization. 
Time-lapse imaging of EAAC1 
constructs by means of TIRF 
microscopy. The clones were 
incubated with 5 µg/mL BFA for 
30 min, before TIRF microscopy 
in the continuous presence o f 
BFA. Representative image 
sequences are shown in the upper 
panel; the time of the individual  
frames  is indicat ed. Bar 5  µm.  
Averaged fluorescence intensity  
curves for wild-type (circles) and 
∆TSQF (squares) EAAC1, 
showing the percentage of 
proteins detect ed at the cell  
surface by TIRFM, are reported 
in the lower panel. Data are 
expressed as the percentage o f 
initial average intensity (I0 ) and 
plotted against time (n = 15). 
 
3.2 Removal of the PDZ target motif delays the surface targeting of 
EAAC1 
We then focused on a possible involvement of PDZ interactions in the biosynthetic pathway 
(Fig. 2). We first used a functional assay to study the transporter surface delivery. Three hours 
after transient transfection, MDCK cells were incubated for 12 hours with 5 µg/ml BFA to 
accumulate a cohort of newly synthesised transporters in the ER (Fig. 2A). The block can be 
removed after extensive washing, thus allowing the synchronised delivery of transporter to 
the plasma membrane, where it can be monitored by uptake experiments (Fig. 2B). Indeed, D-
aspartate does not permeate the plasma membrane and it is taken up only by transporters at 
the plasma membrane [Seal and Amara, 1999].  
Uptake measurements obtained in the continuous presence of BFA were not significantly 
different from GFP-transfected cells, thus indicating that BFA treatment successfully 
entrapped transporters within the cells. After BFA wash-out, the wild type transporter was 
rapidly targeted to the plasma membrane: its surface activity increased over time and reached 
the maximal value within 30 minutes chase (290±23% over GFP-transfected cells). Similarly, 
the ∆TSQF transporter reached the cell surface but its activity was lower than wild type 
transporter already at early time points after BFA wash-out (11.81±0.61% less than wild type 
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at 5 and 10 min chase), suggesting a slower surface appearance of the transporter lacking the 
PDZ interacting sequence (∆TSQF). By 20 minutes’ chase, the truncated transporter activity 
dramatically decreased of 39.4±1.9% relative to wild type transporter (p<0.05), confirming 
also the defect in membrane stability and in endocytic pathway. 
 
 
 
Fig. 2: Plasma membrane 
delivery is impaired in deleted 
transporter. A) Three hours aft er 
transient transfection of wild-type 
and ∆TSQF mutant, MDCK cells 
were incubated with 5 µg/mL 
Brefeldin A (BFA) for 12 h to  
accumulat e proteins in a single 
compartment. Immunofluorescence 
confirmed effi cacy of the treatment. 
B) After BFA wash-out, the surface 
appearance of the transporter was  
evaluated by means of [3H]-D-
aspartat e uptake experiments. Data 
(mean values ± SEM) are expressed 
as a percentage of GFP-transfected 
cells at t0 of chase (n  = 5, in 
triplicate) (∗p < 0.05). 
 
 
These data indicate that the mutant EAAC1 reaches the plasma membrane, although 
inefficiently, but can not accumulate, suggesting both defects in delivery and in the retention 
of mutant transporter at the plasma membrane.  
3.3 PDZ interactions modulate the ER-to-Golgi trafficking 
To understand at which step PDZ interactions control the EAAC1 delivery, we took 
advantage of the glycosylation state of EAAC1 (Fig. 3).  
EAAC1 is a N-glycosylated protein and the normal processing of the N-linked 
oligosaccharides to the complex state occurs within 45 minutes [Yang and Kilberg, 2002]. 
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The N-linked oligosaccharides are processed to the complex state by resident Golgi enzymes, 
preceding surface delivery. Processing of the high mannose type N-linked glycans (core 
EAAC1, arrow) to complex type oligosaccharides (mature EAAC1, arrowhead) in the 
cis/medial Golgi region is reflected by a decrease in the electrophoretic mobility, providing a 
method to monitor the transporter trafficking in the early biosynthetic pathway [Pfeffer and 
Aivazian, 2004]. 
Therefore, the state of oligosaccharide may be used as an indicator of the extent of ER-to-
Golgi trafficking [Yang and Kilberg, 2002]. In particular, the presence of a high mannose 
oligosaccharide indicates that the protein has not left the ER membrane after translation. 
 
 
 
Fig. 3: The removal of the PDZ interaction motif delays the ER-to-Golgi traffic of EAAC1. The ER-to-
Golgi traffi cking of the indicated EAAC1 constructs was  followed by monitoring their glycosylation pattern 
and sensitivity to Endoglycosidase H digestion. 500 µg of total protein extracts were incubated with 
Endoglycosidase H (H) or PNGaseF (F) for 5 hrs, before processing for immunoblotting. A) A represent ative 
immunoblot is shown. The arrowhead and arrow indicate the complex-glycosylated (Hr, mature and resistant  
to EndoH digestion) and the high-mannose (Hs, core and sensitive to Endo H digestion) forms, respectively.  
B) Quantitative analysis is reported. Data (mean value ± SEM) are expressed as a percentage of total EAAC1 
protein (n = 3) [*p < 0.05: ∆TSQF mutants versus wild type (WT)]. 
 
To identify the core form of the transporter, protein samples were treated with 
Endoglycosidase H (Endo H), that selectively recognises and digests high mannose N-linked 
oligosaccharides present in the ER. Samples were also digested with N-Glycosidase F 
(PNGase F), that completely removed all glycans present in the protein. Then proteins were 
separated on SDS-PAGE and immunoblotted with an antibody against GFP. A representative 
blot is shown in figure 3A and the band quantification is reported in figure 3B. The removal 
of PDZ target motif, slightly increased the transporter fraction sensitive to EndoH digestion 
and decreased the complex glycosylated EAAC1 population in the cell lysate, thus indicating 
an effect of PDZ proteins on the ER-to-Golgi trafficking. From ER, the transporter could be 
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either processed by biosynthetic enzymes and progress through the biosynthetic pathway, or 
could be addressed to degradation compartments. 
 
3.4 PDZ interactions affect the biochemical turnover of the truncated 
transporter 
The biochemical turnover of the high mannose form was determined by means of 
Cycloheximide (CHX) chases (Fig. 4). As Cycloheximide (CHX) inhibits protein translation 
in eukaryotes, it allowed us to follow the fate of the previously synthesised EAAC1 high 
mannose form, excluding the appearance and contribution of newly synthesised transporters. 
We incubated EAAC1 expressing clones with 100 µg/ml 
CHX for the indicated times and then cells were lysed 
and proteins were separated on SDS-PAGE (Fig. 4).  
 
 
 
 
 
Fig. 4: ∆TSQF mutant shows different maturation and turnover compared to wild type (WT). The 
turnover of WT and ∆TSQF core- and mature-forms was monitored by their disappearance in the presence 
of 100 µg/ml CHX, by means of SDS–PAGE and immunoblotting. Equal amounts of cell lysates  were 
loaded and blotted against GFP/Actin. A) A representative immunoblot is shown. B) Quantitative analyses  
are shown for both the constructs. Data (mean value ± SEM) were corrected for actin content and were 
expressed as a percent age of total protein (core + mature forms) at t0 of chase (n = 3).  
 60 
In these experimental conditions, if the delivery of the protein is not blocked in the ER, the 
disappearance of the ER form should be accompanied by a concomitant increase of the 
mature form. 
Without CHX chases (0), the amount of the ∆TSQF core form is higher than that of the wild 
type transporter, confirming the previous results. 
However, after CHX chases, the high mannose form (core) of the ∆TSQF transporter was able 
to proceed in the following compartments, as indicated by the progressive decrease of its core 
form, although at a slower rate than wild type. Indeed, ∆TSQF EAAC1 became fully 
glycosylated at longer times (9 hours) than wild type transporter (6 hours). 
This data indicate that the removal of the PDZ target sequence delayed, but did not prevent, 
the ER-to-Golgi progression of ∆TSQF EAAC1.  
CHX experiments suggested also a different turnover rate between the fully glycosylated 
mature form of the wild type and the ∆TSQF transporters, with the latter disappearing faster 
than wild type. To confirm this hypothesis, we measured the half life of mature EAAC1 
constructs by means of metabolic pulse-chase experiments. Transporters were metabolically 
labelled for 3 hours with [35S]methionine and [35S]cysteine, and then chased for 6 hours to 
eliminate the ER form. Then they were immuno-precipitated and separated by SDS–PAGE 
(Fig. 5). The rate of degradation was measured by following the disappearance of the higher 
mature band. We found that deletion of the PDZ target sequence significantly decreased the 
half life of mature EAAC1, thus suggesting that PDZ interactions affect also the post-Golgi 
trafficking of EAAC1. 
 
 
 
Fig. 5: The half life of the complex glycosylated form is decreased for the ∆TSQF 
mutant. Metabolically labelled WT and truncated transporters were chased at 37°C, as 
indicated in the scheme, immunoprecipitated, and analysed on 10% SDS–PAGE. A) The 
figure shows one out of two experiments. B) Data are expressed as a percentage of total  
protein at t0 of chase. The quantisation reflects the average of duplicate experiments, (*p <  
0.05). 
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3.5 The truncated transporter accumulates in post-Golgi compartments 
We then followed the post-Golgi fate of newly synthesized transporters with a morphological 
approach (Fig. 6).  
Three hours after transient transfection, both the wild type and truncated transporters were 
detected in a tubuloreticular network typical of ER, no punctuated pattern was evident. The 
subsequent incubation for two hours at 20°C [Griffiths and Simons, 1986] caused the 
accumulation of both constructs in juxtanuclear structures reminiscent of the Golgi complex 
(Fig. 6). When samples were warmed for 15 minutes at 31°C, the normal protein trafficking 
was restored, and both constructs were found in vesicle-like structures emerging from the 
perinuclear region. However, by thirty minutes chase, the wild type transporter was clearly 
detected at the cell surface, whereas truncated EAAC1 accumulated in vesicular structures 
inside the cells. Because also the ∆TSQF was detected at the cell surface in this condition 
(Fig. 6A, inset), our data are compatible with a defect in both the surface delivery and the 
endocytic retrieval of EAAC1.  
 
 
 
Fig. 6: Removal of the 
PDZ target sequence 
causes the accumulation 
of EAAC1 in post-Golgi 
compartments. 
Immunolocalization of 
newly synthesized wild-
type and ∆TSQF 
transporters. Three hours  
after t ransient transfection, 
MDCK cells were 
incubated for 2 h at 20◦C 
(to block proteins in the 
TGN) and then shifted at  
31◦C for 15 and 30 min 
before imaging. Scale bar: 
10 µm. 
 
 
We have already demonstrated that truncated EAAC1 accumulated in vesicles of the 
endocytic compartments [D’Amico et al., 2010], we now performed double 
immunofluorescence experiments to verify whether truncated EAAC1 accumulated also along 
the biosynthetic pathway (Fig. 7).  
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Fig. 7: The ∆TSQF transporter accumulates in post-Golgi compartments. Double 
immunofluorescence experiments. Non-confluent  MDCK or COS7 cells expressing the 
∆TSQF GFP-EAAC1 transporter (green) were stained with Giantin (red), a marker of the 
Golgi compartment, or TGN 46 (red), to mark the Trans Golgi Network. The figure shows 
both single and merged horizontal confocal sections. In the latter, the yellow/orange 
staining demonstrates the colocalisation of ∆TSQF EAAC1 TGN 46. In the inset is shown 
is a 2x magnification and arrow-heads indicate co-localisation points. Scale bar: 10 µm. 
 
We focused our attention on Golgi and post-Golgi compartments, as during the morphological 
assay we detected a block at the exit from Golgi, rather than in early biosynthetic pathways. 
We did not detect co-localization of ∆TSQF-EAAC1 with giantin (a marker of the Golgi 
complex, Fig. 7A) [Seelig et al.,  1994] in stable clones or in transiently transfected MDCK or 
COS7 cells. A possible accumulation in the trans-Golgi network (TGN) was analysed in 
transfected COS7 cells, because the available antibody against TGN46, a marker of this 
compartment, did not work in MDCK cell line. Under protein delivery to the plasma 
membrane, the transition in this compartment is so fast that it is almost impossible to detect 
an accumulation of the wild type transporter protein. On the contrary the ∆TSQF mutant co-
localized with TGN46 in large vesicles confined to the perinuclear region and small vesicles  
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at the cell periphery, further confirming a defect in the post Golgi trafficking of EAAC1 (Fig. 
7B). 
 
3.6 The ∆TSQF-Y503A double mutant confirms the involvement of PDZ 
interactions in biosynthetic route of EAAC1 
Our results indicate that PDZ consensus sequence, and therefore PDZ interactions, are not 
simply involved in EAAC1 membrane stability, but they also control the efficient delivery of 
the transporter to the plasma membrane.  
 
 
 
Fig. 8: Tyrosine 503 to 
alanine substitution 
increases the surface 
expression of both wild-
type and ∆TSQF 
EAAC1. Distribution of 
Y503A and 
∆TSQF/Y503A EAAC1 
mutants in MDCK cells. 
MDCK clones were 
grown on glass coverslips, 
fixed and analysed by 
means of conventional or 
TIRF microscopy (images  
were collected using 
identical exposure times). 
Scale bar: 10 µm. 
 
 
To confirm this possibility, we took advantage of another mutant (EAAC1 ∆TSQF-Y503A 
double mutant) previously generated in our laboratory. The EAAC1 ∆TSQF-Y503A double 
mutant carries both the deletion of PDZ-consensus sequence and a single substitution 
(Y503A) in the Y503 residue: a tyrosine part of a non-conventional internalisation signal,  
which controls the transporter’s endocytosis from the cell surface (Fig. 8). In this way, any 
defect associated with the endocytic pathway will be repressed, presumably maintaining the 
phenotype linked to the biosynthetic delivery.  
We first verified the surface delivery of the double mutant by means of pulse/chases 
experiments of BFA coupled to uptake assays with [3H]-D-aspartate. The Y503A substitution 
in the ∆TSQF transporter greatly prevented the uptake down regulation observed by 20 min of 
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chase (compare the solid with the dashed lines in the same graph). Although the 
∆TSQF/Y503A double mutant almost completely restored the wild type functional behaviour, 
its surface activity was still lower than that of the Y503A single mutant at each time point 
(18.01±6.03% lower, by 20 min chase), suggesting that a fraction of the total transporter does 
not reach the surface, but is instead retained in intracellular compartments (Fig. 9).  
 
 
 
Fig. 9: The Y503A substitution rescues the internalization defect of the ∆TSQF 
EAAC1 but not its accumulation along the biosynthetic pathway. Cell surface delivery 
of ∆TSQF/Y503A (square) and Y503 mutants (circle). Three hours after transient 
transfection with the indicated constructs, MDCK cells were incubated with 5 µg/mL BFA 
for 12 h. After BFA wash-out, the surface appearance of transporters was evaluated by 
means of [3H]-D-aspartate uptake experiments. Data (mean value ± SEM) are expressed as 
percentage of uptake values in GFP-transfect ed cells (n = 3, in triplicate). To compare the 
effect of the Y503A substitution, the uptake curves of wild-type (WT) or ∆TSQF EAAC1 
are shown in the same graph (dashed lines, from Figure 2B) (*p < 0.05 versus 
∆TSQF/Y503A; # versus ∆TSQF). 
 
To verify an entrapment of transporter in intracellular compartments we measured the ER-to 
Golgi trafficking of the double mutant by Endoglycosydase digestion and analysis on SDS-
PAGE (Fig. 10). Results confirmed that the double mutant retains the defect in the ER-to-
Golgi progression, as indicated by the increased transporter fraction sensitive to EndoH 
digestion (10% relative to wild type) and the decreased fraction of the mature form. 
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Fig. 10: ∆TSQF Y503A EAAC1 transporters maintain a delayed ER-to-Golgi  
maturation. Endoglycosidase digestion of the ∆TSQF/Y503A cell lysate. 500 micrograms o f 
total extracts were incubat ed with Endoglycosidase H (EndoH) or N-glycosidase F (PNGaseF) 
for 5 hrs, before being processed for immunoblotting. A representative immunoblot and the 
quantitative analyses are shown. Data (mean value ± SEM) are expressed as  a percentage o f 
total EAAC1 protein (n = 3) (*p < 0.05: ∆TSQF mutants versus WT). The arrowhead and 
arrow indicate the complex-glycosylated (Hr) and the high-mannose (Hs) forms, respectively. 
 
Moreover, also the ∆TSQF-Y503A mutant co-localised with TGN46, the marker of the Trans  
Golgi Network. A pseudo-colour image reflecting the co-localisation analysis is reported in 
figure 11. The scale ranges from blue to red, indicating low to high co-localisation, 
respectively. 
Taken together, these results confirm that PDZ interactions play a role not only in the 
endocytic trafficking of the transporter but also in the exocytic pathway. 
 
 
 
Fig. 11: The Y503A substitution does not prevent ∆TSQF EAAC1 accumulation along 
the late biosynthetic pathway. Double immunofluorescence staining. 24 hours after transient  
transfection, COS7 cells expressing the ∆TSQF/Y503A transporter (green) were fixed in  
paraformaldehyde and stained with TGN46 (red). Co-localisation between the two channels  
was calcul ated using the Image-ProPlus software (www.mediacy.com technical note#7; Media 
Cybernetics) and a 3D representation is shown. Scale bar: 10 µm.. 
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4 DISCUSSION 
In the past years, we analysed the function of a class I PDZ target sequence localized in the 
EAAC1 C-terminal tail. We found that it controls the transporter’s surface density by 
increasing its surface retention and preventing its internalization in endocytic compartments. 
In the present study, we investigated the involvement of the same PDZ consensus sequence in 
the biosynthetic pathway of EAAC1. Our data indicate also a role of PDZ interactions in the 
surface delivery of transporters. 
4.1 PDZ interactions are required for the efficient ER-to Golgi trafficking 
of EAAC1. 
PDZ interactions promote the transporter’s plasma membrane localization, because the 
deletion of the C-terminal PDZ binding site dramatically decreases the EAAC1 surface 
expression. We provide evidence that PDZ interactions occur early in the biosynthetic 
pathways and are involved in the ER-to-Golgi trafficking of EAAC1. 
Indeed, at the steady state, a higher fraction of the ∆TSQF mutant remains sensitive to EndoH 
digestion, that reveals an early form of glycosylation that occurs in the ER (Fig.3).  
The ER-to-Golgi delay was confirmed by the analysis of biochemical turnover of the 
transporters after Cicloheximide (CHX) chases. In that experiments, the transporter neo-
synthesis is blocked by CHX and the fate of the transporters synthesised before the incubation 
could be followed as a progressive loss of the mature and core bands on a SDS-PAGE at 
different time chases (Fig. 4). The WT core form disappears faster than the corresponding 
∆TSQF band, suggesting that the maturation of the truncated transporter is actually slower 
and occurs three hours later compared to the WT. However, these experiments indicate that at 
longer times (9 hours) the truncated transporter can reach the mature form, thus confirming 
the results of surface expression of ∆TSQF transporter detected by TIRFM experiments. It is 
of note that the complex-glycosylated ∆TSQF increase after 9 hours of CHX chase is due to 
the slower maturation of the core protein and it’s not related to transporter neo-synthesis, that 
it blocked by CHX. 
On the other hand, the biochemical turnover of the complex-glycosylated form indicates that 
the half-life of the ∆TSQF mutant is less compared to the WT: we can estimate that it is about 
6 hours for the former and 9 hours for the latter.  
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Interestingly, pulse and chase experiments on the biochemical turnover of the complex-
glycosylated forms, indicate that removal of PDZ motif determines a faster degradation of the 
transporter (Fig. 5). 
Most likely, the degradation step occurs after the Golgi, as suggested by the fact that the core 
form of ∆TSQF mutant can mature to complex glycosylated.  
Removal of the PDZ motif delays rather then prevents the ER export of the transporter, thus 
indicating that PDZ interactions facilitate the ER-Golgi trafficking. Progression through the 
biosynthetic pathways requires the efficient sorting of cargo molecules into carrier vesicles  
and their subsequent delivery and fusion to the appropriate target membrane. Therefore, PDZ-
interactions may favour the transporters homo-oligomerization, a process required for the 
efficient ER export of EAAC1 [Ruggiero et al., 2008]. In line with this hypothesis are 
findings on CFTR, whose dimerization is promoted by the PDZ proteins NHERF1 and 
NHERF2 [Wang et al., 2000].  
Alternatively, PDZ domain-proteins may couple EAAC1 with protein complexes required for 
the fusion of carrier vesicles to the appropriate target membrane. A similar mechanism has  
been proposed to control the efficient synaptic delivery of NMDA receptors via the PDZ 
protein SAP102 and Sec8; the latter is a component of exocyst, a cytosolic complex that 
directs secretory vesicles to their fusion sites in the plasma membrane [Hsu et al., 1999; Sans  
et al., 2003]. Interestingly, the exocyst complex is also expressed in MDCK cells at regions of 
cell-cell contacts, but its accumulation in intracellular compartments, including the ER and 
the TGN, has also been reported in other cell types [Yeaman et al., 2001]. 
4.2 PDZ interactions are important for the post-Golgi trafficking of 
EAAC1. 
Our data support an involvement of PDZ interactions also in the final stages of the 
biosynthetic pathway, as after Golgi release the ∆TSQF and ∆TSQF/Y503A mutant 
accumulated in intracellular vesicles and co-localized with TGN46 in large perinuclear 
vesicles and in small vesicles beneath the plasma membrane (Fig. 7B and 11) thus suggesting 
a role of PDZ interactions in the efficient transport and fusion of carrier vesicles to the 
appropriate target membranes. 
Interestingly, the sec complex has been shown to be required also in the final steps of the 
biosynthetic pathway. 
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A possibility is that PDZ domain-proteins may couple EAAC1 with protein complexes  
required for the fusion of carrier vesicles to the appropriate target membrane. 
An alternative option is that PDZ proteins may function as scaffolds and link EAAC1 to 
motor proteins required for the transport of carrier vesicles along the microtubules.  
A similar mechanism has been proposed to control the synaptic delivery of N-Methyl-D-
aspartate (NMDA) receptors. Its interaction with the kinesin motor KIF17, mediated by the 
PDZ complex LIN2-LIN7-LIN10, ensures the efficient transport of receptors into dendrites 
[Setou et al., 2000].  
 
These data suggest that PDZ-mediated interactions are involved in different steps of the 
biosynthetic pathway, in the early ER-to-Golgi progression as well as in post-Golgi 
trafficking.  
Given the involvement of PDZ proteins interactions at several steps of the 
biosynthetic/degradative pathways, it is possible that distinct PDZ proteins may interact with 
EAAC1. 
We had identified PDZK1 as an EAAC1 interacting partner, acting at the plasma membrane 
as a retention protein [D’Amico et al., 2010].  
The future perspectives will be to identify the interacting proteins involved in EAAC1 
biosynthetic delivery in physiological conditions and also to understand if cellular response to 
nutrients may involve changes in protein interaction and in the transporter expression at the 
plasma membrane. 
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5 MATERIAL AND METHODS 
5.1 Plasmid construction 
In order to express the transporters in heterologous expression systems, such as mammalian 
cells, we cloned the relative cDNAs in the plasmidic vectors to perform our studies. In 
particular, we generated EAAC1 transporter fused in-frame with the EGFP C-terminus. 
The full-length coding sequence of rabbit EAAC1 (177-1782 bp, GenBankTM accession 
number L12411) was cloned from rabbit intestine by means of RT-PCR using 
oligonucleotides designed with the assistance of Primer3 software 
(http://primer3.sourceforge.net/) [Rozen and Skaletsky, 2000; Vanoni et al., 2004].  
By means of a PCR reaction carried out using the pCB6-EAAC1 [Vanoni et al., 2004] as a 
template and the primers below, we introduced, the BglII  and KpnI  enzyme restriction sites at 
the 5’ and 3’, respectively. 
The PCR product (bp 177-1782) was inserted in frame between the BglII and KpnI sites of 
digested pEGFP-C1 (Clonetech, Figure 1), creating the plasmid pEGFP-EAAC1, which 
expresses a protein with enhanced green fluorescent protein directly fused to the amino 
terminus of the EAAC1.  
The EAAC1 mutants were obtained using a QuickChange site-directed mutagenesis kit using 
the GFP-EAAC1 wild type as a template and specific oligonucleotides (Stratagene).  
 
 
 
FIG. 1: pEGFP-C1 vector 
information 
 
To study the contribution of the PDZ target sequence to the transporter trafficking, the GFP-
EAAC1 ∆TSQF construct was created by replacing the residue T521 of EAAC1, generating a 
stop-codon before the conserved sequence SQF. 
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To repress endocytic defect, the internalisation signal YXXΦ was mutated, obtaining GFP-
EAAC1 Y503A mutants [Sheldon et al., 2006].  
Primers were synthesized by PRIMM or NBS Biotech. The sequences of the resulting cDNAs 
were confirmed by DNA sequencing (PRIMM). 
5.2 Cell culture 
The strain II MDCK cells were cultured in MEME (Minimum Essential Medium Eagle) 
supplemented with 10% foetal bovine serum, 2 mM glutamine, and 100 IU/ml 
streptomycin/penicillin, as previously described [Perego et al., 1997]. MDCK clones were 
grown in the same media, supplemented with 0.3 mg/ml G418 (Sigma-Aldrich). 
COS7 cells were cultured in D-MEM (Dulbecco’s Modified Eagle Medium) supplemented 
with 10% foetal calf serum, 1% glutamine and 1% streptomycin/penicillin. 
Cultures were performed under standard humidified conditions of 5% CO2 at 37° C. 
All media were supplied by Sigma-Aldrich. 
 
Transfection 
Transfection was performed by means of lipofection (LipofectamineTM 2000 reagent, 
Invitrogen) and, 6 / 24 / 72 hours after transfection, the cells were processed for 
immunofluorescence, or functional and biochemical studies.  
MDCK cells were plated at the indicated density in complete standard medium and the 
following day, they were washed with serum-free medium and transfected with a mixture of 
DNA and Lipofectamine reagent, as indicated in the table below: 
 
Well Cells DNA Lipofectamine Reagent 1%Gln MEME 
96-well plates, each 
well 5x10
3
 0.05 µg 0.12 µl 44 µl 
3.5 cm Petri dishes 3x105 1 µg 3 µl 1 ml 
 
Four hours after transfection, complete standard medium was added. 
 
Clonal cell lines. 
Stable MDCK cell clones expressing the various constructs were obtained using G418 
selection (Sigma-Aldrich) [Perego et al., 1997]. 
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Briefly, cells were seeded at the density of 3x105 cells in a 3.5 cm Petri dish; after 24 hours, 
cells were transfected with a mixture of DNA (1 µg) and LipofectamineTM (3 µl) prepared in 
1 ml of serum free media (MEME supplemented only with 1% glutamine); the following day, 
cells were harvested and plated at low density in 10 cm Petri dishes. Clones were selected for 
10 to 20 days in complete MEME supplemented with 0.6 mg/ml G418 and then harvested. At 
least three different clones for each construct were characterised by means of uptake 
experiments, western blotting and cell localisation. Clones expressing similar levels of GFP-
labelled constructs were selected and further analysed.  
5.3 Cell treatments 
BFA 
To synchronise all the neo-synthesised proteins in the exit from the ER, we used Brefeldin A 
(BFA) by Sigma-Aldrich. It is s a fungal metabolite which disrupts the structure and function 
of the Golgi apparatus, thereby creating a whole static organelle and entrapping proteins 
within ER [Dinter and Berger, 1998]. 
 
 
 
FIG. 2: The fungal metabolite Brefeldin A (BFA).  
Sigma Aldrich 
 
TIRFM imaging. 24 hours after plating, the cells were incubated with 5 µg/ml for 30 min at  
37°C, and then processed for TIRFM imaging in the continuous presence of BFA.  
Surface delivery and uptake experiments. 5x104 cells were plated on 96 multiwells plate and 
transiently transfected with Lipofectamine (see above). 3 hours after transfection, the cells  
were treated with 5 µg/ml BFA for 12 hours. After accurate washing, clones were incubated 
with normal medium at 37°C for different times, as indicated, and then subjected to uptake 
experiments.  
 
CHX 
To inhibit protein translation and evaluate EAAC1 maturation and half-life, EAAC1 
expressing MDCK cells were treated with CHX (Cicloheximide, Sigma-Aldrich) at 100 
µg/ml, for different incubation times (0, 3, 6 and 9 hours). Then the medium was removed, the 
cell lysed, loaded on a SDS-PAGE and blotted. 
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FIG. 3: Cicloheximide (CHX).  
Sigma Aldrich 
 
5.4 Antibodies and Immunocytochemistry 
MDCK cells were plated on sterile glass coverslips and grown until 70% confluence in 
standard conditions. Then, after brief washes with PBS (150 mM NaCl, 10 mM Phosphate 
Buffer pH 7.4), cells were fixed in 4% paraformaldehyde or 100% methanol, depending on 
the primary antibody to be used, and permeabilised with 0.5% Triton X-100 (TX-100). Fixed 
cells were then incubated with primary antibody for 2 hours at room temperature in GDB 
solution (150 mM NaCl, 10 mM Phosphate Buffer pH 7.4, 0.2% Triton, 0.2% gelatine). 
Following incubation, cells were washed in PBS and then incubated in GDB with the 
appropriate fluorochrome-conjugated secondary antibodies for 1 hour at room temperature, in 
dark. Then, coverslips were mounted on glass slides with Phenilendiammine (1 mg/ml in 
Glycerol-PBS; Sigma-Aldrich) as antifade reagent and sealed with nail-polish. 
 
Post-Golgi trafficking blockade 
Two hours after MDCK transfection, cells were incubated for 2 hours at 20°C, a temperature 
known to inhibit post-Golgi trafficking [Griffiths and Simons, 1986]. To restore Golgi-to-
membrane traffic, cells were incubated for different time (15 and 30 minutes) at 31°C and 
then fixed with 4% paraformaldehyde, to be imaged. 
 
Antibodies 
The following primary antibodies were used: polyclonal anti-GFP (Santa Cruz Biotechnology 
Inc. and Invitrogen), polyclonal anti TGN46 (Sigma), polyclonal EAAC1 (Alpha Diagnostic).  
Polyclonal anti-giantin was a kind gift from Dr. Manfred Renz [Seelig et al., 1994].  
The secondary antibodies (rhodamine-conjugated anti-mouse and anti-rabbit IgG antibodies) 
came from Jackson Immunoresearch (West Grove, PA, USA). 
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5.5 Image acquisition and analysis 
The images were acquired using a Zeiss Axiovert inverted microscope equipped with a Retiga 
SRV CCD camera or a MRC-1024 laser-confocal scanning microscope (BioRad, Hercules, 
CA, USA). Z series of confocal sections were acquired separately using the FITC and 
rhodamine filters. The laser power and gain were adjusted to maintain the signal below 
saturation levels. Co-localisation between the two channels was calculated using the Image-
ProPlus software (www.mediacy.com technical note#7; Media Cybernetics).  
5.6 Total internal reflection fluorescence microscopy (TIRFM). 
Total internal reflection fluorescence microscopy (TIRFM) allows the selective excitation of 
fluorochromes located in or immediately below the plasma membrane (100 nm above the 
glass coverslip), due to the incidence angle of the excitation light [Axelrod, 2001]. 
This technique is particularly useful in the study of membrane dynamics and traffic, as it  
could reach a high level of resolution. 
 
 
 
FIG. 4: TIRFM principle. The Total 
Internal  Reflection is obtained when the 
sample is immersed in a media with low 
refracting index (n1>n2) and i f the 
excitation light reach the sample with a 
critical angle. In this condition, the 
evanescent field is so faint that it diffuse 
in the sample within 100 nm but it doesn’t 
penetrat e deeper, avoiding illumination of 
deep fluorochromes. 
 
 
Static experiments. 
Non-confluent MDCK cells stably expressing the different constructs were plated onto glass 
coverslips. 24 hours later, cells were fixed with 4% paraformaldehyde and imaged through a 
TIRF microscope (Carl Zeiss Inc.) equipped with an Argon laser at 37°C using a 100 x 1.45 
numerical aperture (NA) oil immersion objective. Green fluorescence was excited using the 
488 nm laser line and imaged through a band-pass filter (Zeiss) onto a Retiga SRV CCD 
camera.  
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Time-lapse experiments 
MDCK clones expressing the different constructs were plated onto glass coverslips at 2x104  
cells/cm2 and, 24 hours after plating, single-cell imaging under TIRF illumination was carried 
out at four frames per minute for three minutes in the continuous presence of BFA at 37°C. 
Up to five cells were imaged on each coverslip in three independent experiments.  
 
Image processing 
For each recorded cell image, five 50x50-pixel regions were randomly selected within the 
cell, and the average fluorescence intensity and its associated standard deviation in each frame 
were calculated using the Image-ProPlus software (Media Cybernetics). The fluorescence 
intensities in the various frames were normalised to their respective initial average intensities  
(I0=100%) and plotted against time. Fluorescence intensities were corrected for bleaching 
during the acquisition of serial images (bleaching was estimated by imaging 
paraformaldehyde-fixed cells). The data come from up to 15 cells for each construct. 
5.7 Endo H or PNGase F treatment 
To verify whether truncated EAAC1 has some defects in exit from ER, we studied the 
glycosylation pattern of WT, ∆TSQF and ∆TSQF Y503A transporters. Alterations in 
glycosylation were determined by differential glycosidase digestions, and were reflected by 
changes in electrophoretic mobility. 
Endoglycosidase H (Endo H), cloned from Streptomyces plicatus, prefentially hydrolyzes N-
glycans of the high mannose type [Kobata, 1979], thus identifying the early form of 
glycosylation. N-Glycsidase F (PNGase F), cloned from Flavobacterium meningosepticum,  
cleaves all types of asparagine-bound N-glycans, from the early to the mature complex forms  
[Tarentino et al., 1985]. 
We used the reagents and the protocol supplied by the manufacturer (New England Biolabs, 
Beverly, MA, USA). Briefly, MDCK clones were lysed in lysis buffer (150 mM NaCl, 30 
mM Tris-HCl, 1 mM MgCl2, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride, and  1 
µg/ml aprotinin and leupeptin) and 500 µg of total protein extracts were denatured in 1x final 
Glycoprotein Denaturing Buffer (stock 10x) for 10 min at 100 °C. Then, samples were split 
into three aliquots: mock digested as control, Endo H or PNGase F digested. G5 buffer (for 
EndoH) or G7 buffer (for PNGaseF) were added to 1x final (stock 10X for both the buffers) 
and samples were subjected to digestion with 1000 units (1 µl) of Endo H (1000 U/µl, New 
England Biolabs) or 500 units (1 µl) PNGase F (500 U/µ l, New England Biolabs). After 5 
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hours of incubation, the samples were precipitated, dissolved in Gel Loading buffer and 
analysed by either SDS-PAGE and protein blotting. 
5.8 Cell lysis, SDS-PAGE and Western blotting analyses. 
Cells were harvested and lysed in lysis buffer (150 mM NaCl, 30 mM Tris-HCl, 1 mM 
MgCl2, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride, and 1 µ g/ml aprotinin and 
leupeptin). After 1 h at 4° C, lysates were centrifuged at 13000 rpm for 10 min, the extracted 
proteins were denaturated with sample buffer (5% SDS, 20% Glycerol, 0.3M β-
mercaptoethanol, blue bromophenol) and separated by 9% SDS-PAGE (Tris-Gly/ SDS buffer: 
25 mM Tris-Base, 192 mM Glycine, 0.1% SDS). Finally, proteins were transferred to a 
nitrocellulose membrane (Shleicher and Shull, Germany) (Transfer buffer: 25 mM Tris-Base, 
192 mM Glycine, 20% Methanol). After membrane incubation with blocking buffer (2% non-
fat milk, 0.1% Tween 20, 20 mM tris HCl pH 7, 150 mM NaCl), the blots were probed with 
the indicated primary antibodies, with peroxidase-conjugated anti-rabbit or anti-mouse IgG as  
secondary reagents, and visualised by ECL (Perkin-Elmer Life Science). 
The X-ray films were analysed by densitometry and the results quantified using NIH Image 
1.59 software. 
5.9 Na+-dependent transport activity 
MDCK cells plated in 96-well plates were transfected with the different constructs (pEFGP-
EAAC1 WT, ∆TSQF, ∆TSQF-Y503A, Y503A). Three hours after transfection, cells were 
incubated for 12 hours with BFA. The next day, we washed BFA out and we followed 
EAAC1 appearance at the cell surface by [3H]-D-Aspartate uptake at different incubation time 
after BFA removal. 
At each time point (0, 5, 10, 15, 20, 30, 60 minutes of chase), cells were washed twice in 
sodium-free solution (150 mM choline chloride, 4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 
mM HEPES, pH 7.5) and then assessed for D-aspartate uptake (3 µCi/ml; specific activity 37 
Ci/mmol, Amersham Biosciences) performed in 200 µl of uptake solution (150 mM NaCl, 4 
mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.5) for 5 min at room temperature. 
Amino acid uptake was stopped by washing the cells twice in ice-cold sodium-free solution. 
The cells were dissolved in 150 µl of SDS 1% for liquid scintillation counting.  
Data are presented as a percentage of GFP-transfected cells. 
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5.10 Metabolic labelling 
Metabolic labelling was performed as described [Perego et al., 1999]. Confluent MDCK 
clones were starved for 30 min in Dulbecco’s modified Eagle’s medium (DMEM) without 
cysteine and methionine, and metabolically labelled for 3 h with 0.1 mCi/ml of Trans35S-
label (ICN Pharmaceuticals) in starving medium [Lisanti et al., 1989]. The cells were washed 
at 4°C and chased for different times (up to 15 hours) in culture medium at 37°C. The cells  
were lysed, and the transporters immunoprecipitated by incubation with polyclonal anti-GFP 
antibody (Invitrogen, 1:1000), followed by a second incubation with protein A conjugated to 
Sepharose beads  (Pierce) [Pietrini et al.,  1994]. The transporters were eluted from the protein 
A–beads by boiling in 0.5% SDS. The immunocomplexes were resolved on 10% SDS–PAGE 
and analysed by 35S emission on film. 
5.11 Statistical analysis 
Statistical significance between groups was determined by means of an unpaired Student’s t-
test; the differences were considered significant at P values of <0.05. 
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CHAPTER III: Expression and pathophysiological role of 
GLT1 transporter in endocrine pancreas 
 
1 ABSTRACT 
Glutamate is the major excitatory neurotransmitter of the central nervous system (CNS) but it  
is also present in endocrine pancreas, where it is secreted by the glucagon producing α-cells  
and acts as signal molecule in the islets of Langerhans.  
In the CNS, glutamate may cause cell death by excitotoxicity, but the effect of glutamate on 
islet cell function and survival is presently unknown. Moreover, although all the glutamate 
signalling system has been charcterized in the islets, less is known about the expression and 
the physiological role of glutamate transporters, that in the CNS are the main effectors of 
glutamate clearance. 
In this study, we demonstrate that exposure to elevated glutamate concentrations induces a 
significant cytotoxic effect also in pancreatic β-cells, while not in α-cells.  Glutamate-induced 
β-cell cytotoxicity is due to the prolonged activation of ionotropic glutamate receptors and 
leads to apoptosis. We provide evidence that the key regulator of the extracellular glutamate 
clearance in the islet is the glial glutamate transporter 1 (GLT1/EAAT2). GLT1 is the only 
high affinity glutamate transporter expressed in the islets and localizes to the β-cell plasma 
membrane. Its main role is to prevent glutamate-induced cytotoxicity and β-cell apoptosis.  
Finally, as diabetes is characterized by an elevated beta cell death, we verified if there were 
some modifications in the localisation of GLT1 in type 2 diabetes mellitus (T2DM) patients. 
We show an altered GLT1 localisation in pancreases from T2DM patients, suggestive of a 
decreased glutamate clearance ability in these subjects. 
In conclusion, our data demonstrate that glutamate-induced citotoxicity could represent a 
mechanism of β-cell death and is physiologically prevented by the activity of the glutamate 
transporter GLT1. 
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2 INTRODUCTION 
2.1 Pancreas 
Pancreas is a voluminous gland localised in the abdomen and implicated in the production of 
two different secreting products: one exocrine, containing enzymes and bicarbonate required 
for the digestion, and the other endocrine, involved in glucose homeostasis and metabolism. 
These two secreting functions are exploited by discrete structures present in the organ. The 
endocrine part is dispersed throughout the exocrine tissue, and it is organised small cell 
aggregates, called islets of Langerhans. 
 
 
 
FIG. 1: Endocrine pancreas. The 
islet of Langerhans is shown in  the 
histological sample. The different  
cell populations are represent ed in  
the scheme, a part from F cells. 
 
[Silverthorn, 2000] 
 
The islets of Langerhans, a miniature organ for regulation of blood glucose level, are 
composed of four major types of endocrine cells that secrete different hormones to regulate 
blood glucose levels and other aspects of metabolism. The four types of islet cells are listed in 
the table below, with their secreting products. 
 
CELL HORMONE 
Alpha (α) Glucagon 
Beta (β) Insulin 
Delta (δ) Somatostatin 
F Pancreatic Polypeptide 
 
TABLE 1: Islet endocrine cells and their secreting products. 
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In the morphology of the islets, the beta cells are the most numerous and the alpha cells are 
larger and less numerous. Moreover, depending on the specie, it has been reported a 
characteristic distribution of this two cell types in the islet: in mice, beta cells are concentrated 
in the centre of the islet, while alpha cells are located at the periphery of the islet. 
The islets are richly innervated by parasympathetic and sympathetic neurons. Several 
different neurotransmitters such as acetylcholine, noradrenaline, and neuropeptides are 
secreted from these nerve endings and regulate the secretion of hormones. 
2.1.1 Insulin secretion 
Pancreatic islets monitor and respond to many dietary nutrients, releasing hormones in order 
to meet the needs of the organism. 
In particular, beta cells release insulin, a peptide hormone present in their secretory vesicles. 
The primary stimulus for insulin secretion is the increase in plasma glucose concentration.  
Another well known characteristic of insulin secretion is its bifasic kinetic, an essential 
feature that is shared between humans, rats and mice (Fig. 2). The response to glucose begins  
after a lag period of 1 to 2 min and is characterized by a stimulation of release that peaks after 
3 to 4 min, and then declines rapidly to a nadir at 8 min. The initial spike of release is defined 
as the first phase. Then, the second phase is characterized by a gradually increasing rate of 
release to a plateau after a further 25 to 30 min. 
 
 
 
FIG. 2: Bifasic insulin release in rat islets.  
The change in glucose concentration (from 2,8 
to16,7 mM) is indicated by the arrow.  
Insulin release appears after 1-2 minutes, when 
the glucose metabolism is enhanced. After 4  
minutes, release rate has a fast increase, as 
indicated by the peak, and then it decreases. 
The second secretion phase is charact erized by 
a slow increase of secretion rate, until it reaches  
a plateau.  
 
[Straub and Sharp, 2002] 
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FIG. 3: Simplified representation of the 
main pathways for insulin release. KATP 
Channel dependent and independent pathways  
are shown. Acetylcholine and GLP1 can 
enhance insulin release, acting on G-protein 
receptors. 
KATP Channel: ATP-dependent Potassium 
Channels. 
VDCC: Voltage Gated Calcium Channels. 
GLUT-2: Glucose transporter. 
DAG: DiAcylGlycerol. 
 
[Straub and Sharp, 2002] 
 
The presence of these two phases is related to two different pathways for vesicle release (F ig. 
3): K-ATP channel dependent and K-ATP channel independent, involving different pools of 
insulin granule and responding to different nutritional stimuli.  
The first phase of insulin release, also identified as K-ATP channel dependent pathway, is 
driven by glucose metabolism, and has been defined Glucose stimulated insulin secretion 
(GSIS). 
Indeed, during GSIS, the glucose metabolism enhances cytoplasmatic ATP/ADP ratio, that in 
turn reduces the open probability of ATP sensitive K+ channels in the plasma membrane, thus  
leading to depolarization and subsequent opening of voltage gated Ca2+ channels, responsible 
for exocytosis.  
The second phase, K-ATP channel-independent pathway, potentiates the secretory response to 
the increased [Ca2+]I, and can also be induced by DAG or phorbol esters. 
Several metabolic factors downstream glucose entry in the beta cell have been proposed to 
support the second phase of insulin release.  
First, glucose anaplerosis induces an increase in the amount of mitochondrial citrate, which is  
exported to the cytosol and transformed in malonyl-CoA. The latter induces the inhibition of 
carnitine palmitoyl transferase 1 (CPT1), thus blocking transport of long-chain acyl-CoA into 
the mitochondria. Accumulation of long-chain acyl-CoA in the cytosol leads to an increase in 
intracellular calcium levels [Corkey et al., 1989; Prentki et al., 1992; Chen et al.,  1994; Brun 
et al., 1996]. 
Second, glucose induces an increase in the production of glutamate in the mitochondria, that 
is exported to the cytosol. It has been proposed that in the cytosol, glutamate sensitizes the 
secretory machinery to Ca2+, perhaps by an action on the insulin-containing granules  
[Maechler and Wollheim, 1999; Rubi et al., 2001; Maechler and Wollheim, 2000]. Another 
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hypothesis is that glutamate may exert an additive action on mitochondrial malate/aspartate 
shuttle function [Newsholme et al., 2010]. 
Another speculation predicts that increased glucose concentrations provoke changes in 
concentrations and ratios of nucleotides such as ATP, adenosine diphosphate (ADP), GTP, 
and guanosine diphosphate (GDP) that may participate in regulation of the KATP channel-
independent pathway [Henquin, 2000; Sato and Henquin, 1998; Detimary et al., 1996; 
Detimary et al., 1998]. 
Other metabolic factors and substances have been shown to play important roles in the 
regulation of hormone release. We tried to summarize the different regulatory factors in the 
table below: 
 
 
 
 
 
 
 
 
In particular, an emerging role has been attributed to lipids and amino acids, that are thought 
to be involved in the second phase of insulin release (KATP channel independent). 
The role of lipids as insulin secretagogues has been debated, since they seem to have different  
effects on hormone release, depending on the acute or chronic exposure: the former promotes 
insulin release, whereas the latter inhibits it [Zhou and Grill, 1994; Gravena et al., 2002]. 
Lipid effect is also linked to the saturation and the length of the acyl chain [Gravena et al.,  
2002]. 
Compared to the other nutrients, plasma amino acids seem to be the more effective on insulin 
release: in vivo amino acids derived from dietary proteins and those released from intestinal 
epithelial cells, in combination with glucose, stimulate insulin secretion. 
The hypothesis is that the stimulatory action of amino acids on insulin secretion can be 
attributed to different possibilities [Newsholme et al., 2010; Mc Clenaghan NH et al., 1996]:  
1- amino acid metabolism with generation of ATP (glutamine, leucine) 
2- direct membrane depolarization (cationic amino acids, arginine) 
3- Na+/amino acid co-transport with consequent depolarization (alanine) 
4- receptor activation (glutamate, see below) 
Insulin secretagogues Insulin secretion inhibitors 
Glucose Somatostatin 
Mannose 2-Deoxyglucose 
Amino acids Mannoeptulose 
Enteric hormones Galanin  
β-ketoacids Phenitoin 
AcetylCholine Diazoxide 
Glucagon Insulin 
cAMP Tiazolidinic diuretics  
β-adrenergic agonist  α-adrenergic agonist 
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2.2 Endocrine pancreas and glutamate 
2.2.1 Glutamate signalling and hormone release 
A particular amino acid that must be analysed for its modulatory action on pancreatic 
hormone release is glutamate.  
In the pancreas, the presence of glutamate as a signalling molecule is well established 
[Hayashi et al., 2003] and paracrine-like signalling has been proposed as a novel regulatory 
mechanism for islet hormone secretion [Moriyama and Hayashi, 2003]. 
Glutamate could function as an intercellular signal mediator in the islets as they possess all 
the necessary elements of L-glutamate mediated transmission. Several research groups have 
reported that islets cells and clonal islet cells express functional glutamate receptors [Hayashi 
et al., 2003; Molnár et al., 1995; Weaver et al., 1996; Tong et al., 2002] and vesicular 
glutamate transporters [Bai et al., 2003] 
 
iGluRs mGluRs VGLUT 
Ampa, Kainate, 
NMDA Group I, II, III VGLUT 1 and 2 
 
TABLE 2: Expression of glutamate signalling molecule in pancreas.  
[Hinoi et al., 2004] 
  
L-glutamate is co-stored and co-secreted with glucagon in alpha cells and the stoichiometric 
amounts of glutamate and glucagon are 2000:1 (molar ratio), respectively [Bai et al., 2003]. 
Glutamate in alpha cells might originate not only from intracellular synthesis by means of 
glutaminase, but it has also been proposed that it can derive by uptake of plasma L-glutamate 
through a sodium dependent glutamate transporter [Weaver et al., 1998]. 
For vesicle loading, vesicular glutamate transporters, with a H+ dependent uptake activity, 
were found in alpha cells but not in gamma cells, suggesting that only alpha cells are able to 
store glutamate [Bai et al., 2003]. 
 
Several independent lines of evidence indicate expression of both iGluRs and mGluRs in 
pancreatic islets.  
Among ionotropic glutamate receptors, AMPA are functionally distributed in alpha and beta 
cells [Gonoi et al., 1999; Inagaki et al., 1995; Molnar et al.,  1995; Weaver et al., 1996; 
Morley et al., 2000; Weaver et al., 1998]. On the other hand, the expression of functional 
kainate receptors is negligible, even though it has been reported that pancreatic β cells express 
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both AMPA and kainate currents similar to those reported in neuronal cells [Weaver et al.,  
1996]. Some laboratories have detected the expression of NMDA receptors in the islets, 
although neither NMDA receptor subunits, nor NMDA evoked ion transport have been 
observed. 
It has been reported that AMPA and kainate stimulate insulin secretion from perfused or 
isolated islets or clonal cells in the presence of high level of glucose [Gonoi et al., 1999; 
Inagaki et al., 1995; Bertrand et al., 1992 and 1995]. Considering just the paracrine role of 
glutamate, this evidence is not completely convincing in normal physiological conditions, 
because L-glutamate is co-secreted with glucagon when the islets are immersed in low blood 
glucose levels. In that situation, glutamate signalling should not be directly involved in insulin 
secretion, that usually occurs in the opposite condition of high glucose levels. In line with this 
hypothesis, a recent work by Cabrera, did not show any influence of glutamate signalling on 
the regulation of insulin secretion [Cabrera et al., 2008].  
However, the role of glutamate in modulating insulin release can not be completely ruled out, 
as it could also originate from plasma, where it could reach a concentration of 50-200 µM.  
L-glutamate and AMPA have been shown to stimulate glucagon secretion from the perfused 
pancreas and in mice, where activation of iGluRs is needed for efficient glucagon secretion in 
response to hypoglycaemia [Brice et al., 2002; Bertrand et al., 1993; Cabrera et al., 2008]. 
A more widespread expression pattern of mGlu receptors has been reported in the islets and in 
clonal cells. It has been demonstrated that also mGluRs participate in hormone secretion from 
pancreatic islets. Agonists of group I and II increase the release of insulin in the presence of 
glucose at low concentration, whereas a group III agonist inhibits insulin release at high 
glucose concentrations [Brice et al., 2002]. By contrast, a class III metabotropic receptor 
antagonist, inhibits glucagon secretion [Uehara et al., 2004; Tong et al., 2002]. 
Thus, the activation of glutamate receptors does not always correlate with hormone secretion, 
but these results may be influenced by the metabolic state of the organism wherein the 
glutamate appears in the interstitial space.  
2.2.1.1 ISLET PARACRINE INTERPLAY 
A proposed function for glutamate as an extracellular signal mediator is to participate in islet 
cross-talking, that can be significant in the control of hormone release (Fig. 4). 
Indeed, β cells store GABA in Synaptic-like micro-vesicles (SLMVs), which are secretory 
vesicles distinct from insulin granules, and secrete GABA by Ca2+-dependent exocytosis 
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[Thomas/Reetz et al., 1993; Anhert-Hilger et al.,1996]. On the other hand, in alpha cells  
glutamate is co-stored with glucagon in stoichiometric amounts. 
 It has been proven that low glucose conditions result in co-secretion of stoichiometric 
amounts of glutamate and glucagon from αTC6 and isolated islets, which triggers GABA 
secretion from β cells [Reetz et al., 1991; Hayashi et al., 2003]. In particular, in the presence 
of low glucose, stimulation of AMPA receptors facilitates GABA secretion from beta cells  
with little effect on insulin secretion. [Hayashi et al., 2003]. The GABA mediated signalling 
from beta cells in turn inhibits glucagon and glutamate secretion from alpha cells, by 
activation of GABA A receptors on alpha cells [Rorsman et al., 1989]. Also stimulation of 
mGlu8 receptors on alpha cells inhibits glucagon secretion, suggesting a role of glutamate in 
autocrine signalling. 
It is likely that L-glutamate signalling also triggers  somatostatin secretion, which in turn 
inhibits glucagon secretion, through somatostatin sst2 receptors [Muroyama et al., 2004; 
Moriyama and Hayashi, 2003]. 
 
 
 
FIG. 4: Hypotetical role 
of neurotransmitters in 
regulation of pancreatic 
hormone secretion. 
 
[Moriyama and Hayashi, 
2003] 
 
2.2.1.2 GLUTAMATE TRANSPORTERS 
The cellular response to glutamate could be controlled, directly and indirectly, by regulating 
transport of amino acid across the plasma membrane. In particular, flux through glutamate 
transporters may act as a modulator of hormone secretion by increasing intracellular amino 
acid content or by controlling extracellular amino acid concentration and therefore receptor 
activation.  
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There are few evidences of glutamate transporter expression in endocrine pancreas and they 
lack some information regarding their physiological roles.  
Sodium dependent glutamate uptake has been detected in the mantle region of islets [Weaver 
et al.,1998], most probably alpha cells, that are able to sequester glutamate from the 
interstitial space of the islets. The expression of genes encoding sodium dependent glutamate 
transporters has been detected in isolated islets [Manfras et al., 1994]. Moreover, it has been 
proposed that a high affinity glutamate transporter expressed in pancreatic islets of 
Langerhans, modulates insulin secretion stimulated by glucose [Weaver et al., 1998].  
2.2.2 Glutamate in islet pathological conditions 
Islets of Langerhans show a sophisticated glutamate paracrine system, where all the elements  
required for glutamatergic transmission, including ionotropic receptors are expressed. 
Glutamate derives both from plasma amino acid pool and from alpha cell granules. In 
addition, it has been demonstrated that during diabetes the islet or plasmatic glutamate level 
may further increase.  
2.2.2.1 DIABETES 
Although there are several subtypes of diabetes mellitus, each with a different pathogenesis, it  
is now recognised that diabetes is characterised by a defect in insulin secretion caused by a 
deficit and/or functional impairment in insulin producing β cells and by the consequent 
development of hyperglycaemia. The time of onset, the speed of progression and the nature of 
precipitating factors (external or genetic) that cause the defect in insulin secretion vary in the 
different subtypes. It seems that beta cell death may be what connects type 1 and type 2 
diabetes [deKoning et al., 2008]. 
 
Type I diabetes 
Currently type 1 diabetes affects 0,5% of the population in developed countries and it is  
increasing in incidence. It is not known what triggers it and there is little understanding of the 
genetic and the environmental factors regulating its progression. Thus, it is not known how to 
prevent or reverse type 1 diabetes. 
Type 1 diabetes is an autoimmune disease resulting from specific destruction of the insulin 
producing beta cells of the islets of Langerhans in the pancreas [Tisch and McDevitt, 1996]. It 
has two distinct phases: insulitis, when leucocytes invade the islet, and diabetes, when most of 
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the beta cells have been killed, and there is no longer sufficient insulin production to regulate 
blood glucose levels, resulting in hyperglycaemia. 
Destruction of beta cells is a crucial event at disease outset, initiating autoimmunity. Indeed, 
type 1 diabetes is primarily a T-lymphocyte mediated disease [Tisch et al., 1996; Bach and 
Mathis, 1997].  
 
Type II diabetes 
Type 2 diabetes is by far the most common subtype, and its occurrence is increasing rapidly 
because of an imbalance between food intake and energy expenditure, which leads to obesity 
and insulin resistance [Wild et al., 2004].  
The pathogenesis of the type II diabetes is non-autoimmune in nature and remains  
controversial, although there is a general agreement that both insulin resistance and a beta cell 
defect contribute to the disease. Depending on genetic or environmental factors, a fraction of 
type 2 diabetics may exhibit abnormal beta cell death, that may degenerate to such a degree 
that insulin therapy becomes necessary in advanced stage of the disease. As a consequence of 
reduced beta cell mass, type 2 diabetes is characterized by the absence of a first phase insulin 
response and abnormalities in insulin pulsatility [Leahy et al., 1988].  
Many observations indicate a negative effect of high glucose concentration, termed 
glucotoxicity, on glucose sensing, insulin gene expression, insulin secretion and beta cell 
survival [Robertson 2004; Leahy et al., 1992].  
A support for a progressive decline in beta cell mass during the course of the disease is  
provided by in vitro experiments, where elevated glucose concentrations, analogous to those 
seen in type 2 diabetics, can induce apoptosis of cultured human islets [Federici et al.,  2001]. 
Better evidence for beta cell death in late stages of type 2 diabetes comes from animal 
models: when Psammomys obesus (gerbil) is kept in captivity and is fed with high energy 
diet, an increase in apoptosis occurs and it develops diabetes [Bar-On et al., 1999; Donath et 
al., 1999]. A modest reduction in the beta cell mass of type 2 diabetes individuals at autopsy 
has been reported [Clark et al., 1998]. 
In Caucasians, compared to obese normoglycaemic subjects, relative beta-cell mass is reduced 
by 40% in obese subjects with impaired fasting glucose, and by 63% in obese subjects with 
type 2 diabetes [Sakuraba et al.,  2002; Yoon et al., 2003]. Moreover, an increased number of 
apoptotic beta cells was observed in the islets of diabetic subjects compared with those of 
normoglycaemic subjects [Butler et al., 2003]. One possible mechanism of beta cell death 
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could be a decrease in the ratio of anti-apoptotic to pro-apoptotic members of the bcl 2 family 
[Federici et al., 2001].  
2.2.2.2 GLUTAMATE AND DIABETES 
Many studies have underlined alterations in glutamate homeostasis that correlated with both 
type one and type two diabetes, even though it is not described any clear relationship between 
the two phenomena.  
Variations in plasma glutamate concentration have been reported in T1DM and T2DM, 
although deriving from different origin.  
In children who later progress to type 1 diabetes, alterations in the metabolic profile 
characterize the early pathogenesis of the disease, suggesting a role in its progression. The 
appearance of insulin and glutamic acid decarboxilase autoantibodies (IAA and GADA) in the 
serum is preceded by abnormally high glutamic acid (13 fold increase). Glutamic acid 
increase is dependent on the time when autoantibodies appeared: 0-9 months before the 
seroconversion, there is a peak of serum glutamic acid (32-fold), that slightly decreased in the 
following months (to 5.2 fold), while after the seroconversion, the metabolic profile is  
partially normalised. Such evidences could suggest that the initial autoimmune response is 
physiological and aimed at restoring the metabolic homeostasis [Oresic et al., 2008]. 
During the pathological development and the drug intervention of type 2 diabetes mellitus 
(T2DM), is involved altered expression of serum low molecular weight metabolites, including 
carbohydrates, long chain fatty acids and amino acids. In particular, among amino acids, 
serum glutamate is significantly increased in diabetic subjects. Interestingly, three treatments 
used for the therapy of T2DM were tested in patients and were able to down-regulate the high 
level of glutamate [Bao et al., 2009]. 
In addition, changes in glutamate concentration may occur also in the islet microenvironment  
and might contribute to disease progression as well as participate in the late stages of the 
disease. 
Indeed, during lymphocyte islet infiltration in type 1 diabetes, glutamate regulates the 
initiation of immune response [Pacheco et al., 2006]. Human dendritic cells (DC) release 
significant amounts of glutamate, that acts on mGluR1 expressed on T cells after antigen 
presentation, and it mediates enhanced T cell proliferation and secretion of Th1 and 
inflammatory cytokines. Normal human T cells express also high levels of AMPA ion 
channel receptors, that can trigger integrin mediated T cell adhesion to laminin and 
fibronectin [Ganor et al., 2003].  
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Moreover, both T1DM and T2DM are characterised by an increase in beta cell death, thereby 
leading to a change in alpha/beta cell ratio [Clark et al., 1988; Unger and Orci, 2010]. In 
particular, in type two diabetes, in the corpus (body, tail and anterior part of the head of the 
pancreas) the mean α/β-cell ratio increased from 0.27 in control subjects to 0.57 in Type 2 
diabetic patients [Clark et al., 1988]. Thus, during the response to physiological stimuli, the 
increased number of alpha cells is able to secrete more glutamate in the extracellular space. 
In addition, in the normal physiology of the islets, glucagon (and therefore glutamate) 
secretion is under control of a negative paracrine feedback from GABA A receptors present 
on alpha cells. In an imbalanced situation of low percentage of GABA secreting beta cells,  as  
happens during diabetes, this negative feedback could be impaired, leading to a massive 
glutamate release.  
Furthermore, in both types of diabetes, has been described a paradoxical effect of 
hyperglycaemia on glucagon release. In normal conditions, immediately after the ingestion of 
a carbohydrate-containing meal, a spike of insulin release occurs and is believed to be the 
cause of glucose-induced glucagon suppression (fig.5). 
 
 
 
FIG. 5: Demonstration of the 
reciprocal responses of insulin 
and glucagon to 20 mg/dL 
changes in the concentration of 
glucose perfusing the isolated 
pancreas of 
rats. Dotted lines mark the full  
contour of the first phase. 
 
In T1DM, glucose increases without a parallel insulin increase and hyperglycaemia will 
paradoxically stimulate glucagon and therefore glutamate secretion [Braaten et al., 1974; Le 
marchand, et al. 2010]. 
In T2DM the initial spike is lost, thus glucagon remains unsuppressed and elevated relative to 
the ambient glucose concentration, exaggerating the postprandial hyperglycaemia [Unger and 
Orci, 2010]. 
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FIG. 6A: In T1DM, due to the absence of 
juxtaposed insulin-secreting cells, basal glucagon 
levels are increased and they increase further in a 
paradoxical response to hyperglycaemia from a 
carbohydrate-containing meal.  
 
 
FIG. 6B: In T2DM, α-cells are not suppressed by 
the hyperglycaemia, because of the loss of the first-
phase spike of insulin release immediat ely aft er the 
ingestion of a carbohydrate-containing meal.  
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In the CNS, activation of glutamate ionotropic receptors has been identified as the mechanism 
underlying glutamate toxicity [Choi et al., 1987] and it has been reported that glutamate can 
also be toxic outside the CNS [Said et al., 1996].  
The effect of glutamate on islet cell function and survival is presently unknown, thus we 
thought that it could be interesting to understand whether and how islets can become resistant 
to the toxicity of blood glutamate.  
There are two ways to explain the glutamate resistance: in pancreatic cells, glutamate 
ionotropic receptors may not have a drastic effect on survival, or an efficient system that 
removes glutamate from the extracellular space exists. 
The presence of glutamate receptors in the islets has been characterised and their subunit  
assembly and conductances seem to be similar to the one in the CNS. 
We previously found that clonal β cells selectively express GLT1 transporter (Fig. 7A). We 
confirmed the expression of GLT1 in human pancreases, by means of double 
immunofluorescence analysis (Fig. 7B) [Tesi di Laurea Magistrale-Di Cairano, 2007]. 
 
 
 
FIG. 7A: Expression of high-affinity glu tamate transporters in αTC1 and βTC3 cell s. RT-PCR analysis of 
SLC1A glut amate t ransport er subtypes (+).  Negative cont rols (-):  PCR reactions performed in  the absence of 
cDNA. Posi tives cont rols: Tubulin ampli fi cation; primers consi stency was checked using B rain cDNA as a 
templat e; INS1E cDNA to confirm GLT1 expression in β cells. Markers on the left indi cat e bp. 
 
In this work, we investigate its physiological role in the islets. 
Moreover, since alterations in glutamate homeostasis have been observed in patients affected 
by diabetes and glutamate transporters have been proposed as key regulators of the 
extracellular glutamate concentration, we investigated whether GLT1 may be involved in 
diabetes progression. 
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 FIG. 7B: GLT 1 locali zes to th e plasma memb ran e of the β -cell s. Immunofluorescence 
staining of human pancreas sections with anti-GLT1 (red) and hormones (green) as markers of 
di fferent endocrine cell types. S cale bar = 10 µm. In t he i nset, a parti cul ar of t he i slet is shown at  
higher magni fi cation (2x). The yellow/orange st aining indi cates co-locali zation between the 
transport ers and the hormones.  
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3 RESULTS 
3.1 βTC3 cells are vulnerable to glutamate-induced cytotoxicity  
We first determined whether β- and α-cell lines were vulnerable to extracellular glutamate.  
βTC3 and αTC1 were cultured in freshly prepared medium in the presence of different  
glutamate concentrations (ranging from 0.05 to 5 mM) and cell viability was assayed by the 
MTT test. Exposure to glutamate induced a dose- and time-dependent decrease of βTC3 
viability (Fig. 1A, B). As previously shown in MIN6 cells [Morley, 2000], we did not observe 
glutamate-induced cytotoxicity after a 20 min incubation at 5 mM, as usually occurs in 
neurons [Perego et al., 2000]. Notably, αTC1 cells were resistant to glutamate-induced 
toxicity showing a small decrease in viability only after 5-day exposure to 5 mM glutamate 
(Fig.1A). 
 
 
 
FIG. 1: Ch ronic incubation wi th glutamate impairs β -cell viability (A). αTC1 and βTC3 
cell viability measured by MTT assay after cell incubation with the indi cat ed glut amate 
concent rations for 5 days. The R elative Growth R ate (R GR) is present ed as  percent age of 0  
mM glut amate and dat a are mean ± s.e.m., n= 7 with 8 repli cat es. (* p< 0.0001 vs Ct r; ** 
p<0.01 vs Ctr). (B). βTC3 vi abi lity measured by MTT assay aft er i ncubation with 5 mM 
glutamate for the indicat ed times. Data are present ed as  percent age of each rel ative Ct r (no 
glutamate) and are mean ± s.e.m. n=4 with 8 repli cates. (* p<0.001 vs Ctr). (C ). βTC3 
viabi lity measured by MTT assay aft er i ncubation with DMEM media supplemented with 
the indi cat ed glut amate concentrati ons. Data are present ed as percent age of 0 mM glut amate 
and dat a are mean ± s. e.m., n=3 with 8 repli cates (* p< 0.05 or **p< 0.01 vs Ct r). 
 101 
As βTC3 and αTC1 usually grow in different media, RPMI and DMEM respectively, the 
latter containing no glutamate, we assessed glutamate toxicity in βTC3 in the presence of 
DMEM media. Also in this media, βTC3 showed a significant decrease in viability, that is 
similar to that obtained in RPMI media (Fig. 1C). 
Glutamate-induced cytotoxicity caused βTC3 apoptosis. In fact, 5-day incubation in the 
presence of 0.5 mM glutamate, a physiological relevant concentration, significantly increased 
the number of TUNEL positive βTC3 (Fig. 2). 
 
 
 
FIG. 2: β -cell d eath is mediated  by apop tos is. Determination of βTC3 cells  
apoptosis by TUNEL assay aft er incubation with 0.5 mM glutamate for 5 days. Cell  
nucl ei were l abell ed with Propidium iodide. On the left panel is shown fluorescence 
image, scal e bar: 50 µm. On the right panel is shown quanti fi cation of TUNEL-
positive β -cel ls. Data are the mean ± s. e.m. of 3  independent  experiment s performed 
in dupli cat e (* p< 0.05) 
 
These data indicate that β-cells, similarly to oligodendrocytes and neurons, are vulnerable to 
glutamate-induced cytotoxicity while α-cell are resistant [Choi et al., 1987]. 
 
3.2 Excitotoxicity is responsible for glutamate-induced βTC3 apoptosis 
To determine whether glutamate-induced βTC3 toxicity was mediated by excitotoxicity, we 
exposed βTC3 to high glutamate concentrations in the presence of specific ionotropic 
receptors’ antagonists (Fig. 3A). We could therefore demonstrate that glutamate toxicity was 
partially prevented by the co-administration of 6-Cyano-7-nitroquinoxaline-2,3-dione 
(CNQX), a non-selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
and kainate receptor antagonist (46.3+2.7% increase in RGR relative to 5 mM glutamate; 
p<0.005) but not by D-2-Amino-5-phosphonovaleric acid (APV), a selective N-methyl-D-
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aspartate (NMDA) receptor antagonist. In the absence of glutamate supplementation, βTC3 
viability was not affected by the presence of both glutamate receptor antagonists. These data 
indicate that glutamate-induced βTC3 cytotoxicity is in part mediated by chronic activation of 
AMPA and/or kainate ionotropic glutamate receptors and can be therefore referred as  
“excitotoxicity”, as occurs in the CNS [Choi et al., 1987].  
 
 
 
FIG. 3: Mechanisms of β -cell death : ionotropic recep tors’ activation and oxidative 
stress. (A). Viability  of βTC3 cells after incubation for 5 days with 0.025 mM CNQX or 
0.1 mM APV, with or without 5 mM glut amate measured by MTT assay. Data are 
present ed as  RGR  and are mean ± s. e.m. n= 3 with 8 repli cat es.  (#p<0.05 vs  0 mM 
glutamate Ct r; *p<0.05 vs 5 mM glutamate Ct r). (B). Evaluation of tot al SH content i n  
βTC3 cells aft er incubation with 5 mM glut amate. Data are expressed as % of CTR and 
are the mean ± s. e.m. of 4  independent  experiments performed in dupli cate (*p<0.05).  In  
the inset is shown RT-PCR analysis of xCT subunit i n βTC3 cells. 
 
As CNQX was not able to completely restore βTC3 viability during glutamate exposure, we 
investigated if other mechanisms were involved in glutamate toxicity. It has been 
demonstrated that increased extracellular glutamate may also lead to cell death by oxidative 
stress (oxidative glutamate toxicity) which is mediated by the glutamate/cysteine exchanger 
(x-c) [Tan et al., 2001]. Thus, we first demonstrated that xCT subunit of the x-c exchanger is  
expressed in βTC3 cells by RT-PCR analysis (Fig. 3B, inset). Given xCT expression in βTC3, 
after a 5 day cell treatment with 5 mM glutamate, we measured total SH content as an 
indicator of oxidative stress. We found that chronic incubation with glutamate caused a 
significant reduction in the total SH content (Fig. 3B), thus suggesting that glutamate may 
induce β-cell death also via oxidative stress. 
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3.3 Excitotoxicity can be prevented by treatment with Exendin-4 
To confirm the excitotoxic mechanism of β-cell death, we have exposed βTC3 cells to high 
glutamate and Exendin-4 (Ex-4). Ex-4 is a synthetic long lasting analogue of the enteric 
hormone glucagon-like peptide 1 (GLP-1), recently approved by the Federal Drug 
Administration for the treatment of diabetes. It is known to preserve β-cell mass by reducing 
apoptosis [Farilla et al., 2003; Wajchenberg et al.,  2007] and to protect cultured rat 
hippocampal neurons against glutamate induced apoptosis [Perry et al., 2002]. We 
demonstrated that Ex-4 alone did not alter the viability of βTC3 cells at the concentrations 
tested, but significantly reduced glutamate-induced excitotoxicity (Fig. 4). This mechanism 
can be considered specific, as treatment with glutamate and DPP-IV (dipeptidyl-peptidase 
IV), the enzyme responsible for GLP-1 inactivation, did not show any improvement in βTC3 
viability. 
 
 
FIG. 4: Ph armacological p revention of exci totoxici ty  
restores β -cell survival. Determination of β-cell  
viabi lity by MTT assay after incubation for 5  days  in 10 
or 100 nM Exendin-4 and 10 mM DPPIV with or without  
5 mM glutamate. Data are present ed as RGR and are 
mean ± s.e.m.; n=3 with 8 repli cat es. (*p< 0.005, vs Ct r 
in 5 mM Glutamate). 
 
3.4 GLT1 protects βTC3 from excitotoxicity 
The selective expression of GLT1 transporters in β cells has been established in previous  
studies [Tesi di Laurea Magistrale-Di Cairano, 2007]. We then investigated its physiological 
relevance in islets. Therefore, we tested whether a function of GLT1 is to protect against  
excitotoxicity, as occurs in the CNS [Choi et al., 1987]. To this aim, we thought to assess  
beta cell viability during pharmacological inhibit ion of the transporter. 
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First, we t ested the inhibition ability of dihydrokainate (DHK), a selective GLT1 inhibitor 
[Arriza et al., 1994], in βTC3 cells, where acute exposure to DHK induced a dose-
dependent inhibition of Na+-dependent [3H]-D-aspart ate uptake, with an IC5 0= 0.05 mM 
DHK, in line with previous reported Ki [Kawahara et al., 2002] (Fig. 5A). We avoided 
higher concentrations (1 mM), known to affect ionotropic receptor activation [Wang et al.,  
1998], to isolate the specific effect on GLT1 transporter. 
 
 
 
FIG. 5: Th e GLT1 transporter con trols th e extracellular 
con cen tration of glu tamate and β -cell viability. (A). The Na-dependent  
[3H]-D-Aspart at e upt ake in  βTC3 cel ls was  measured in  the presence of 
increasing DHK concent rations. Data are expressed as cpm/well/ 15 min 
and are mean ± s.e.m. ; n=3 performed in t ripli cat e. (*P< 0.01: vs CTR).  
(B ). Determinat ion of ext racel lul ar glut amate concent rati on by enzymati c 
assay aft er βTC3 cel ls incubation with or without 0.1 mM DHK for 5  
days. Data are expressed in mM and are mean ± s.e.m.; n= 4, performed in  
tripli cat e (*p<0.05). (C ). Determination of βTC3 cell s vi abilit y by MTT 
assay aft er incubation with DHK for 5 days. Data are expressed as RGR  
and are mean ± s. e.m. n=3 wi th 8 repl icat es. (*p<0.05, vs CTR). 
 
In presence of GLT1 inhibition (0.1 mM DHK in cell medium for 5 days), we measured 
in the medium of βTC3 cells a significant increase of glutamate level, that reached 
concentrat ion of the same order of magnitude of that toxic for beta cells (F ig. 5B). In 
agreement with this observat ion, DHK induced a decrease in βTC3 viability that was  
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already maximal at 0.05 mM DHK (Fig. 5C), indicating a role of GLT1 in prevent ion of 
glutamate toxicity. Cytotoxicity was due to apoptosis, as revealed by a TUNEL assay  
performed on βTC3 incubated with 0.1 mM DHK for 5 days (Fig. 6). An increase in the 
number of apoptotic nuclei was  observed after DHK treatment. 
 
 
 
FIG. 6: GLT1 inhibition  by DHK indu ces  β -cells apoptosis. Assessment  of β-cells  apoptosis  
by TUNEL assay aft er 5  days i ncubation with 0. 1 mM DHK. C ell nuclei  were labelled with 
Propidium Iodide. S cal e bar:  50 µm. In  the right panel, quanti fi cation of TUNEL-positi ve β-
cells is shown. Data are mean ± s.e.m. of 3  independent experiments performed in dupli cat e.  
(*P<0.05, vs CTR). 
 
Similar results were obtained by reducing the expression of the GLT1 gene in βTC3 by  
means of shRNA (Fig. 8). We first tested whether shRNAs (small hairpin RNAs) were 
effect ive in reducing the tot al express ion of GLT1, by means of western blotting and 
uptake experiments (Fig. 7A, B). From that analysis , we concluded that SH1 and SH3 
were the more promising shRNA to be used in the following exp eriments of GLT1 
down-regulation. 
A 35% down-regulation of GLT1 activity achieved by SH1 was sufficient to increase 
βTC3 cell apoptosis after a 24-hour incubation in 0.5 mM glutamat e, by two to four 
folds (F ig. 8). More int erestingly, the shRNA constructs increased βTC3 apoptosis also 
in the absence of glutamat e supplement ation, suggest ing that impaired GLT1 activity is  
“per se” sufficient to induce βTC3 cell death (F ig. 8), as previously demonstrat ed by  
DHK treat ment. 
Altogether, these data demonstrate a pivotal role of GLT1 in β-cell physiology and in 
protecting β-cells from excitotoxicity. 
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FIG. 7: Validation  of shRNAs against GLT1 transp orter. βTC3 cells were transfected with 
different GLT1 shRNAs (SH1, SH2 and SH3) or a control shRNA (SHC). (A). Determination o f 
GLT1 surface expression by means of Na-dependent  [3H]-D-Aspart ate uptake. Data are expressed as  
percentage of SHC and are mean ± s.e.m. of 3 independent experiments performed in triplicat e 
(*p<0.01, vs SHC). (B). Immunoblotting of 30 µg of whole βTC3 lysate with anti-GLT1 and anti-actin 
antibodies (internal standard). A representati ve blot is  shown. (C). Quanti fication of GLT1 
expression by densitometry. Data were normalized for actin content and expressed as  
percentage of SHC and are mean ± s. e.m. of 3 independent experiments. 
 
 
 
FIG. 8: GLT1 knock down by shRNA causes β -cells death by apoptosis. One day aft er shR NAs 
transfecti on, βTC3 cells were incubated for 2 days wi th or without 0.5 mM glut amate, and apoptosi s  
assessed by TUNEL. C ell nucl ei were l abell ed wi th Propidium iodide. Scal e bar: 50 µm. In the l eft  
panel, quanti fi cation of TUNEL-pos itive β-cel l is report ed. Data are expressed as percent age of t ot al  
cells/ field and are mean ± s.e.m. of 3 i ndependent experiments performed in dupli cat e. (*p< 0.05 vs  
SHC Ctr; **p<0.005 vs SHC 0.5 mM glut amate). 
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3.5 β-cells death can be pharmacologically prevented by treatment with 
Ceftriaxone 
To further support the involvement of GLT1 in the control of β-cell survival, we tried the 
opposite approach compared to DHK/shRNA, that aimed at up-regulating GLT1 expression 
or function. 
 
 
 
FIG. 9: GLT 1 upregulation by Cef triaxone res tores β -cell su rvival. (A). Aft er 
incubation of βTC3 cells with the indi cat ed CEF and glut amate concentrations, 100 µg 
of each cell lysate were immunoblotted with anti-GLT1 and actin antibodies. A representat ive 
blot is shown. (B). Quanti fication of GLT1 expression by densitomet ry. Data were 
normali zed by actin  content  and are expressed as mean ± s.e.m. of 3 independent  
experiments. (*p<0. 01, vs CTR). (C). Determination of β-cell vi abilit y by MTT assay 
aft er incubation for 5 days with the i ndi cat ed C eftri axone (CEF ) and glut amate 
concent rations. Data are expressed as RGR  and are mean ± s. e.m. n=3 with 8 repli cat es.  
(*p<0. 05, 100 µM C EF vs rel ative Ctr; # p<0.05, vs 0 mM glut amate 0 CEF).  
 
Ceftriaxone (CEF) is a β-lactam antibiotic which has been shown to increase brain 
GLT1/EAAT2 expression and activity and to induce neuroprotection in models of ischemic 
injury and motor neuron degeneration by protecting from excitotoxicity [Rothstein et al.,  
2005; Lipski et al., 2007]. This compound may exert its protective function acting on GLT1 
promoter and increasing its expression. Actually, western blot analysis proved that a 5-day 
incubation with CEF induced a 100% increase in GLT1 expression also in βTC3 cells,  
reaching saturation already at 10 µM (Fig. 9A,B). A representative blot is shown in figure 9A 
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whereas band quantification by densitometry was performed on three independent 
experiments using Actin as an internal standard (Fig. 9B). In those conditions, CEF 
determined a dose-dependent protection from glutamate-induced toxicity, as shown by MTT 
experiments carried after a 5-day treatment with glutamate in presence of CEF at different 
concentrations (Fig. 9C).  
Our data show that Ceftriaxone exerts a significant anti-excitotoxic effect on βTC3 cells,  
probably by increasing GLT1 expression. 
3.6 Human islets express GLT1 
Given the possible implications in β-cell physiology and pathology, we next validated our 
findings in humans. 
We confirmed the expression of GLT1 in native human tissues by immuno-histochemistry 
performed on human and monkey pancreatic sections. As shown in Fig. 10A, in both human 
and monkey (Cercopiths) pancreases anti-GLT1 reactivity was limited to the islets while 
absent in the exocrine tissue, indicating that GLT1 is a selective target in endocrine tissue. In 
both species, but even more clearly in the human, GLT1 staining was almost exclusively 
localized to the cell membrane. 
We tested specificity of these staining by incubating human pancreatic sections with a 
preimmune serum or in the presence of a blocking peptide. In these conditions, islets did not 
show GLT1 stain, confirming the specificity of the previous results (Fig. 10B). 
To rule out cross reactions with other members of the high affinity glutamate transporter 
family, we stained sections with an anti-EAAC1/EAAT3 or anti-GLAST1/EAAT2 antibodies  
(Fig. 10C). Also in this case, results were in agreement with a selective staining, indicating 
also that GLT1 is the only high affinity glutamate transporter expressed in the islet of 
Langerhans. 
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 FIG. 10: GLT1 is th e only high affinity glutamate transp orter 
expressed  in the isl et of L angerh ans (A). Immunohistochemist ry staining 
of human or cercopiths  pancreas secti ons with a selecti ve rabbit anti -GLT1 
antibody. Slides were counterst ained with Mayer’s haemalum, to st ain  
cytoplasm and nuclei. 40x image magni fi cations are shown. (B). Human 
pancreas sections were st ained with anti-GLT1 antibodies directed against 
different epitopes (C-terminal epitope and N-terminal epitope). Staining with the 
N-terminal anti-GLT1 antibody was prevented by incubation with 10 fold excess 
of N-terminal blocking peptides. No labelling was detected using a rabbit serum. 
40x image magni fications are shown. (C). No reactivity was detect ed after 
staining of human pancreas sections with anti-GLAST or anti-EAAC1 
antibodies.  
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3.7 Human islets are vulnerable to excitotoxicity that is exacerbated by 
GLT1 inhibition 
Having established the presence of GLT1 in human tissues, we next tried to confirm our data 
on glutamate toxicity and GLT1 cytoprotection in human isolated islets, an in vitro model 
system which has been proven useful to explore the mechanisms involved in β-cell death 
induced by high glucose (glucotoxicity) [Hinoi et al., 2004]. 
Isolated is lets were isolated from human cadaveric donors us ing the method by Ricordi 
at San Raffaele Scientific Institute and Ospedale Niguarda Cà Granda. Islets purity was  
checked and only islets with purity above 80% were used in our exp eriments. 
The first step was to confirm GLT1 express ion in the model. By RT-PCR we found that  
GLT1 mRNA is expressed by purified human islets of Langerhans (F ig. 11A) and 
immunoprecipitat ion exp eriments confirmed protein presence (Fig. 11B). The bands  
corresponding to oligomer and monomer (120 and 60 kDa, respectively) were clearly  
identified in the immunoprecipit ate and mat ched perfectly with those of the brain lysate. 
On the other hand, in the islet lysate, only the monomer was det ectable, probably due to 
the different enrichment in GLT1 between the two samples. A non specific band was  
also detected in islets samples, but it did not affect our observat ions , as it was  well 
segregated from the GLT1 bands. 
Uptake experiments revealed that islets expressed glutamate transport systems, both 
sodium dependent and independent, but the former prevailed; we found that GLT1 is  
functional in the islets and it is the main regulator of glutamate clearance in the is let as  
shown by the fact that the select ive inhibitor DHK almost complet ely inhibit ed the 
sodium dependent glutamate uptake act ivity (Fig. 11C).  
The cellular-specific localisation in the islets was assessed by immunofluorescence 
experiments performed on isolated islets plated onto glass coverslips and using hormone 
staining as markers of the different cell subtypes. Staining confirmed the membrane 
expression of the transporter and showed that GLT1 co-localised with Insulin, as underlined 
by yellow-orange colour in the merge image (Fig. 11D). 
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FIG. 11: GLT1 is expressed in human isolated islets (A). Determination of GLT1A expression in  
human isolated islets by means of RT-PCR. PCR product were analysed on a gel. Negative control “ C”: 
PCR ampli fi cation performed in the absence of cDNA. Positive control is represented by Tubulin 
amplification (TUB). Left: DNA Marker (M). (B). Immunoprecipitation of human islets whole lysat e 
extract with rabbit serum (IgG) or GLT1 antibody. 50-100 µg of brain or islet extract (Lys) was loaded in  
the same gel. Markers on the right indicat e kDa; **oligomer; *monomer; ° non-speci fic band. (C). [3H]-
D-Aspart ate upt ake measurements in 40 human islets. 0.3 mM DHK was added to the uptake solution. 
Data are expressed as a percentage of the Na-dependent uptake (NaCl) and are mean ± s.e.m. of at least 3 
independent experiments performed in triplicate. (*P<0.001, vs NaCl). (D). Immunolocalization of GLT1 
(green) and insulin (red) on dispersed human islets seeded on glass coverslips. Scale bar: 10 µm.  
 
Taken together these results indicate that GLT1 is mainly expressed in the beta cells of the 
isolated human islets of Langerhans, it is functional and it represents the main glutamate 
uptake system present in the islets. 
We next explored the vulnerability of human islets to glutamate toxicity. 
As isolated islets are more susceptible to insults and show degenerative features when 
cultured in vitro, we choose to reduce the time of exposure to glutamate, to avoid the extreme 
results deriving from excessive islet stress. 
After 3-day exposure to glutamat e, we assessed human islets viability by MTT test, that 
was decreased in a dose dependent manner only in the presence of high glucose, and it was  
statistically significant at 5 mM glutamate (Fig. 12A). These results may indicate an additive 
effect of glutamate on glucose toxicity. The glutamate-induced islet toxicity, observed in the 
presence of high glucose, increased further in the presence of 0.1 mM DHK, suggesting that 
also in the human isolated islets GLT1 is important to prevent glutamate toxicity (Fig. 12B). 
By TUNEL assay performed in dispersed islet cells, we observed that the cell death was due 
to apoptosis and was restricted to the β-cells as shown by double staining for insulin (Fig. 
12C). 
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FIG. 12: GLT1 inhibition indu ces β -cell death b y apop tosis  in human i solated isl ets. 
(A). Determination of β-cell vi abili ty by MTT assay after i ncubation of 20 human i slet s for 
3 days wi th the indi cat ed glutamate concentrati ons in the presence of 3.3 mM or 16.7 mM 
glucose. Data are expressed as RGR and are mean ± s.e.m. n=4 with 8 repli cat es (*p<0.01 
16.7 vs 3.3 mM glucose; #5 mM vs 0 mM glut amate i n 16.7 mM glucose). (B ). 
Determination of β -cell vi ability by MTT assay aft er incubation for 3 days with t he 
indicat ed glut amate and DHK concentrati ons in the presence of 16.7 mM glucose. Data are 
expressed as  RGR and are mean ± s.e.m.; n=4 with 8 replicat es (*p<0.01 0.1 mM vs 0 mM 
DHK). (C). Determination of β -cel l apoptosis (green) by TUNEL assay aft er 3 days  
incubation with 0.5 mM glutamate (GLU), 0.1 mM DHK (DHK) or both (GLU+DHK) in  
the presence of 3.3 mM glucose. β-cell s were st ained with insulin (red). Scal e bar = 10 µm. 
 
3.8 Type 2 diabetes patients show impaired GLT1 expression  
Type 2 Diabetes Mellitus (T2DM) is characterised by insulin resistance and impaired glucose 
homeostasis, but in the advanced stage of the disease it is also present an increased beta cell 
death [Federici et al., 2001]. Glucose represents the exemplary toxic stimuli for beta cells in 
T2DM, but we have proved that also glutamate can at least in part contribute to beta cell 
death. Thus, we reasoned that GLT1, as the main system for glutamate clearance in the islets,  
could be involved in type 2 diabetes. 
To verify this hypothesis, we carried out immunohistochemistry experiments on pancreases  
from normal and type 2 diabetic subjects, aiming at determining whether patients have 
different GLT1 expression (Fig. 13). 
Pancreases from normal individuals confirmed GLT1 expression in the islet and the 
subcellular localisation was mainly at the cell membrane, as indicated by the brown colour 
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concentrated at cell-cell boundaries (Fig. 13). In contrast, type 2 diabetic pancreases revealed 
an altered expression of GLT1. In particular, it is evident that GLT1 is not exclusively 
expressed at the plasma membrane but it is also present in intracellular compartments, 
suggesting that the transport activity can be impaired in these patients, as only plasma 
membrane GLT1 can be functional for glutamate clearance. 
 
 
 
FIG. 13: GLT1 
memb rane expression 
is imp aired  in T2DM 
pancreases. 
Immunohistochemistry 
staining of human 
pancreas sections from 
normal subj ects and 
T2DM pat ients with a 
sel ective rabbit anti 
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4 DISCUSSION 
The main finding of our research is that chronic exposure to high glutamate concentrations 
exerts a cytotoxic effect on the pancreatic β-cells. This effect is physiologically prevented by 
the activity of the glutamate transporter GLT1. 
There are several reasons that prompted us in the study of glutamate and its clearance system 
in endocrine pancreas. 
First, glutamate-mediated signalling as been recognised as a modulator of hormone secretion 
in the islets, but there were few and incomplete evidences regarding the expression and 
physiological function of high affinity glutamate transporters. In the CNS, these transporters 
control the concentration of glutamate in the extracellular space and therefore they limit 
activation of receptors and prevent the overstimulation of ionotropic receptors, that triggers  
excitotoxicity. We reasoned that it could be of particular interest studying the effect of 
glutamate on cell viability in endocrine cells and to understand if glutamate uptake may 
represent an efficient clearance system in the islets. 
Glutamate is present in the islets and in the blood circulation, and it is toxic to neuronal cells,  
that share common features with endocrine cells [Alpert et al., 1988]. The precise 
concentration of extracellular glutamate in the islet microenvironment is presently unknown 
but it is likely remarkably high. Blood glutamate concentration is relatively high (50-200 µM) 
as compared to the CNS [Federici et al., 2001] and can increase up to ~500 µM under 
glutamate-enriched diet [Stegink et al., 1987; Graham et al., 2000]. Moreover, islets are 
highly vascularised structures [Bonner-Weir et al., 1982] and glutamate may reach very high 
concentrations in islet’s capillaries, especially after a meal. In addition, glutamate is  
physiologically co-secreted with glucagon [Hayashi et al., 2003], thus it is released any time 
the glucagon is secreted, i.e. during hypoglycaemia. Extracellular glutamate concentrations 
may increase further in the islets of humans with T2DM which are characterized by inverted 
β-cell/α-cell ratio and glucagon hypersecretion [Clark et al., 1988; Dunning et al., 2007; 
Guardado-Mendoza et al., 2009] but also in T1DM islets since dendritic (DC) and T cells 
release glutamate to activate and improve chemotactic migration [Pacheco et al., 2006; Ganor 
et al., 2003]. DC-T cell interaction at the early stages of lymphocytic islet infiltration might  
trigger a vicious cycle that increases islet inflammation and extracellular glutamate levels. Of 
note, increased glutamate levels have been found in sera of subjects with both T1DM [Oresic 
et al., 2008] and T2DM [Bao et al., 2009] thus suggesting that glutamate may represent a 
common factor underlying the two types of diabetes.  
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We reasoned that if β-cells are exposed to high extracellular glutamate levels they might be 
vulnerable to excitotoxicity, unless they also express an efficient glutamate clearance system. 
Actually, we demonstrate that clonal β-cells, whereas not α-cells, are susceptible to 
glutamate-induced toxicity, that mediates apoptosis. The different sensitivity of the two cell 
types may be ascribable to different receptors and signalling pathways in alpha and beta cells,  
as the two cell types express different subtypes of ionotropic and metabotropic glutamate 
receptors [Hayashi et al., 2003; Molnár et al., 1995; Weaver et al., 1996; Tong et al., 2002].  
It is not surprising that glutamate mediated toxicity does not occur at short incubation time, as  
happens in the CNS, because pancreatic cells are more frequently exposed to high levels of 
glutamate and may have developed a sort of glutamate resistance, necessary for their survival.  
In beta cells, glutamate toxicity is mediated by the activation of the ionotropic AMPA/kainate 
glutamate receptors, as inhibition of these receptors significantly improved β-cell survival. On 
the contrary, we did not measured any change in beta cell survival during NMDA receptors 
inhibition. In line with this finding, we did not detect NMDA expression in our cell model 
(data not shown). 
Nonetheless, glutamate receptor inhibitors did not completely prevent β-cell death, suggesting 
that, other mechanisms might be involved in glutamate-induced toxicity, as the oxidative 
glutamate toxicity. Originally described in astrocytes, excess of extracellular glutamate 
reverts the activity of the glutamate/cystine-antiporter system x-c, thus depleting the cells of 
cysteine, a building block of the antioxidant glutathione [Chen et al., 2000]. A similar 
mechanism can be relevant for β-cells which express the x-c exchanger (Fig.3B, inset) and are 
particularly vulnerable to oxidative stress [Numazawa et al., 2008]. In agreement with this 
possibility, we measured reduced free SH content after incubation with glutamate (F ig.3B). 
Oxidative stress can at least in part explain the need of chronic glutamate exposure to observe 
changes in beta cell viability, in contrast to the acute glutamate action in neurons.  
Glutamate-induced toxicity also affects human islets (Fig. 12), but it occurs only in the 
presence of high glucose and is quantitatively small as islets viability decreases of only 10%. 
However, these data most likely underestimate the real impact of excitotoxicity in human β-
cells because isolated islets preparations are an heterogeneous cell population including 
endocrine non-β and contaminant non-endocrine cells which are resistant to glutamate 
toxicity. Indeed, the TUNEL assay performed on dispersed human islet cells stained for 
insulin showed a cons iderably higher number of apoptotic β-cells, because we were able 
to distinguish among the cell types present in the islets (F ig. 12C).  
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Alike in neurons, also in the β-cells, glutamate-induced toxicity is physiologically prevented 
by GLT1 activity. By using molecular, biochemical, pharmacological and physiological 
approaches we found that GLT1 is selectively expressed by the β-cells, while it is virtually 
absent in all the other islet cell types. Immunohistochemistry and confocal microscopy of 
human pancreatic sections showed that GLT1 is prevalently located to the plasma membrane 
[Tesi di Laurea Magistrale-Di Cairano, 2007 and present data]. None of the other known high 
affinity glutamate transporter subtypes (EAAT1/GLAST, EAAT3/EAAC1) were detected in 
the islets. Our observation that GLT1 is selectively expressed in the β-cell contrasts with 
previous data showing a Na+-dependent glutamate/aspartate transport activity confined to the 
non-β islet’s cell mantle [Weaver et al., 1998]. This discrepancy may be explained by 
considering that in the latter study the localization of the transporter’s substrate (glutamate), 
and not the transporter itself was assessed. In agreement with the lack of GLT1 expression, 
we did not detect measurable Na+-dependent glutamate uptake in αTC1 cells, neither we 
revealed the presence of any other high affinity glutamate transporter by RT-PCR [Tesi di 
Laurea Magistrale-Di Cairano, 2007]. Interestingly, our findings and recent results indicate 
that α-cells express a functional glutamine uptake system (ASCT2 and SAT2) and a 
phosphate-dependent glutaminase activity suggesting that glutamate in these cells may 
prevalently derive by glutamine transamination [Montero et al., 2007]. 
In this study, GLT1 was identified as the main regulator of the extracellular glutamate 
clearance in the islet, and it is demonstrated that its normal function is critical for β-cell 
survival. Indeed, GLT1 down-regulation by pharmacological blockade or by shRNA 
interference is sufficient to determine β-cell death also in normal physiological growing 
conditions. The most important function of GLT1 in the CNS is to regulate the extracellular 
glutamate concentration and to prevent excessive glutamate receptor activation and 
excitotoxicity [Rothstein et al., 1996; Tanaka et al., 1997]. Accordingly, data show that 
pharmacological blockade of GLT1 by the selective inhibitor DHK, induces an increase in 
extracellular glutamate concentration to a degree which is toxic for the β-cells. Vice versa 
GLT1 upregulation by CEF, a β-lattamic known for its ability to increase GLT1 expression in 
neurons and to provide neuroprotection against excitotoxicity, increased GLT1 expression 
also in beta cells and therefore reduced glutamate-induced β-cell death (Fig. 9). 
Thus, CEF, and other compounds capable to increase GLT1 expression or/and activity may 
represent novel therapeutic strategies to achieve β-cell cytoprotection. Interestingly, β-cell 
toxicity could be also prevented by Ex-4, a GLP1 analogue employed for the treatment of 
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T2DM and known for its glucose-dependent insulinogenic action and its antiapoptotic effect 
on the β-cell [Wajchenberg et al., 2007]. Thus, the anti-excitotoxic action mediated by Ex-4 
provides a novel mechanism through which it may exert its known β-cell cytoprotective 
effect. 
Because of GLT1 selective localization in insulin positive cells and its involvement in β-cell 
survival, we reasoned that it could be involved in diabetes. In particular we hypothesised that 
its expression may be altered in patients with diabetes, a disease characterised by beta cell 
death and impaired glutamate homeostasis. The time of beta cell death appearance is different  
in the two types of diabetes: it is generally recognised that beta cell death occurs before the 
onset of impaired glucose homeostasis in type 1 diabetes, whereas in type 2, it characterizes 
later stage of the disease. 
Our data show that GLT1 subcellular localisation is altered in pancreases of type 2 diabetes 
patients. In particular, the plasma membrane localisation of GLT1 is lost and the transporter 
seems to accumulate in intracellular compartments, where it can not accomplish to its uptake 
function. 
Although these evidence need further support, they suggest that the transporter may play a 
role in T2DM progression. 
The hypothesis to be confirmed is that glutamate homeostasis can be altered in islets of 
diabetic patients. Glutamate clearance may be low, due to an increased beta cell death or the 
impaired GLT1 localisation, whereas the high alpha/beta cell ratio could lead to an increase in 
glutamate release from alpha cells, thereby exacerbating islet conditions. 
 
In conclusion, our findings demonstrate that β-cells are sensitive to glutamate-induced 
cytotoxicity and the high affinity glutamate transporter GLT1 is fundamental to 
physiologically prevent β-cell death. These results may be of particular interest, as GLT1 
plasma membrane localisation seems altered in type 2 diabetes patients. 
Any novel indication in the islet physiology could be potentially interesting for application in 
diabetes, one of the more widespread pathology and cause of morbidity in the population of 
occidental countries. In particular, could be remarkable to find elements controlling hormone 
release and beta cell survival, as the common notes between the two types of diabetes are 
represented by beta cell death and impaired glucose homeostasis. 
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5 MATERIAL AND METHODS 
5.1 Cell lines 
Cell lines  represent a useful model to isolate and study the peculiar characteristic of each cell 
type present in the islet of Langerhans. Moreover, they can be grown in vitro for a 
considerable number of passages, maintaining their characteristic and their similarity to the 
native cells. However they can not be the only model for this work as they differ from the 
physiological conditions, where exist interaction and cross-talk between all the cell types in 
the islet. 
Mouse βTC3 and αTC1 cells were kindly provided by Prof. Douglas Hanahan (Department of 
Biochemistry and Biophysics, University of California, San Francisco, CA). αTC1 and βTC3 
cells derive from pancreas of transgenic mice generated with a fusion gene between SV40 
large T antigen and glucagon and insulin promoters, respectively [Powers 1990; Efrat 1988].  
ßTC3 were grown in RPMI 1640 (from the name of the institute where the media was 
developed: Roswell Park Memorial Institute) 11 mM glucose supplemented with 10% heat 
inactivated foetal bovine serum, 2 mM L-glutamine, and 100 IU/ml streptomycin/penicillin.  
αTC1 were cultured in DMEM (Dulbecco’s Modified Eagle’s Medium) 25 mM glucose 
supplemented with 10% heat inactivated foetal bovine serum, 2 mM glutamine, and 100 
IU/ml streptomycin/penicillin. 
Cultures were performed under standard humidified conditions of 5% CO2 at 37° C. 
All media were supplied by Sigma-Aldrich. 
5.2 Cell viability assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  
MTT is a water soluble tetrazolium salt, with a yellow colour. When added in the cell media, 
active mitochondrial dehydrogenases of living cells convert the MTT in an insoluble purple 
formazan by cleavage of the tetrazolium ring; in contrast, death cells do not cause this change. 
Thus, this method is useful to measure cytotoxicity, as previously demonstrated [Carmichael 
et al., 1987]. 
The MTT assay was performed on ßTC3 cells seeded at a density of 8 x 103 cells/well onto 
96-well culture plates. Cells were allowed to attach and grow for 24 h in standard medium, 
then medium was replaced with fresh medium containing glutamate, DHK, Ceftriaxone, 
Exendin 4, DPPIV and glutamate receptor inhibitors APV and CNQX at the indicated 
concentrations. If not differently stated, after five days incubation, cell viability was assessed 
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using the MTT method, according to the manufacturer’s protocols. Briefly, MTT solution was 
added to the media in each well, to a final concentration of 0,5 mg/ml; after a 4 hour 
incubation, the media was removed and the formazan precipitates were solubilised in 100% 
DMSO. The coloured formazan product was determined spectrophotometrically at 540 nm, 
with a reference wavelength of 655 nm, yielding a function of the formazan concentration. 
DMSO absorbance in empty wells was taken as a blank and subtracted from each well. 
Data were analysed as percentage of viability relative to control treatment (%RGR, Relative 
Growth Rate). Results are shown for a at least three independent experiments, performed with 
eight replicates. 
All reagents are from Sigma Aldrich. 
5.3 Quantification of apoptosis in β-cells and isolated human islets 
The apoptosis of human isolated islets and βTC3 cells was estimated using the terminal 
deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labelling assay (TUNEL, 
Promega). This method, measures nuclear DNA fragmentation, an important biochemical 
hallmark of apoptosis. Fragmented DNA is enzymatically labelled at 3’-OH end with FITC 
(Fluorescein IsoTioCyanate) conjugated nucleotides. 
Cells and islets were plated on glass coverslips and, following each indicated treatment, they 
were fixed in 100% methanol, washed in PBS (150 mM NaCl, 10 mM PO4 buffer pH 7.4), 
permeabilized in PBS-0,2% Triton X-100 and incubated with Equilibration Buffer (200 mM 
Potassium Cacodylate pH 6.6, 25 mM TrisHCl pH 6.6, 0.2 mM DTT, 0.25 mg/ml BSA, 2.5 
mM Cobalt chloride). Then the coverslips were incubated for 1 hour at 37°C with terminal 
deoxynucleotidyltransferase (rTdT) in the presence of FITC labelled dUTPs. After abundant 
washes, cell were incubated with Propidium Iodide (1 µg/ml) or with insulin antibodies (see 
immunofluorescence protocol for details),  as a positive control and as a marker for beta cells,  
respectively. Tunel-positive cells were counted by two independent observers using a 40X 
objective from at least 40 randomly selected fields per coverslips. The data were plotted as 
number of TUNEL positive cells/field. 
5.4 Quantification of total SH content 
To evaluate the redox conditions in the βTC3 cells after treatment with glutamate, we 
performed Ellmann test, in which quantification of SH groups is related to protein oxidative 
stress. 
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Cells were incubated for 5 days in 5 mM Glutamate and then lysed for 45 minutes in lysis 
solution (150 mM NaCl, 30 mM Tris-HCl, 1 mM MgCl2, 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride, and 1 µg/ml aprotinin and leupeptin). Cleared lysate was then 
incubated in reaction buffer (0.1 M sodium phosphate, pH 8; 1 mM EDTA) and DTNB (5’5’-
dithiobis (2-nitrobenzoic acid); stock solution 4 mg/ml) at room temperature. This reagent is  
able to react with SH groups, resulting in colour variation from colourless to yellow, 
depending on SH concentration. Absorbance at 412 nm was measured after 30 minutes. Lysis 
buffer absorbance was taken as a blank and subtracted from each sample. Standard curve: 0-
0.5 mM reduced GSH. Data deriving from interpolation are presented as a ratio between total 
SH and total protein in the sample. 
5.5 RNA isolation and RT-PCR analysis 
To assess transporter expression in our models, we performed RNA isolation and RT-PCR 
analysis. 
Total RNA represents about 1% of the total weight of mammal cells and is composed of 
coding RNA, i.e. tRNA, rRNA and mRNA, and non-coding RNA, which represents the major 
amount. We are interested in mRNA, because it can be taken as an indicator of gene 
expression. 
 
TOTAL RNA EXTRACTION 
Beta TC3 were grown in a 6 cm plate until confluence or 1500 isolated human islets of 
Langerhans, from post-mortem sampling were harvested. 
Total RNA was extracted with RNA fast isolation system following manufacturer’s protocol 
(Molecular Systems-San Diego, CA). This reagent is composed of guanidine salts and urea as  
denaturating agents, phenol to selectively isolate total RNA from chromosomal DNA. 
The system consists mainly of distinct phases: cell/islets homogenisation, followed by RNA 
extraction, using chloroform and centrifugation and finally RNA precipitation by adding 
isopropanol. After over night RNA precipitation, pellet was washed twice with 75% Ethanol 
and resuspended in 15 µl of UltraPure™ DNase/RNase-Free Distilled Water (GIBCO, 
Invitrogen) to obtain adequate concentration for subsequent reactions. 
Quality of total RNA wash checked by electrophoresis and its concentration was measured 
using spectrophotometric absorbance (260-280 nm) and a molar extinction coefficient of 40 
µg/ml. The RNA purity was confirmed by the relative absorbance at 260 versus 280 nm. 
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DNASE DIGESTION 
This step was useful to remove any DNA contamination from our RNA extract.  
We treated 2 µg of total RNA with DNAse (Promega) and its suitable buffer in presence of 
RNAse OUT (Invitrogen) for 30 minutes at 37°C. The reaction was stopped adding Stop 
Solution (Promega) and followed by 10 minutes incubation at 65°C to inactivate the enzyme.  
 
RT-PCR 
For cDNA synthesis, 2 µg of digested RNA was reverse-transcribed using random primers (to 
a final concentration 12.5 ng/µl; Promega) and 200 U of M-MLU reverse transcriptase 
(Invitrogen) in presence of RNAse OUT, DTT 0,1 M (Invitrogen) and dNTPs (Promega). 
The first reaction step was performed with RNA, oligos and UltraPure™ DNase/RNase-Free 
Distilled Water (GIBCO, Invitrogen) at 65°C for 5 minutes; then the other reagents were 
added and the reaction was incubated for 50 minutes at 37°C. Finally the reaction was led to 
95°C for 5 minutes to inactivate the reverse transcriptase. 
 
PCR 
PCR amplification of the reverse-transcribed RNA was carried out using specific primers in 
the 3’ end of cDNA, to obtain about 200 bp PCR product, crossing the STOP codon. The 
reason why we choose to have a short fragment is to have more possibility to check the 
expression of the gene products. Indeed, bad quality RNA can be really short, thus impairing 
the annealing of the forward primers even if the gene has been transcribed, therefore 
generating false negatives. Choosing primers near each other increases the probability to have 
a PCR product. The primers were selected with a melting temperature near 60 °C and keeping 
G/C near 40% of the whole primer. 
In mouse cell lines we used the following primer: 
Mouse  Primer PCR product 
xCT Forw 
Rev 
CCCAGATATGCATCGTCCTT 
CGTCTGAACCACTTGGGTTT 207 
 
The primers used in human islet of Langerhans are listed below: 
Human  Primer PCR product 
GLT1-A Forw 
Rev 
CTTTTGGGGCTGGGATAGTC 
TTGGCTGCCAGAGTTACCTT 211 
Tubulin Forw 
Rev 
CCTCACCATTGCCATTATCC 
GCTTCCACTTTCACCTCAGC 
451 
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Reaction was performed with PCR Master Mix (Promega) adding cDNA, oligos and water to 
a final volume of 25 µl. Cycling conditions were 2 minutes at 95°C; 30 seconds at 95°C, 30 
seconds at 60°C, 1 minute at 72°C, for 40 cycles; and a final elongation at 72°C for 
10 minutes. To confirm absence of genomic contamination in the RNA samples, reverse 
transcriptase-negative controls were introduced in each experiment (no M-MLU reverse 
transcriptase). 
Amplified DNA fragments were analyzed by electrophoresis in a 1.5% agarose gel and 
compared to a 250 bp ladder (Invitrogen).  
5.6 Cell lysis and Western blotting analysis 
ßTC3 cells were seeded onto 6-cm tissue culture plates and allowed to attach and grow until 
confluence. Cells or 1500 isolated human islets were harvested and lysed in 100 µl lysis 
buffer (150 mM NaCl, 30 mM Tris-HCl, 1 mM MgCl2, 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride, and 1 µ g/ml aprotinin and leupeptin). After 1 h at 4° C, lysates 
were centrifuged at 13000 rpm for 10 min, the extracted proteins were solubilised with 
denaurating β-mix (5% SDS, 20% Glycerol, 0.3M β-mercaptoethanol, blue bromophenol) and 
separated by SDS-PAGE (Tris-Gly/ SDS buffer: 25 mM Tris-Base, 192 mM Glycine, 0.1% 
SDS). Finally, proteins were transferred to a nitrocellulose membrane (Transfer buffer: 25 
mM Tris-Base, 192 mM Glycine, 20% Methanol). After membrane incubation with blocking 
buffer (2% non-fat milk, 0.1% Tween 20, 20 mM tris HCl pH 7, 150 mM NaCl), the blots 
were probed with rabbit anti-GLT1 (Alpha Diagnostic), an affinity purified rabbit anti-GLT1 
(kindly provided by Dr. Grazia Pietrini [Perego et al., 2000]) or anti-actin (Sigma) antibodies  
as a primary reagents in the blocking solution. This incubation was followed by anti-rabbit  
HRP-conjugated IgG (80 ng/ml; Amersham, GE Healthcare), and visualised by ECL (Perkin-
Elmer Life Science, Boston, MA). 
Band quantification was performed using NIH J-image software and results were normalised 
for actin content and shown in bar graphs. 
 
P2 brain extract: Total homogenates of rat brain tissues were prepared as previously 
described [Perego et al.,  2000]. Briefly, rat cortex were suspended and homogenised 
mechanically in Homogenisation buffer (0.32 M Saccarose, 10 mM Tris-HCl pH 7.5, 5 mM 
EDTA, 5 mM EGTA and fresh protease inhibitors as above). After multiple centrifuge steps 
and a ultracentrifugation, the final pellet (called P2) was resuspended in 5 volumes of lysis 
buffer (RIPA buffer: 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% NP-40, 0.5% 
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Deoxycholate, 0.05% SDS and freshly prepared protease inhibitors) and incubated under 
constant agitation at 4°C for 1 hour. The cleared lysate was diluted 1:1 with the denaurating 
β-mix (5% SDS, 20% Glycerol, 0.3M β-mercaptoethanol, blue bromophenol). 
5.7 iRNA and Cell transfection 
To suppress GLT1 gene expression, the retroviral silencing plasmid (pRS) encoding short 
hairpin against GLT1(Origene, see Table below) was transfected in βTC3 cells. The short 
hairpin SH1, SH2 and SH3 are against GLT1, targeting different portions of the transcribed. 
The SH C (control) contain a non-effective shRNA cassette. 
Sequences of the tree short hairpin against GLT1 are listed in the table below: 
 
 
 
 
 
The shRNA expression cassette consist of 29 bp target gene specific sequence, a 7 bp loop, 
another 29 bp reverse complementary sequence and a termination sequence polyT, to 
terminate the transcription by RNA polymerase (Fig. 1). 
Once the plasmid is inserted into the cells, the short hairpin RNA is expressed as a RNA 
duplex, thus achieving RNA interference and inhibiting GLT1 expression.  
 
 
FIG. 1 
 
105 or 3 x 105 βTC3 cells were plated into 24 well plates and 3.5 diameter Petri’s plates, 
respectively. After 24 hours, cells were transfected with pRS-SH Ctr / 1 / 3 using Lipofast 
Reagent (Promega).  
Name 5’-3’ Sequence 
SH1 GGATGGAGGACAGATTGTGACTGTAAGCC 
SH2 ATCAAGGACTTAGAAGTGGTTGCTAGGCA 
SH3 GGTGTATTACATGTCCACGACCATCATTG 
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A mixture of DNA (pRS-SH C /1/3) and Lipofast Reagent was prepared in a serum free 
media (RPMI supplemented only with 1% glutamine): 
 
Well DNA Lipofast Reagent 1%Gln RPMI 
24-well plates, each 
well 1 µg 3 µl 0.2 ml 
3.5 cm Petri dishes 5 µg 15 µl 1 ml 
 
Cells were washed twice in the serum free media and then the mixture was added. After 4 
hours of incubation, media was substituted with complete RPMI. 
24 hours later, cells were assessed by 3[H]-Asp uptake experiments or were lysed to verify 
GLT1 down-regulation. 
After the silencing has been verified, the silencing experiments were performed on βTC3 
plated on glass coverslips in 3.5 cm Petri dishes. Transfection was followed by a 2 day 
treatment in standard complete medium supplemented with 0.5 mM glutamate and analysed 
by TUNEL (Promega). 
5.8 Immunofluorescence 
Immunofluorescence technique is a powerful tool for the identification and localisation of 
transporters in cells and tissues, by means of antibodies conjugated to fluorescent dyes. 
Antibodies allow to recognise each type of protein in the sample, due to their specificity and 
selectivity. On the other hand, fluorescent dyes let to display proteins through fluorescence 
microscopy. 
 
In isolated islets 
20 hand-picked islets were seeded onto glass coverslips covered with polylisine (Sigma-
Aldrich) to facilitate adhesion and cultured in RPMI medium. After 24 hours islets were fixed 
in ice-cold 100% methanol and immunostained with anti-GLT1 and anti insulin antibodies, as  
follows.  
Fixed cells were then incubated with primary antibody for 2 hours at room temperature in 
GDB solution (150 mM NaCl, 10 mM Phosphate Buffer pH 7.4, 0.2% Triton, 0.2% gelatine). 
Following incubation, cells were washed in PBS and then incubated in GDB with the 
appropriate fluorochrome-conjugated secondary antibodies (Jackson) for 1 hour at room 
temperature, in dark. Then, coverslips were mounted on glass slides with Phenilendiammine 
(1 mg/ml in Glycerol-PBS; Sigma-Aldrich) as antifade reagent and sealed with nail-polish. 
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5.9 Immunohistochemistry 
Immunohistochemistry has been performed in formalin fixed human pancreas paraffin 
embedded sections.  
The ABC immune complex served for the identification of GLT1. After removal of paraffin 
and rehydratation of tissue, the pancreas sections were first treated with an hydrogen peroxide 
solution to suppress possible endogenous peroxidase activity and then heated in citrate buffer 
10 mM pH 6 using a microwave oven to expose antigens. This was followed by 
permeabilization with TBS-Triton 0,2% (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 0.2% 
Triton X-100) and by an incubation with normal serum to quench nonspecific protein binding; 
finally the sections were incubated with a primary antibody, o/n at 4°C. Unbound antibodies 
were washed with TBS-Triton 0,2% and then the signal was amplified using secondary 
antibodies biotin conjugated, incubated at room temperature for 2 hours, followed by an 
incubation with Peroxidase conjugated-streptavidin (Chemicon). The reaction was performed 
with freshly activated 40% DAB (Diaminobenzidine, Sigma-Aldrich). The colour 
development was stopped by washing the slides thoroughly in tap water. To stain cytoplasm 
and nuclei, the sections were then counterstained with Mayer's haemalum, turned with tap 
water and dishydratated. Coverslips were mounted with an hydrophobic mounting medium 
(Dako Corp.). 
5.10 Antibodies 
The followed primary antibodies were used: rabbit anti-GLT1 (Perego et al., 2000; and Alpha 
Diagnostic); rabbit anti-EAAC1 (Alpha Diagnostic); rabbit anti-GLAST (Alpha Diagnostic); 
guinea pig anti-insulin (Roche). Secondary antibodies: biotin-conjugated anti-rabbit IgG; 
Rhodamine-conjugated anti guinea pig (Jackson Immunoresearch: West Grove, PA); 
Peroxidase conjugated-streptavidin (Chemicon).  
Incubation with GLT1 competing peptide (Alpha Diagnostic): 20 µg of competing peptide+ 2 
µg of GLT1 antibody were mixed in TBS and incubated over night at 4°C under constant 
agitation. The following day, the mixture was used to stain pancreatic section. 
Negative control: rabbit pre-immune serum [Perego et al., 2000] and rabbit normal serum 
(Sigma-Aldrich). 
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5.11 [3H]D-aspartic acid uptake 
Radioactive amino acid uptake is a reliable method to verify the expression and the 
functionality of transporters expressed at the plasma membrane. Changes in amino acid 
uptake can either reflect changes in amount of expression and either changes in transporter 
activity. 
150.000 cells/well were plated in a 24-wells plate and grown until confluence. Cells were 
incubated for 10 minutes in 200 µl of Na+-dependent (150 mM NaCl 2 mM KCl, 1 mM 
CaCl2, 1 mM MgCl2, 10mM Hepes pH 7.5) or Na+-independent (150 mM ChCl, 2 mM KCl, 1 
mM CaCl2, 1 mM MgCl2, 10mM Hepes pH 7.5) uptake solution containing 5 µCi/ml of 
[3H]D-Aspartic acid (specific activity 37 Ci/mmol; Amersham Biosciences). The amino acid 
uptake was stopped by washing the cells twice in ice-cold sodium-free solution. Cells were 
dissolved in 150 µl of SDS 1% for liquid scintillation counting. For transport inhibition, DHK 
was added to the uptake solution at the indicated concentrations. For uptake measurements in 
human isolated islets, 20 islets were selected and uptake experiments were performed as  
described.  
5.12 Human islet isolation and culture 
The islets used in this study were kindly provided by San Raffaele Scientific Institute and 
Ospedale Niguarda Ca’ Granda. Islets were isolated from seven cadaveric multiorgan donors  
by using the procedure already described [Ricordi et al.,  1988] in conformity to the ethical 
requirements approved by the Niguarda Ca’ Granda Ethical Board and HS Raffaele. 
When necessary, islets were cultured in RPMI 1640 media, 5.5 mM glucose, supplemented 
with 10% heat inactivated foetal bovine serum, 2 mM L-glutamine, and 100 IU/ml 
streptomycin/penicillin. To mimic a high glucose condition, cells were cultured in 16.7 mM 
glucose, whereas 3.3 mM glucose was used as a low glucose condition, as described 
[Marchetti et al., 2002]. 
5.13 Immunoprecipitation 
2500 isolated islets were harvested and resuspended in 300 µl of RIPA buffer without SDS 
(150 mM NaCl, 50 mM Tris/HCl, pH 7.6, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate) 
supplemented with 100 µg/ml PMSF and a cocktail of protease inhibitors. After 6 minutes of 
sonication, islets were lysed for 1 h at 4°C under constant agitation. The lysate was then 
cleared by centrifugation and 100 µg of the total lysates were incubated over night with anti-
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GLT1 rabbit antibody (kindly provided by Dr. Grazia Pietrini) or a preimmune rabbit serum 
as a negative control. The following day, samples were subjected to immunoprecipitation 
incubating 20 µ l of Protein A-Sepharose conjugate (Pierce) for 2 hours at 4°C under constant 
agitation. Then, Sepharose was washed once with RIPA buffer, twice with Buffer 4 (50 mM 
Tris-HCl, pH 8) and dried using a Pasteur Pipette. Proteins were solubilised by adding the 
denaurating β-mix (5% SDS, 20% Glycerol, 0.3M β-mercaptoethanol, blue bromophenol). 
5.14 Glutamate Determination 
To assess GLT1 effect on extracellular glutamate, cells were treated with DHK and then we 
measured glutamate concentration in the medium by enzymatic assay (Glutamate-Glutamine 
Determination Kit; Sigma-Aldrich). The reaction consists in dehydrogenation of L-glutamate 
to α-ketoglutarate, accompanied by a reduction of NAD+ to NADH. 
The βTC3 cells were plated on 6-cm Petri dishes, grown in standard medium for 24 hours and 
then treated for 5 days with 0.1 mM DHK (Sigma-Aldrich). Cell media from treated and 
control plates were collected and used to assess glutamate concentration following the 
manufacturer’s protocols. Essentially, media or standard solutions were incubated 1 hour at  
room temperature in the presence of Tris-EDTA Hydrazine Buffer, 1.5 mM NAD, 0.5 mM 
ADP and GLDH 0.1 U/ml. The standard curve was carried out from 0 to 1 mM glutamate. 
The conversion of NAD+ to NADH is measured spectrophotometrically at 340 nm and is 
proportional to the amount of glutamate. 
5.15 Statistical Analysis 
Statistical significance of difference between groups was determined by unpaired Student's t-
test. Differences were considered significant at P<0.05. 
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CHAPTER IV: Yeast Two Hybrid Screening 
 
The experimental work presented in this chapter was performed under the supervision of 
Franco Folli MD PhD, Professor of Medicine and Director of Metabolic and Molecular 
Research, at the Diabetes Division, Dept. of Medicine, University of Texas Health Science 
Center at San Antonio (UTHSCSA), located at San Antonio, TX-USA. This work is part of 
and was supported by NIH grant RO1 DK080148 and UTHSCSA start-up funds, to Franco 
Folli. 
I thank also Lily Dong PhD, Associate Professor of Cellular and Structural Biology, 
UTHSCSA, for kindly providing the library employed in the screening and helpful advice 
throughout this work. 
 
The period spent at UTHSCSA, offered me the opportunity to learn a technique useful to 
study protein-protein interactions, that may be relevant to unravel the proteins interacting with 
glutamate transporters. Yeast two hybrid screening has first been described in 1989 [Fields  
and Song, 1989], and now it is a consolidated tool to identify proteins involved in direct  
interactions in a high-throughput scale. 
 
1 ABSTRACT 
IAPP (Islet Amyloid Pancreatic Polipeptide) is the major constituent of pancreatic amyloid 
deposits, which correlate with β cells apoptosis and α cells replication in Type 2 Diabetes 
Mellitus (T2DM). Abnormal IAPP processing, folding and secretion could contribute to the 
formation of islet amyloidosis (IA). In this kind of aggregates, protein-protein interaction 
could play a key role in the folding and aggregation pattern and therefore in the severity IA. 
Aim of the work is to find out which proteins can interact with hIAPP, by means of Yeast  
Two Hybrid screening from a brain library. 
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2 INTRODUCTION 
2.1 Protein misfolding and diseases 
Many human diseases arise from the conversion of specific peptides or proteins, from soluble 
forms, their native functional conformational state, to highly ordered fibrillar aggregates. In 
general,  these pathological conditions are defined as protein misfolding diseases and may 
include neurodegenerative diseases, such as Alzheimer and Parkinson, or non-neuropathic 
diseases both systemic or localised, as Type II Diabetes Mellitus. 
The impairment in folding efficiency may result in a loss of function linked to the reduction in 
the quantity of the protein available to play its normal role. However, the largest group of 
misfolding diseases is associated with the presence of insoluble fibrillar aggregates. 
For most of the pathologies related with any of the amyloid disease, it is known the 
predominant component of the deposits, that forms the core, but also additional associated 
species are present [Hirschfield et al., 2003; Alexandrescu et al., 2005]. 
It is generally recognized that amyloid formation shows a nucleated growth mechanism 
[Pedersen et al., 2004]. 
Polypeptide chains can adopt a multitude of conformational states and interconvert between 
them on a wide range of timescales and not all the conformations are in the form of insoluble 
aggregates (Fig.1).  
The protein sequence influences the relative stabilities of all conformational states and will 
thereby contribute to the susceptibility of a given polypeptide chain to convert into amyloid 
fibrils. Also hydrophobicity, charge and secondary structures can strongly influence amyloid 
formation. 
It has been hypothesized that misfolded oligomers may interact with cellular components, 
such as membranes, small metabolites, proteins or other macromolecules. Such events, may in 
turn lead to the malfunctioning of crucial aspects of cellular machinery. 
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FIG. 1: Schematic representation of some conformational  
states that can be adopted by polypeptide chains and of the 
possible interconversion passages. [Chiti and Dobson, 
2006] 
 
2.2 Type II diabetes mellitus and amyloid 
Type II Diabetes Mellitus (T2DM) is a highly prevalent metabolic disorder, characterized by 
impaired glucose homeostasis. It is generally recognised that both insulin resistance and 
reduced mass of insulin producing beta cells contribute to the disease. 
In T2DM, β cells apoptosis correlates with the presence of Islet Amyloidosis (IA), a term 
created to describe pancreatic amyloid deposits in the islets of Langerhans. Amyloid deposits 
have been observed in both the cytoplasm of beta cells and extracellular space [Guardado-
Mendoza et al., 2009; Zucker-Franklin and Franklin, 1969] and they are mainly composed of 
Islet Amyloid Pancreatic Polypeptide (IAPP or amylin) [Westermark et al., 1987; Cooper et 
al., 1987]. 
IAPP is a 37-amino acid polypeptide hormone of the calcitonin family, localised and 
cosecreted with insulin in secretory granules of pancreatic islet cells [Kahn et al., 1990]. Its 
physiological function is to reduce food intake and regulate meal size. 
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FIG. 2: IAPP in its native conformation. 
 
The primary sequence of IAPP is closely conserved between species, but there are some 
important differences in amino acids 20–29, the region believed to be important for its 
propensity to form oligomers [Westermark et al., 1990]. Primates and humans share close 
homology in IAPP 20–29 region, and synthetic forms of these peptides form amyloid. In 
contrast, in rats and mice amino acids 20–29 are identical but they are not amyloidogenic, due 
to three proline residues  that render rat and mouse IAPP water soluble [Westermark et al.,  
1990]. 
 
 
 
FIG. 3: IAPP protein sequence in di fferent species. The amylodogenic region is reported in red. [Guardado-
Mendoza et al., 2009]. 
 
Longitudinal studies in Macaca nigra and Macaca mulatta showed that progression to T2DM 
correlated with the IA severity and that IA may play a role in beta cell death [de Koning et al.,  
1993, Howard et al.,  1986; Weir and Bonner-Weir 2004; Federici et al.,  2001]. In baboons, a 
well known non-human primate model for T2DM that shows insulin resistance [Chavez et al.,  
2008 and 2009], severe IA (>50%) was not only associated with increased beta cell apoptosis 
and decreased relative beta cell volume, but also with alpha cell replication and increased 
relative alpha cell volume [Guardado-Mendoza et al., 2009]. 
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The toxic form of amyloidogenic proteins appears not to be the extracellular amyloid fibrils  
detected by light microscopy, but rather smaller nonfibrillar oligomers [Janson et al., 1999; 
Konarkowska et al., 2006]. It has been proposed that IA can cause beta cell death by 
occupying extracellular space, thereby impairing nutrients and oxygen uptake. In addition, 
small IAPP oligomers can form non-selective ion permeable membrane pores, leading to 
increased intracellular calcium concentrations, endoplasmic reticulum stress and apoptosis 
[Clark at al.,  1988; Huang et al., 2007; Lorenzo et al., 1994; Mirzabekov et al, 1996; Ritzel et 
al., 2007; Westermark et al., 1978].  
2.2.1 Role of interactions in IAPP misfolding 
Abnormal IAPP processing, folding and secretion could contribute to the formation of islet  
amyloidosis (IA). In this kind of aggregates, protein-protein interactions could play a key role 
in the folding and aggregation pattern and therefore in the severity of IA. 
Specific interactions between soluble forms of IAPP and insulin were demonstrated in vitro 
by immunoprecipitation and surface plasmon resonance (SPR) experiments [Jaikaran et al.,  
2004]. The structural basis of this interaction indicated that insulin binds to IAPP (residues 1-
18) via salt bridges  
and hydrophobic interactions (Fig. 4) [Wei et al., 2009].  
 
 
 
FIG. 4: Structural representation of the 
insulin-IAPP complex. [Wei et al., 2009]. 
 
It has also been proposed that Annexin A5, a Ca2+-dependent membrane-binding protein, is  
codeposited with misfolded proteins. It likely interacts with a subset of h-IAPP molecules that 
are in a pathogenic conformation and/or on the pathway toward fibril formation and interferes  
with this process [Bedrood et al., 2009] 
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Moreover, other cellular components are involved in IAPP interactions. Zinc, which is found 
at millimolar concentrations in the secretory granule, significantly inhibits IAPP 
fibrillogenesis, increasing the lag-time for fiber formation and decreasing the rate of addition 
of IAPP to existing fibers. However, zinc at higher concentrations has the opposite effect on 
IAPP fibrillogenesis [Brender et al., 2010]. 
Mature IAPP has been shown to bind both heparin and heparan sulfate equally, and such 
interaction promotes aggregation [Abedini et al.,  2006; Castillo et al., 1998; Watson et al.,  
1997]. 
Characterization of the role of interaction within protein aggregates and between aggregates  
and the various components of living organisms could provide novel insights into folding 
physiology and the rationale for alternative therapeutic strategies. 
 
Aim of this project was to find out which proteins can interact with hIAPP, by means of 
Yeast Two Hybrid screening from a brain library.  
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3 EXPERIMENTAL PROCEDURES AND PRELIMINARY RESULTS 
3.1 Yeast two hybrid 
Yeast two hybrid screening, represents a powerful tool to identify protein-protein interactions  
in a high-throughput scale. The protein of interest, whose interacting partners are still 
unknown, can be used as a bait to get one (or more) prey from a library of proteins, as 
described below. 
In this kind of screening, the two eucariotic transacting transcriptional regulators DNA 
binding domain (DNA-BD) and Activation Domain (AD) are physically separated in two 
different vectors: pLexA and pB42AD, respectively. When the two vectors are co-expressed 
in the same yeast cells, the two regulators can interact and activate transcription only if they 
are in close proximity. Generating fusions of these domains to genes encoding proteins that 
potentially interact, it’s possible to detect an interaction between the two proteins with two 
reporter systems: nutritional selection and X-Gal assay. 
 
Reporter gene Phenotype 
Leu Ability to grow in Leucine lacking media 
Lac Z Development of blue colour during X-Gal assay 
 
There is also an additional system to control the experiments: the pB42AD library of proteins 
is under the control of an inducible promoter, that can be activated only in the presence of 
Galactose in the media. Once the promoter is activated, the library proteins are transcribed 
and translated and they may interact with the bait (Fig. 5). If the interaction occurs, the 
transcription of the reporter genes can be verified from the yeast phenotype, as stated above. 
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FIG. 5: Schematic represent ation 
of pB42AD inducible expression 
 
Accordingly, we expected two main effects during the screening after the induction with 
Galactose media:  
1) If there was not interaction between our bait and the protein X (pray) cloned in the library, 
we would find out none or few, small and pale colonies, that then would result negative at the 
X-Gal assay. 
 
 
 
2) If there was an interaction between the bait and the prey, we would find out many big 
healthy colonies, with a yellowish colour, that would give blue colour during X-Gal assay. 
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However, this technique presents some drawbacks, mainly linked to the high number of false 
positives that may arise during the screening. Some of the false positives depend on technical 
aspects, on protein sequence or are casual. In addition, it has to be taken into account that all 
the potential interactions that are found in vitro have to be checked also in vivo. Indeed, many 
proteins may not be available for interaction in vivo, due to expression in different cell types 
or diverse localisation in cell compartments and therefore those interaction are not of 
physiological relevance. 
3.1.1 Bait construction 
We inserted hIAPP as a bait in the pLexA vector (Clontech), and a brain library containing a 
pool of possible interacting proteins (prays) was inserted in the pB42AD vector (Clontech, 
kindly provided by Prof. Lily Dong, UTHSCSA) [Mao et al., 2006; Dong et al., 2000]. 
 
 
 
FIG. 6A: The library vector 
pB42AD. In yeast cells it 
confers Tryptophan Auxotrophy. 
   
 142 
 
FIG. 6B: The bait vector 
pLexA. In yeast cells it confers  
Histidine Auxotrophy. 
 
We were interested in the mature form of hIAPP, from 1 to 37th amino acid, but it was too 
short to be cloned in a vector easily. Thus, we decided to use a multi-step procedure to obtain 
the minimum length for the plasmid construction (I thank Dr. Carla Perego for the useful 
advices in molecular biology). 
 
- hIAPP was previously cloned in Prof. Folli laboratory and inserted in pTOPO vector 
(Invitrogen). 
- Starting from pTOPO-hIAPP as a template, a STOP codon was introduced after the 37th 
amino acid of mature IAPP (362nd bp) using PCR-site directed mutagenesis with the 
following primers: 
Primer Sequence 5’-3’ 
Forward GGATCCAATACATATTGAAAGAGGAATGCAGTAGAGG 
Reverse CCTCTACTGCATTCCTCTTTCAATATGTATTGGATCC 
 
The product was called pTOPO-hIAPP STOP and checked by sequencing. It was an 
intermediate. 
- Using pTOPO-hIAPP STOP as a template, by means of PCR, a small portion of the vector 
was amplified: from the 1s t amino acid of mature IAPP (252nd bp) until 507th bp, generating 
a product of 255 bp and inserting EcoRI (5’ end) and XhoI (3’end) restriction sites. 
The following primers were used: 
Primer Sequence 5’-3’ 
Forward GGAATTCAAATGCAACACTGCCACAGT 
Reverse CCGCTCGAGCACACTGGAGATCAAAAG 
 
- The PCR product, as well as pLexA vector, were digested with EcoRI and XhoI, and the two 
DNA were then ligated by T4 ligase (Promega) with a 1 to 3 ratio, respectively.  
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Note: all the base pair numbers refer to NM_000415.2 in nucleotide NCBI database 
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The final product was: pLexA-hIAPP STOP, in which mature hIAPP was inserted in EcoRI-
XhoI restriction sites of pLexA vector. The resulting clones were sequenced and the frame for 
the chimeric protein DNA-Binding Domain/IAPP was checked. 
3.1.2 Bait test 
Before the screening, the first step was to verify if the bait was not toxic for the yeast and if 
the bait alone could activate transcription and therefore turn on reporter genes. To this 
purpose, a small scale yeast transformation was carried out. In the case of a positive result, the 
bait would not be suitable for the screening. 
We used a yeast strain (EGY48) already transformed for p8OPLAC7 (from Prof. Dong 
laboratory), a plasmid that provided the ability to respond to the X-Gal assay in case of 
protein-protein interactions. 
 
      EGY48 (p8OPLAC7) yeast cells  were transformed in a small scale with: 
- pLexA-hIAPP stop 
- empty pLexA + empty pB42AD 
- pLexA-hIAPP stop + empty pB42AD  
      And as positive controls: 
- pLexA-APPL2  
- pLexA-APPL2 + empty pB42AD  
 
The co-transformants were selected in SD-His-Trp-Ura plates: this minimum media is lacking 
the three indicated amino acids, thus only colonies carrying the LacZ operon and the two 
plasmids can grow. 
Expected results: 
 
Transformation Growth in SD-His-Trp-Ura plates 
pLexA-hIAPP stop - 
Empty pLexA + Empty pB42AD + 
pLexA-hIAPP stop + Empty pB42AD + 
pLexA-APPL2 - 
pLexA-APPL2 + empty pB42AD  + 
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In these conditions, the assay gave the supposed results and yeast grew also in the presence of 
the pLexA-hIAPP stop, suggesting that the bait is not toxic for the yeast cells. 
Then, after the incubation in the induction media (SD Gal-Raf -His-Leu-Trp-Ura), that 
induced expression of the pB42AD vector, 10 colonies of each transformation were assessed 
with X-Gal Assay. 
 
Transformation Growth in SD-Gal-Raf -His-Leu-Trp-Ura  X-GAL 
pLexA-hIAPP stop - - 
Empty pLexA + Empty pB42AD - - 
pLexA-hIAPP stop + Empty pB42AD - - 
pLexA-APPL2 + + 
pLexA-APPL2 + empty pB42AD  + + 
 
The yeast gave positive results at X-Gal Assay using the positive control APPL2, but it gave 
negative results using the bait, indicating that the bait itself can’t activate the reporter gene, 
therefore is suitable for yeast two hybrid screening. 
3.1.3 Screening 
Once the bait was validated, we proceeded with the screening, using a big scale 
transformation. 
 
     Day 1: Transformed in a library scale EGY48 (p8OPLAC7) yeast cells with: 
- pLexA-hIAPP stop 
- pB42AD-library (prepared in Prof. Dong laboratory) 
Plated all the co-transformants on 60 150 mm-plates using SD-His-Trp-Ura as a 
selection media, to select the co-transformants carrying p8OPLAC7, pLexA- 
hIAPP stop and pB42AD-library. Let them grow for 4 days at 30°C. 
 
Day 5: Harvested the library co-transformants and combined them in a unique tube to 
make a glycerol stock (stored in aliquotes at -80°C). Titered the glycerol stock in 
100 mm-plates, with SD -His-Trp-Ura or SD Gal-Raf-His-Leu-Trp-Ura (Induction 
media, containing Galactose), to have a ratio of the growing colonies. Let them 
grow until they were easy to count. 
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Day 9: Screening library co-transformants for two-hybrid interactions. 2×106 library 
transformants were plated in each of the 60 150 mm-induction plates (SD Gal-Raf-
His-Leu-Trp-Ura). We let them grow at 30°C and every huge, healthy colony that 
showed up in the following 10 days was harvested and plated on a 100 mm replica 
plate with the same media. In this way, the nutritional selection was done: only the 
colony in which the two proteins interacted could grow in a Leu lacking media as  
big colonies. After 24 hours, the replica colonies were tested also with Colony Lift 
Filter Assay, to check the activation of the other reporter system (X-Gal 
conversion to a blue product by β-galactosidase, the second reporter gene). 
 
In total, 92 colonies were positive for X-Gal assay, with a peak between those 
harvested from day 6 to day 7. 
 
In the following days, the positive yeast colonies from the master plates of the replica were 
inoculated in SD -His-Trp-Ura liquid media and grown o/n at 30°C under constant agitation. 
The next day, the positive clones were stored at -80°C as glycerol-MgSO4 stocks and the 
DNA was extracted using the standard protocol. The DNA was stored at -20°C in 20µl 
aliquots.  
 
Retested all the positive yeast clones: all the positive clones were plated in a unique 150 mm 
induction plate (SD Gal-Raf-His-Leu-Trp-Ura) and, after 48 hour growth, tested with colony 
lift filter assay. The X-Gal incubation was performed for 8 hours at 30°C and then the filter 
was dried under the chemical hood. A filter image was acquired with the scanner and the 
optical density of each spot was measured using Scion Image Software. Each optical density 
was corrected for the background and then normalized to the positive control intensity. Not all 
the positive colonies were confirmed. 
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3.1.4 Clone identification 
3.1.4.1 KC8 COLI TRANSFORMATION 
KC8 Coli are a particular bacteria strain that can be transformed with just one molecule of 
DNA for each cell. This is particularly useful to select DNA extracted from yeast, that is a 
mixture of the two plasmidic DNA used in the transformation, i.e.  pLexA and pB42AD. 
Indeed, at this stage we were interested in identifying the protein encoded by pB42AD vector, 
the one deriving from the library and that showed a potential interaction with the bait.  
Moreover, this strain is unable to grow in Trp lacking media, unless the plasmid pB42AD is 
present, as it confers Trp auxotrophy.  
Thus, exploiting both this characteristics, we were able to select only the bacteria clones  
carrying pB42AD vector with the relative insert to be identified.  
In addition, the step in bacteria allowed us to amplify the yeast DNA, that was extracted with 
a low yield. 
After o/n growth in plates with M9 Minimum media lacking Trp, 10 KC8 coli colonies were 
harvested and grown o/n in the corresponding liquid media. The following day, clones were 
lysed and the plasmidic DNA extracted. 
3.1.4.2 DNA DIGESTION 
To verify that the plasmid pB42AD contained an insert, that could encode for a protein of the 
library, we digested extracted DNA with restriction enzymes, as well as the empty vector and 
a positive control. To excide the library inserted fragment, we used EcoRI and XhoI restriction 
enzymes (New England Biolabs). After 3 hour digestion, the products were loaded on a 1% 
agarose gel and the presence of two bands was checked. As expected, two bands were found 
for the digested products: one for the linear plasmid, around 6 kb, and another band for the 
insert, the putative interacting protein, of various length. In all cases, the 10 clones reveled the 
same pattern in the gel, thus only two KC8 colonies from each yeast DNA transformation 
were selected for the sequencing. 
3.1.4.3 DNA SEQUENCING 
KC8 clones were grown o/n at 37°C under constant agitation. The following day, plasmidic 
DNA was extracted using the MiniPrep Kit (Promega) to obtain a high purity suitable for the 
subsequent reaction of sequencing (DNA Core Facility, UTHSCSA). The reaction time was  
based on insert length determined by the previous gel electrophoresis. 
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The primer used for the sequencing was: 5’- CCAGCCTCTTGCTGAGTGGAGATG -3’, that 
is 40 bp before the fusion between Activation Domain and the protein.  
3.1.4.4 SEQUENCE ANALYSIS 
Chromatograms obtained from the DNA core facility were checked with Sequence Scanner 
v1.0 (Applied Biosystems) and when some areas were indefinite, the sequencing reaction was  
repeated. 
First, the reading frame of the sequences were determined comparing the known sequence of 
the Activation Domain with the insert sequences. Then, the sequences were translated with 
the correct reading frame using a resource available on-line at the following website: 
http://nbc11.biologie.uni-kl.de/framed/left/menu/auto/right/JDT/. Only the sequences that 
gave more than 6 amino acids were analysed in the subsequent steps. 
Both the nucleotide sequences and the relative translated protein were matched with the 
databases by the nucleotide/protein BLAST tool in NCBI website (http://ncbi.nlm.nih.gov). 
Also the ExPasy on-line resources (http://expasy.org/) were used to check translated proteins, 
but only in few cases they gave different results compared to BLAST results. 
At this step, the insert sequences were identified, but especially for the short sequences, some 
of the identified proteins were from bacteria or other inferior organisms and were rejected. 
 
The next step will be to confirm the potential interaction between the identified protein and 
the bait, by transforming yeast cells in a small scale with this two constructs. This step is 
necessary to isolate the effect of that particular interacting protein from the whole library, 
because during the library screening more than one pB42AD plasmid could enter the yeast 
and by chance we could have isolated the one that is not responsible for the interaction. 
Then, if the interaction was confirmed, further studies would be needed to demonstrate that it 
occurs also in vivo, by means of affinity chromatography or immunoprecipitation from native 
tissues. 
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4 ADDITIONAL METHODS 
4.1 Yeast Transformation 
EGY48 yeast cell with p8OP-LacZ reporter plasmid were grown overnight to the stationary 
phase in YPD medium at 30 °C under constant agitation. The following day, the yeast culture 
was transferred to fresh YPD medium and grown to produce an O.D.600 nm close to 0.5/0.6. 
Cells were then centrifuged and resuspended in 1X TE/LiAc solution to render them 
competent. Next, a mixture of DNA and 1X PEG/LiAc was added to the cells and we let them 
grow for 30 minutes at 30°C under constant agitation. Recovered cells were heat shocked for 
15 minutes at 42°C in the presence of DMSO and then plated in the appropriate plates. 
 
All yeast media were supplied by Clontech and prepared following the manufacturer 
protocols. 
10X TE solution: 0.1 M Tris HCl pH 7.5, 10 mM EDTA 
10X LiAc solution: 1M LiAc 
PEG/LiAc solution: 40% PEG, 1X TE, 1X LiAc 
4.2 Colony Lift Filter Assay 
24 hours after plating the yeast in 100 mm induction plates (Gal/Raf-His-Leu-Trp-Ura), 
colonies were lifted on a filter presoaked with Z Buffer/X-Gal solution (Z-Buffer, 38 mM β-
mercaptoethanol, 0.3 mg/ml X-Gal). Yeast cells were then lysed by thermal shock, immersing 
the filters in liquid nitrogen two times and then incubated for 8 hrs maximum at 30 °C.  
 
Z-Buffer: 16.1 g/l Na2HPO4x7 H2O, 5.5 g/L x H2O, 0.75 g/l KCl, 0.246 MgSO4x7H2O- pH 7 
4.3 Yeast DNA Extraction 
Yeast clones positive for X-Gal assay were grown overnight in SD-His-Trp-Ura at 30°C 
under constant agitation. Cells were then sedimented and resuspended in the freshly prepared 
suspension buffer: 10 mM Tris-HCl pH 8, 1 mM EDTA, 4.5 U/µl Lyticase. After an 
incubation at 37°C for 30 minutes, lysis buffer was added (2% Triton X-100, 1% SDS, 100 
mM NaCl, 10 mM Tris-HCl pH 8, 1 mM EDTA). Following mechanical disruption of yeast 
cells with glass beads, the DNA was extracted with Phenol-Chloroform-Isoamylalchool and 
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precipitated with Sodium Acetate and Ethanol. The final pellet was resuspended in 20 µl of 
water. 
4.4 Yeast Glycerol stock 
30%Glycerol/MgSO4 solution 
4.5 KC8/JM109 competent cells transformation 
To insert plasmidic DNA into bacterial competent cells we used electroporation. Competent 
KC8 or JM109 cells were incubated with 2 µl of DNA in a cuvette on ice and then subjected 
to electroporation (Biorad apparatus) using the program “EC2” from the manufacturer. Only 
products with a time constant near 5 were plated. Pre-warmed SOC media was immediately 
added to the cells, that were grown for one hour at 37°C under constant agitation. Then, 
bacteria were plated on agarose plates. 
 
SOC MEDIA: 2% Tryptone, 0.5 % Yeast extract, 0.05% NaCl, 0.5 % MgSO4, 0.04% Glucose 
LB plates (JM109): Luria agar (Sigma Aldrich) prepared following the manufacturer protocol 
M9 Media (KC8): 1X M9 salts (Sigma Aldrich), 1.8 % Agar, DO-Trp (Clontech), 1 mM 
MgSO4, 0.4 % glucose, 0.1 mM CaCl2, 0.05 mg/ml Ampicillin, 0.03 mM thiamin 
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APPENDIX 
 
1 ADDITIONAL RESEARCH ACTIVITY PERFORMED 
1.1 Expression and function of EAAC1 in Schwann cells 
Schwann cells represent the myelinating cells of the Peripheral Nervous System (PNS) and 
recently glutamate has been involved in the proliferation and differentiation of these cells  
[Fink et al.,  1999; Kinkelin et al., 2000]. Thus, the control of the extracellular glutamate level 
by glutamate transporters may be crucial for Schwann cell physiology.  
Aim of this study was to identify the glutamate transporters expressed in Schwann cells and to 
verify if they were functional. 
By means of RT-PCR, we observed that the high affinity glutamate transporter EAAC1 was 
expressed by Schwann cells. EAAC1 was present and functional at the cell surface and 
modulated by exposure to 10 nM allopregnanolone (ALLO), a progesterone’s metabolite, 
known to influence PNS myelinogenesis and myelin protein expression [Melcangi et al.,  
2005; Schumacher et al., 2007]. We found that transport up-regulation did not involve protein 
neo-synthesis and was prevented by actin depolimerization, suggesting a change in the 
transporters’ trafficking. To verify this hypothesis, Schwann cells were transfected with the 
GFP-tagged EAAC1 transporter and its surface density was measured by Total Internal 
Reflection Microscopy (TIRFM). ALLO induced the actin cytoskeleton reorganization and 
caused the EAAC1 redistribution from intracellular compartments to the plasma membrane, at  
the tips of filopodia structures. 
 
Taken together, our data demonstrate that EAAC1 is present in Schwann cells as a functional 
glutamate uptake system. Its surface activity can be dynamically up-regulated by ALLO 
through a mechanism which involves increased delivery of EAAC1 to the cell surface. Novel 
findings on glutamate uptake modulation might be relevant in neurophaties, where glutamate 
excitotoxicity is involved [Watkins, 2000], and in regenerative processes, since glutamate has  
a role in Schwann cell proliferation.  
1.2 References 
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